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Summary 
Background:  Irritable bowel syndrome (IBS) is a common gastrointestinal (GI) disorder.  GI 
symptoms and impaired quality of life affect between 10-20% of all adults, corresponding to 
about 25-50% of all patients who visit a gastroenterologist’s clinic.  In recent years, several 
novel mechanisms of IBS that likely relate to previously established theories have been 
identified.  Inflammation, postinfectious low-grade inflammation, immunological and genetic 
predisposition along with altered microbiota are critical in IBS development, while several 
dietary factors may also play a role in this syndrome.  However, none of these factors accounts 
for the full repertoire of IBS symptoms, and the pathophysiology of this condition is not fully 
understood.    The overarching aim of this study was to investigate the nutrient intakes, GI 
microbiota and the effect of Lactobacillus plantarum (L.plantarum) 299v in IBS patients.  
Sub-aims: 1) Update healthcare professionals on current probiotic information and provide an 
overview of probiotic treatment approaches, with special emphasis on IBS, 2) conduct a well 
designed randomised, double blind, placebo-controlled trial (RCT) with L. plantarum 299v as 
part of an intervention and establish whether a course of probiotics may alleviate undesirable 
symptoms of IBS and improve quality of life, 3) assess nutrient intake in patients with irritable 
bowel syndrome (IBS) compared to dietary recommendations,  4) validate and assess the 
reproducibility of food records and 5) identify possible nutrient risk components for establishing 
GI microbiota involved in IBS and as part of an intervention, determine whether a course of 
probiotics may alter stool microbiota.   
Results: 1) A review article published by the author provides an overview of current probiotic 
treatment options to health care professionals and indicates certain probiotics are a promising 
therapeutic treatment option for management of IBS symtpoms, 2) the effects of the single strain 
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probiotic, L. plantarum 299v, supplementation was evaluated in a RCT.  Compared to placebo, 
the probiotic supplementation showed no significant reduction in GI symptom severity scores, 
particularly abdominal pain relief.  Quality of life was also not improved in the treatment versus 
control group.  Both the treatment and placebo groups improved significantly over the trial 
period, indicating a large placebo effect, 3) nutrient intakes of the IBS patients compared to 
current dietary reference recommendations indicates that this group of patients are at risk for 
nutrient inadequacies in key macro and micronutrients, 4) the validity and reliability of the 
dietary data showed good reliability but poor validity as measured by plasma fatty acids and 5) 
the GI microbiota composition in the phenotypically different diarrhoea-predominant IBS (D-
IBS) vs. constipation-predominant IBS (C-IBS) showed that D-IBS patients had significantly 
lower counts of Lactobacillus plantarum compared to C-IBS patients.  The probiotic had no 
significant effects on the GI microbiota as measured by quantitative polymerase chain reaction 
(qPCR).  It was found that nutrient intakes had a significant impact on the microbiota.  Lower 
fibre intakes were associated with higher Bacteroides spp., lower Bifidobacteria bifidum and 
Lactobacillus plantarum counts in both IBS groups.  
Conclusion:  Taken together, L.plantarum 299v did not alleviate the GI symptoms of IBS, nor 
was it associated with significant changes in the GI microbiota.  IBS patients may be at risk of 
key nutrient inadequacies.  The influence of nutrient intakes on the GI microbiota provides an 
attractive explanation as a potential pathophysiological factor for IBS.     
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Opsomming 
Agtergrond: Prikkelbare derm-sindroom (PDS) is ‘n algemene gastro-intestinale (GI) stoornis.  
GI simptome affekteer die lewenskwaliteit van 10-20% van alle volwassenes.  Dit stem ooreen 
met ongeveer 25-50% van alle pasiënte wat ‘n gastroënteroloog konsulteer.  Verskeie 
oorspronklike meganismes vir die ontwikkeling van PDS is onlangs identifiseer. Inflammasie, 
post-infektiewe lae-graadse inflammasie, immunologiese en genetiese vatbaarheid tesame met 
veranderde mikrobiota is krities vir die ontwikkeling van PDS. Sekere dieetfaktore mag ook 
bydraend wees tot hierdie sindroom. Geen van hierdie faktore is egter verantwoordelik vir die 
volle spektrum van PDS simptome nie en die patofisiologie van die toestand word ook nog nie 
ten volle verstaan nie. Die oorkoepelende doel van hierdie studie is om nutriëntinname, GI 
mikrobiota en die uitwerking van L.plantarum 299v in PDS pasiënte bepaal. 
Sub-doelwitte: 1) Om gesondheidswerkers in te lig aangaande die nuutste inligting oor 
probiotika en om ‘n oorsig van probiotika behandelingsopsies te verskaf, met spesiale klem op 
PDS, 2) om ‘n goed beplande ewekansige, dubbel-blinde, plasebo-beheerde kliniese studie met 
L.plantarum 299v as deel van die intervensie uit te voer om sodoende te bepaal of ‘n kursus 
probiotika ongewensde simptome van PDS kan verbeter en lewenskwaliteit sodoende verhoog, 
3) om nutriëntinname in pasiënte met PDS te bepaal vergeleke met dieet aanbevelings, 4) om die 
geldigheid en herhaalbaarheid van voedselrekords te bepaal en 5) om  moontlike nutriënt 
risikokomponente vir die ontwikkeling van GI mikrobiota betrokke in PDS te identifiseer en om 
as deel van ‘n intervensie te bepaal of ‘n kursus probiotika stoelgang mikrobiota patrone 
verander. 
Resultate: 1) ‘n Oorsigartikel gepubliseer deur die kandidaat dui probiotika aan as ‘n belowende 
terapeutiese opsie in die behandeling van PDS simptome, 2) die effek van ‘n enkelstam 
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probiotikum, L.plantarum 299v, is evalueer deur ‘n ewekansige, dubbel-blinde, plasebo-
beheerde kliniese studie. Vergeleke met die plasebo, het probiotiese aanvulling geen 
betekenisvolle vermindering in die GI simptome in PDS pasiënte tot gevolg gehad nie. 
Lewenskwaliteit het ook nie verbeter in die behandelde versus die kontrole groep nie.  Beide die 
behandelde en plasebo groepe het aansienlik verbeter oor die studietydperk, wat ‘n groot plasebo 
effek aandui, 3) nutriëntinname van die PDS groep vergeleke met huidige dieetaanbevelings, dui 
daarop dat hierdie groep pasiënte ‘n risiko het vir die ontwikkeling van kern nutriënttekorte 
(makro- en mikronutriënte), 4)  die geldigheid en betroubaarheid van die dieetdata dui op goeie 
betroubaarheid, maar swak geldigheid soos bepaal deur plasma vetsure en 5) die dermkanaal 
mikrobiotiese samestelling in die verskillende fenotipes, diarree-oorheersende PDS (D-PDS) vs. 
konstipasie-oorheersende PDS (K-PDS) dui daarop dat D-PDS pasiënte aansienlike minder 
Lactobacillus plantarum gehad het vergeleke met K-PDS pasiënte.  Die probiotikum het geen 
beduidende uitwerking op die oorheersende mikrobiota gehad nie, soos gemeet deur 
kwantitatiewe polimerase kettingreaksie (kPKR).  Daar is gevind dat dieet ‘n beduidende impak 
op die mikrobiota gehad het.  Daar is ‘n verband tussen laer vesel inname en hoёr Bacteroides 
spp. en laer Bifidobacteria bididum en Lactobacillus plantarum tellings gevind in beide PDS 
groepe.   
Gevolgtrekking: Die L.plantarum 299v enkelstam probiotikum het nie die gastrointestinale 
simptome van PDS pasiënte verlig nie en daar is ook geen beduidende veranderinge in die 
mikrobiota gevind nie. PDS pasiënte mag ‘n verhoogde risiko toon vir kern nutriënttekorte. Die 
invloed van nutriëntinname op GI mikrobiota verskaf ‘n belowende verduideliking as ‘n 
potensiële patofisiologiese faktor in PDS.  
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A good set of bowels is worth more to a man than any quantity of brains. 
Josh Billings (Henry Wheeler Shaw), AD 1818 - 1885 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
viii 
 
Abbreviations 
Abbreviations used in the introduction and discussion sections only   
5-HIAA 5-hydroxyindoleactic acid 
5-HT  5-hydroxytryptamine 
5-HT3  5-hydroxytrptamine receptor 3 
5-HT4  5-hydroxytrptamine receptor 4 
5-HT5  5-hydroxytrptamine receptor 5 
5-HTT LPR Serotonin transporter-linked polymorphic region 
AI  Adequate intake 
A-IBS  Alternating irritable bowel syndrome  
AMDR Acceptable macronutrient distribution ranges 
CFTR  Cystic fibrosis transport regulator 
cfu  Colony forming unit 
CI  Confidence interval 
C-IBS  Constipation predominant irritable bowel syndrome 
CIC-2  Chloride channel protein 2 
CNS  Central nervous system 
Stellenbosch University  http://scholar.sun.ac.za
ix 
 
D-IBS  Diarrhoea predominant irritable bowel syndrome 
DNA  Deoxyribonucleic acid 
DRI  Dietary Reference Intake 
EPS  Exopolysaccharides 
FA  Fatty acid 
FAME  Fatty acid methyl esters 
FBD  Functional bowel disorder 
FGID  Functional gastrointestinal disorder 
FISH  Fluorescent in situ hybridisation 
FODMAP Fermentable Oligo-Di-and Mono-saccharides and Polyols 
GC – C Guanylate cyclase - C  
GC-MS Gas chromatography and mass spectroscopy 
GI  Gastrointestinal 
GIT  Gastrointestinal tract 
GNß3  ß3 subunit of the G protein 
HITChip Human Intestinal Tract Chip 
HREC  Health Research Ethics Committee 
Stellenbosch University  http://scholar.sun.ac.za
x 
 
IBS  Irritable bowel syndrome 
IBS-DGDG Irritable bowel syndrome Dietetic Guideline Development Group 
IBS-QOL Irritable bowel syndrome quality-of-life 
IL-10  Interleukin – 10 
IOM  Institute of Medicine 
MCID  Minimally clinically important difference 
M-IBS  Mixed irritable bowel syndrome 
mRNA  Messenger ribonucleic acid 
NNT  Number needed to treat 
NSP  Non-starch polysaccharide 
PI-IBS  Post infectious irritable bowel syndrome 
QoL  Quality of Life 
qPCR  Quantitative polymerase chain reaction 
RCT  Randomised controlled trial 
SACN  Scientific Advisory Committee on Nutrition 
SCFA  Short chain fatty acids 
SERT  Serotonin transporter gene 
Stellenbosch University  http://scholar.sun.ac.za
xi 
 
SGA  Subjective Global Assessment 
SIBO  Small intestinal bacterial overgrowth 
SIGN  Scottish Intercollegiate Guidelines Referral 
Spp.  Sub species 
USA  United States of America 
VAS  Visual analogue score 
vs.  Versus 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
xii 
 
Tables and Figures 
Tables and figures used in the introduction and discussion sections only  
Introduction  
1. Table 1. The Rome I, II and III criteria for IBS  4 
2. Figure 1. Biopsychosocial model of IBS depicting the relationship    7  
         between pathophysiology, symptom expression and clinical outcome 
3. Table 2. Pharmacological treatment for IBS     19   
4. Table 3. Summary of culture and molecular studies of colonic microbiome  28 
5. Table 4.  Methodology scores for RCTs assessing L.plantarum 299v in IBS  34 
6. Table 5. Dietary clinical practice recommendations for IBS 43 
7. Table 6. Associations of the human intestinal microbiota with habitual  51 
             dietary patterns or interventions 
8. Figure 2. Conceptual framework depicting possible influences of nutrient intake,   56 
the GI microbiota and probiotics on the pathogenesis of irritable bowel  
syndrome and health outcomes 
Discussion 
1. Table 1.  Methodology score for this RCT assessing L.plantarum 299v in IBS 196 
2. Figure 2. Conceptual frame work depicting the contribution of knowledge gained  203 
                from the research   
Stellenbosch University  http://scholar.sun.ac.za
xiii 
 
Acknowledgements 
A man’s heart plans his way, But the LORD directs his steps (Proverbs 16:9) 
This research project has been a God-given opportunity that I have been thankful to have been 
able to grasp, run with and complete.  
 
Heartfelt thanks go out to the following people who have made this project possible: 
The opportunity would not have been possible without Dr Ernst Fredericks, who so 
graciously opened his practice to me for data collection, was a co-investigator and 
encourager. 
Special thanks to the very full-of-life septuagenarian, Sr Doreen McLeod, who taught me 
the art of data collection. 
Thank you to the rest of the staff at Dr Fredericks practice for their friendliness and 
willingness to help. 
My promoters Profs Saartjie Roux and Renée Blaauw and Mrs Janicke Visser.  I was 
really blessed to have these three researchers as my mentors.  I learnt many other things 
from them besides research, what an enriching life experience.   
Prof Daan Nel for all his help and time with the statistics. 
The participants involved in this research. 
Stellenbosch University  http://scholar.sun.ac.za
xiv 
 
Sponsorship received from the National Research Foundation and Nestlé Nutrition 
Institute Africa. 
I come from a big family.  This project has not just only been about me, but the whole 
family who supported me.  Thank you and much appreciation to you all!  I started the 
project with a one year old son, Daniel and am finishing with two more added, David and 
Michael.  I would like to especially thank my mom, Liz, and mom-in-law, Franky, for 
looking after the outjies when needed and their belief in me that I could finish this; their 
kindness and encouragement spurred me on.  Thanks also to my sister, Taryn, and 
brother-in-law, Daryl, for counting and dispensing thousands of capsules. Linda Momo, 
for her love and care towards our family.  My husband, Ian, for his sense of humour, 
support and love shown, many a night the house and kitchen were cleaned by him so I 
could knuckle down and work!  This has been a team effort. 
 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
xv 
 
Contents 
Declaration   II 
Summary   III    
Opsomming   V 
List of abbreviations   VIII  
List of tables and figures   XII 
Acknowledgements   XIII  
Chapter 1 
1. Irritable bowel syndrome 2 
1.1 Definition and diagnosis 2 
1.2 Epidemiology 5 
1.3 Social and economic impact 5 
1.4 Pathophysiology 6 
1.4.1 Genetics 8 
1.4.2 Serotonergic disorder 9 
1.4.3 Low grade inflammation and mast cell involvement 10 
1.4.4 Abnormal motility 11 
1.4.5 Visceral pain hypersensitivity 12 
1.4.6 Brain-gut interaction 14 
1.4.7 Psychosocial factors 15 
Stellenbosch University  http://scholar.sun.ac.za
xvi 
 
1.5 Current IBS treatment 17 
1.5.1 Pharmacological treatment 17 
1.5.2 Psychological treatment 22 
2. Gastrointestinal microbiota 
2.1 Human intestinal microbiota 23 
2.2 Intestinal microbiota in IBS 24 
2.3 Overview of methods for analysing microbiota 30 
2.4 Probiotics – definition and health effects 30 
2.5 Probiotic clinical trials in IBS 32 
3. Nutrient intake and IBS 35 
3.1 Reproducibility and validity of dietary data in IBS 36 
3.1.1 Reproducibility 37 
3.1.2 Validity 38 
3.1.3 Biomarkers 40 
3.2 Dietary management of IBS 41 
3.2.1 Milk and dairy products 45 
3.2.2 Nonstarch polysaccharides 45 
3.2.3 Fermentable carbohydrates 46 
3.2.4 Elimination and empirical diets 48 
4. The GI microbiota and diet 49 
5. Rationale for study 53 
5.1 Aim of the study 57 
5.2 Sub-aims of study 57 
Stellenbosch University  http://scholar.sun.ac.za
xvii 
 
5.3 Study design 58 
5.4 Study population and participants 58 
5.5 Null hypothesis 59 
5.6 Chapter overview, contribution of candidate and scope of work 59 
6. References 63  
Chapter 2 103 
Article 1: Review - Probiotics, with special emphasis on their role in the management of  
irritable bowel syndrome  
Chapter 3    113  
Article 2: Randomized clinical trial: Effect of Lactobacillus plantarum 299v on 
symptoms of irritable bowel syndrome 
Chapter 4 121 
Article 3: Food avoidance in irritable bowel syndrome leads to a nutrition-deficient diet 
Addendum 1 of Chapter 4 128   
    
Chapter 5 132 
Article 4: Validation and test-retest reliability of estimated food records in irritable bowel 
syndrome patients 
 
Stellenbosch University  http://scholar.sun.ac.za
xviii 
 
Chapter 6 158 
Article 5: The effect of nutrient intakes and a probiotic on gastrointestinal microbiota in 
patients with irritable bowel syndrome 
 Chapter 7              185   
Concluding discussion and summary 
Addenda 213   
    
   
 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 
 
Chapter 1 
Introduction 
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Literature overview   
1. Irritable bowel syndrome 
1.1. Definition and diagnosis 
Irritable bowel syndrome (IBS) belongs to a group of functional bowel disorders (FBD), which 
also includes functional bloating, functional constipation, functional diarrhoea and unspecified 
bowel disorder.
1
  The main feature of IBS is recurrent abdominal pain or discomfort that is 
associated with disordered defecation and changes in bowel habit.
2  
Other symptoms 
characteristic for IBS and classified as supportive symptoms include: abnormal stool frequency 
(≤3 stools/week or > 3/day), abnormal stool form, defecation straining, urgency, incomplete 
bowel movements, mucus and bloating.  Based on the supportive symptoms, IBS can be 
subdivided into diarrhoea predominant IBS (D-IBS), constipation predominant IBS (C-IBS) and 
a mixed or alternating IBS (A-IBS).  The syndrome is chronic in nature, but associated with a 
good prognosis and no increased mortality in the long-term follow-up.
3   
 
The diagnosis of IBS is based on the identification of symptoms consistent with the condition 
and on case-by-case evaluated exclusion of other diseases with similar clinical features.
2  
The 
first symptom-based diagnostic criteria were published by Manning in 1978,
4
 and have been 
widely utilised in epidemiological and clinical studies.  The multinational Rome working 
committee published its first criteria for IBS in 1989
5
 and has since then regularly published 
updated versions.
6,7  
The most current version, the Rome III criteria, was issued in 2006.
2  
To date 
there is only one validation study for the Rome III criteria;
8 
this highlights the need for further 
validation studies with the criteria.
9  
The Rome I, II and III criteria appear in Table 1.  Given the 
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lack of definitive sine qua non biomarkers that firmly indicate a diagnosis of IBS, it remains a 
clinical diagnosis that is largely based on symptom-based criteria.   
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Table 1. The Rome I, II and III criteria for IBS 
  Rome 1 criteria
6
 
At least three months of continuous or recurrent symptoms of: 
1. Abdominal pain or discomfort which is: 
Relieved with defecation 
and/or associated with a change in frequency of stool 
and/or associated with a change in consistency of stool, and 
2. Two or more of the following, at least a quarter of occasions or days: altered stool frequency; altered 
stool form (lumpy/hard or loose/watery stool); altered stool passage (straining, urgency or feeling of 
incomplete evacuation); passing of mucus; and bloating or the feeling of abdominal distension. 
Rome II criteria
7
 
At least 12 weeks, which need not be consecutive, in the preceding 12 months of abdominal discomfort or 
pain that has two or three features: 
1. Relieved with defecation; and/or 
2. Onset associated with a change in frequency of stool; and/or 
3. Onset associated with a change of form (appearance) of stool 
The following symptoms cumulatively support the diagnosis of IBS: abnormal stool frequency; abnormal 
stool form (lumpy/hard or loose/watery stool); abnormal stool passage (straining, urgency of feeling or 
incomplete evacuation); passing of mucus; and bloating or feeling of abdominal distension. 
Rome III criteria
*2
 
Recurrent abdominal pain or discomfort
**
 at least 3 days per month in the last 3 months associated with 2 
or more of the following: 
1. Improvement with defecation 
2. Onset associated with a change in frequency of stool 
3. Onset associated with a change in form (appearance) of stool 
*
 Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis 
**
 Discomfort means an uncomfortable sensation not described as pain.  In pathophysiology research and 
clinical trials, a pain/discomfort frequency of at least 2 days a week during screening evaluation is 
necessary for subject eligibility. 
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1.2. Epidemiology 
In a recent meta-analysis by Lovell et al. the global pooled prevalence of IBS was 11,2%.  The 
prevalence varied according to country (from 1,1% to 45,0%) and the criteria used to define 
IBS.
10  
Though the majority of prevalence findings are from Western populations, increasing data 
reveal that the syndrome is at least as prevalent in non-Western societies such as China, South 
Korea, India and Malaysia.
11-14  
There is little data available on IBS prevalence in Africa, 
however data from Kenya and Nigeria shows prevalence between 8 – 33%.15-17  A study 
conducted in South Africa almost 30 years ago indicated that the prevalence in the black 
population group was 8,1%.
18  
The prevalence of IBS in the general South African population is 
unknown.   However, the progressive westernisation of diets and lifestyles of less-privileged 
populations is likely to be associated with an increased incidence of bowel disease and IBS.  IBS 
patients can account for up to 30-50% of gastroenterology clinic visits.
19  
In general, there is a 
clear female predominance among IBS patients.  IBS can affect people at any age, but the 
condition is most commonly diagnosed between ages 20 – 40, whereas organic gastrointestinal 
predominates in the over 60 years.
20
   
 
1.3. Social and economic impact 
Although IBS is not life-threatening, it is a painful, bothersome and distressing condition that 
interferes with daily life and places a considerable economic burden on a country’s health care 
system.  This is seen in both direct and indirect medical costs such as lost productivity and 
absenteeism, in addition to the less quantifiable costs of a diminished quality of life.  In 2004, 
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annual IBS medical care in the United Sates was believed to be between $1.7 - $10 billion in 
direct costs and $20 billion for indirect costs.
21
  
 
1.4. Pathophysiology 
The discovery of a single unifying pathway of pathogenesis for IBS has been elusive, and there 
are no biochemical or physiologic markers.
9  
However, one such pathway may not exist for IBS 
since IBS is likely multi-faceted in its aetiology and is seen as a complex biopsychosocial 
condition in which a number of major mechanisms at the central and peripheral level interact.
1  
These include environmental factors (psychological disturbances and stress), previous infection, 
low grade mucosal inflammation, altered bowel motility and/or secretion, visceral 
hypersensitivity, genetic links (select gene polymorphisms, including those in interleukin-10, G-
protein GNb3, alpha-adrenoreceptor and serotonin reuptake transporter), small GI bacterial 
overgrowth, food intolerance, altered central nervous system sensory processing, disturbed 
autonomic nervous system regulation and serotonin dysregulation.
22,23  
The contribution of the GI 
microbiota and diet/nutrient intakes to the pathophysiology of IBS will be discussed separately 
under sections 2.2 and 3.2 respectively.  The prominence of any particular factor may vary from 
patient to patient.  Figure 1 illustrates the interaction between the various mechanisms involved 
in the pathophysiology.   
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Figure 1. Biopsychosocial model of IBS depicting the relationship between pathophysiology, symptom 
expression and clinical outcome (modified from Drossman
1
). 
 
 
Figure 1 illustrates the relationships between psychosocial and physiological factors and 
functional GI symptoms and clinical outcome.  Early in life, genetics, in addition to 
environmental factors such as family influences on illness expression, abuse, major losses or 
exposure to infections, may affect one’s psychosocial development in terms of one’s 
susceptibility to life sress or psychological state and coping skills, as well as susceptibility to gut 
dysfunction – abnormal motility, altered mucosal immunity or visceral pain hypersensitivity.  
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Furthermore, these ‘brain-gut’ variables reciprocally influence their expression.  Therefore, IBS 
is a clinical product of this interaction of psychosocial factors and altered GI physiology via the 
brain –gut axis.  The clinical outcome will, in turn, affect the severity of the disorder (note the 
double-sideed arrow in Figure 1).
1 
 
 
1.4.1. Genetics 
The possible role of genetics and putative susceptibility loci for IBS has been an area of growing 
investigation and interest.  Multiple family studies have consistently reported that familial 
aggregation occurs in IBS.
24-27  
Furthermore, the majority of twin studies have demonstrated a 
significant genetic liability in IBS.
27  
Although it remains unclear whether these findings are 
secondary to common genetic versus early environmental factors, there has been an active 
interest in various candidate genes.  Current IBS candidate genes consist of serotonin transporter 
(SLC6A4), norepinephrine transporter (NET), alpha-2A-adrenergic receptors (ADRA2A), 
interleukin-10 (IL-10), G protein β3 subunit (GNβ 3) and sodium channel (SCN5A).28   
Regarding genes controlling inflammation, a meta-analysis indicated that high producer IL-10 (-
1082 G/G) polymorphism diminishes the IBS risk in the European IBS population, whereas 
tumor necrotic factor (TNF) (-308 G/G) polymorphism increases IBS susceptibility and TNF (-
308 G/A) polymorphism decreases IBS susceptibility in the Asian IBS population.
29  
Genetic 
variation in the genes controlling bile acid synthesis may contribute to abnormal bowel pattern 
and symptoms in IBS.  Bile acid malabsorption stimulates colonic motility and secretion and has 
been associated with D-IBS.
30  
Hepatic bile acid synthesis is partially controlled by feedback 
inhibition via the fibroblast growth factor 19 (FGF 19); FGF19 binds to the FGF receptor 4 and 
the co-receptor Klotho-beta (KLB), leading to the rate-limiting enzyme in bile acid synthesis.
31  
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Wong et al. reported that a single nucleotide polymorphism in the KLB gene (rs17618244) is 
associated with accelerated colonic transit in D-IBS.
32  
A genetic approach to IBS remains an 
exciting area of exploration.  Future direction of investigation includes genome-wide approaches 
and further delineation of the role of epigenetic factors in IBS.
31
 
 
1.4.2. Serotonergic disorder 
Serotonin, or 5-hydroxytryptamine (5-HT), is a biogenic monoamine neurotransmitter that is 
largely contained within the GI tract in enterochromaffin cells.
34  
Enterochromaffin cells release 
5-HT in response to luminal stimuli, such as the passage of chyme, with 5-HT having a wide 
range of GI effects given that receptor subtypes are found on smooth muscle, enteric neurons and 
enterocytes.
35  
Given the integral role of 5-HT in GI signalling and function, there has been 
growing interest in its potential role in IBS.    It has been suggested that disruption of 
serotonergic equilibrium may have a role in IBS due to observations made in IBS patients, which 
include increased postprandial levels of circulating 5-HT in patients with D-IBS; elevated 
platelet-depleted plasma 5-HT levels in both fasting and fed states in patients with D-IBS; lack 
of elevation in plasma 5-HT after meal ingestion in patients with C-IBS and decreased mucosal 
5-hydroxyindoleactic acid (5-HIAA)/5-HT ratio in those with C-IBS.
36-38  
These findings suggest 
there may be relative 5-HT excess in D-IBS and 5-HT insufficiency in C-IBS.  Furthermore, the 
role of serotonin transporter gene (SERT) function has been of interest given findings of reduced 
mucosal SERT activity in IBS.
39  
However, the role of SERT function in IBS is unclear and 
differences in mucosal expression of SERT in patients with IBS has not been found.
40
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Perhaps some of the most compelling evidence that IBS is a serotonergic disorder stems from 
results from 5-HT receptor modulating agents as therapies in IBS; specifically, alosetron and 
tegaserod.  Both alosteron and tegaserod were withdrawn from the United States of America 
(USA) market due to serious adverse events with constipation and ischemic colitis and post 
marketing reports of higher cerebrovascular and cardiac events, respectively.  Nonetheless, both 
appeared to be effective therapeutic agents in IBS (and alosetron was re-released in the USA).  
As a 5-HT3 antagonist, alosetron was shown to be an effective agent in the treatment of D-IBS 
with improvements in global IBS symptoms, relief of abdominal pain, improvement of both 
frequency and consistency of bowel movements, inhibition of intestinal secretion, delay of 
colonic transit time, and central effects that may have resulted in beneficial effects on sensation 
in D-IBS.
41-46  
Tegaserod, a selective partial agonist of the 5-HT4 receptor has been shown to 
improve global IBS symptoms and constipation in C-IBS patients.
42,45,47,48 
 Despite the 
significant adverse events associated with alosteron and those potentially reported for tegaserod, 
their consistently demonstrated effectiveness as targeted therapies for IBS is supported by the 
literature.  They have served to further strengthen the hypothesis that serotonin is key in the 
pathophysiology of IBS, which has led to the development of other novel serotonergic agents.   
 
1.4.3. Low grade inflammation and mast cell involvement 
There is increasing evidence emerging on the role of low-grade inflammation in the pathogenesis 
of IBS, and in particular in the role of mast cells.  Mast cells play a critical role in normal 
immune function and respond to antigen stimuli through degranulation resulting in the release of 
the inflammatory mediators histamine and tryptase.
49  
Numerous studies have reported on the 
increased number of mast cells found throughout the GI tract in patients with IBS.
50-54
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Furthermore, both the degree of cellularity of mucosal mast cells and proximity to sensory 
nerves has been found to be correlated with abdominal pain in IBS.
52  
Increased mast cell activity 
as measured by release of histamine and tryptase, has also been reported in patients with IBS.
50,52
 
The GI microbiota may contribute to the low-grade inflammation and intestinal immune 
activation described in IBS through effects of cytokine levels and toll-like receptor activity.
55-57
 
In a study of patients with IBS (n = 77) undergoing colonoscopy to rule out inflammatory bowel 
disease (IBD), patients were categorised based on biopsy as non-inflamed IBS, nonspecific 
microscopic colitis or lymphocytic colitis.  Increases in lymphocytic populations were observed 
in all patient subgroups, even those without overt signs of inflammation, suggesting a 
pathophysiologic role of immune activation in IBS.  The authors speculated that bacterial 
antigens could be one of the factors triggering immune activation.
58
  
 
1.4.4. Abnormal motility 
A variety of motor abnormalities have been described throughout the GI tract in IBS.  Several 
distinct patterns of motility that vary in their intensity, type and location normally occur within 
the human GI tract. Overall, patients and healthy controls differ in quantitative, rather than 
qualitative, aspects of these motility patterns.  In comparison with controls, IBS patients appear 
to have a delayed gastric emptying,
59,60
 though not all studies support this.
61  
Small bowel 
motility is altered in IBS in several ways: typical findings include a shorter duration of 
postprandial motor activity combined with episodes of clustered, recurring contractions 
correlating with abdominal pain.
62  
Furthermore, abnormal duodenal pressure waves that 
correlate with symptom severity have been observed in D-IBS.
63  
Small bowel transit time is 
significantly shorter in D-IBS and longer in C-IBS, compared to controls.
64  
 Both in the small 
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and large bowel, IBS patients show an exaggerated response to a range of provocative stimuli.  
For instance, hypermotility of the small bowel in IBS patients is seen after infusions of 
cholecystokinin, a fatty meal, or ileal distension,
65 
and colonic motor activity is exaggerated after 
a meal, an anger stressor or cholecystokinin.
66-68  
During cholecystokinin administration, 
abdominal pain coincided with >90% of the large-bowel high-amplitude contractions, suggesting 
that abnormalities in these vigorous colonic contractions may be one of the causes of pain.
68  
Basal non-stimulated large-bowel motility parameters, such as the myoelectric activity
69
 and 
sigmoid-colonic motor activity,
68,70  
also appear to be altered in IBS.  Similarly to the small 
bowel transit times, the whole-gut and colonic transit times are shortened in D-IBS and 
prolonged in C-IBS.
64,68    
Although abnormal GI motor patterns are frequently observed in IBS, 
the mechanism behind such dysmotility is largely unknown. It has been proposed that disordered 
functioning of the enteric nervous system and serotonin signalling may be involved. This is 
corroborated by abnormal serotonin levels and turnover in IBS
37,39
 and by the observation that 
endogenous 5-HT concentrations clearly correlate with the colonic activity index in IBS.
38
 
 
1.4.5. Visceral pain hypersensitivity 
Visceral hypersensitivity, defined as an increased sensation in response to intestinal stimuli, is 
one of the most commonly found hallmarks of IBS and other functional gastrointestinal 
disorders.
71  
Evidence of visceral hypersensitivity in humans is principally based on barostat tests 
that measure the pain sensation caused by GI balloon distension.   Lower pain threshold to 
colonic distension was observed in most of patients with IBS than healthy subjects, furthermore 
there was no difference in pain threshold to colonic distension between D-IBS and C-IBS.
72
  
Some brain regions such as the anterior cingulate cortex (ACC) may play a major role for 
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generating pain and/or pain-related emotion in humans.  IBS patients showed greater activation 
in the perigenual ACC during painful rectal distension compared with healthy controls.
72  
The 
influence of GI microbiota on visceral hypersensitivity has been suggested in a variety of animal 
models.  In one study, the transfer of faecal microbiota of patients with IBS to germ-free rats was 
accompanied by a transfer of visceral hypersensitivity (assessed by colorectal distension) when 
these IBS human microbiota-associated (HMA) rats were compared with healthy HMA rats.
73
 
An investigation of whether changes in GI flora and GI inflammatory cell activity impacted 
visceral hypersensitivity in mice demonstrated that, in the absence of sterile precautions (i.e. 
allowing for the fluctuation of GI bacterial content), the mice had a substantial increase in 
visceral hypersensitivity over time that was associated with a slightly increased activity of 
inflammatory cells.
74  
When an anti-inflammatory agent (i.e. dexamethasone) was administered, 
both inflammatory activity and visceral hypersensitivity were reduced, lending further support to 
the interplay between inflammation and visceral hypersensitivity.  Overall, these results support 
the hypothesis that perturbations of the GI microbiota are associated with small changes in 
inflammatory activity in the GI tract that can change visceral perception, this is a possible 
rationale for the administration of certain probiotics for IBS.
56  
In rats with induced post-
inflammatory chronic hypersensitivity to colorectal distension, the administration of a probiotic 
resulted in the normalization of visceral hypersensitivity.
75
 Although these animal data are 
interesting, the association between GI microbiota and visceral hypersensitivity remain 
speculative and require clinical investigations in patients with IBS.      
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1.4.6. Brain-gut interaction 
Perturbations in the brain-gut axis are increasingly recognised as underlying pathophysiological 
factors in functional GI disorders.
76  
Environmental, cognitive and emotional states can affect 
intestinal sensory perception.  The brain-gut axis is considered a model describing the complex 
bidirectional neural pathways connecting the brain with the gut neuroendocrine centres, the 
enteric nervous system and the immune system.
77   
Disturbed brain-gut communication is not an 
independent pathophysiological factor in IBS, as the brain-gut axis is the key regulator of e.g. gut 
motor activity and visceral perception, both known to be changed in IBS.  Altered 
communication between the central nervous system (CNS) and the gut is thus tightly interlinked 
with other established pathophysiological phenomena in IBS.  Overall, brain-gut interactions 
play an important role in the regulation of many vital functions both in health and in disease.  
Digestive functions, including motility, secretion, mucosal transport and blood flow are 
coordinated by the CNS in a top-down mann.
78  
Conversely, signals from the gut play a role in 
reflex regulation and pain perception in a bottom-up manner.
79  
The CNS functions as a “filter” 
with regard to the perception of peripheral afferent signals and the brain-gut communication is 
for the most part not consciously perceived: only very few of the signals reaching the brainstem 
and thalamus are consciously perceived in the cortex.
80  
The brain-gut axis is stimulated by 
various stressors, as shown by the fact that acute intestinal inflammation is associated with 
central sensitisation,
81 
whereas psychological events alter gut function.
82,83 
Symptoms of IBS are 
thought to be produced by primary alterations in the CNS, by primary alterations in the 
periphery, or by a combination of both.  Evidence for central alterations in IBS comes from 
studies using functional brain imaging techniques where different brain areas involved in pain 
processing are activated in IBS patients vs. controls following painful rectal stimuli.
84,85
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Moreover, IBS patients appear to have an altered processing of anticipated pain, since sham 
distension resulted in similarly low pain scores in IBS patients and healthy subjects, but a 
differential brain activation pattern.
85
  Central processing may also distinguish between different 
bowel habits, as demonstrated by lower parasympathetic tone and higher autonomic nervous 
system balance in C-IBS vs. D-IBS patients.
86  
The role of the central and the autonomic nervous 
system in IBS pathophysiology is supported by findings of sleep disturbances, and especially an 
enhancement of rapid eye movement sleep in IBS.
87  
Studies presenting elevated levels of 
corticotrophin-releasing and adrenocorticotropic hormones as well as alterations of the visceral 
perception in IBS patients following mental stress also point towards disturbed brain-gut 
interaction.
88  
Numerous neurotransmitters are involved in the regulation of the brain-gut axis.  
Amongst those, serotonin is of particular interest since its effects on gut motility, secretion and 
sensation as well as on cognition and mood make it of paramount relevance in IBS 
pathophysiology.
89  
Acute lowering of serotonin synthesis reduces the threshold for 29 painful 
stimuli and induces a depression-like memory bias both in IBS patients and in control subjects, 
illustrating the essential role of serotonergic modulation in the brain-gut axis.
90
  In contrast, 
increased 5-HT activity induced by citalopram is associated with enhanced affective memory 
performance biased towards positive words.
90    
Another important group of molecules affecting 
the brain-gut axis are prostaglandins, which appear to exert their effects via peripheral 
mechanisms in the GI tract rather than via central mechanisms.
91
 
 
1.4.7. Psychosocial factors 
Psychosocial factors are not believed to cause IBS, but they exert a strong influence on some 
patients.  Psychological stress and emotions produce GI symptoms in almost all individuals, but 
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IBS patients appear to be particularly susceptible to an exacerbation of symptoms by stress.
92
 
Psychological symptoms and comorbidity frequently exist in IBS, especially in those seeking 
health care.  Commonly encountered conditions in these patients include depression, 
somatisation, anxiety disorder, panic disorder and phobic anxiety disorder.
93,94  
Both physical and 
sexual abuses are common and underestimated among IBS patients.
95  
In addition, these victims 
often manifest severe pain perception, psychological distress, and poorer health outcome.
96
   
Early life trauma is able to increase future visceral pain perception. Accordingly, maternally 
separated neonatal rodents were used to create a model to study the relationship between early 
life stress, visceral sensation and depression related disorders including IBS.  It was indicated 
that water avoidance stress increased pain perception and activated somatosensory cortex, 
periaqueductal gray and hippocampus in the maternally separated rats.
97  
 In addition, maternally 
separated rats had significantly increased 5-HT content after colorectal distension.
98
  This model 
also pointed out that the colon of maternally separated rats had elevated circulating levels of 
interleukin-6 in addition to gut dysfunction.
99  
Considered together, neonatal maternal separation 
appears a stress in rats with exacerbated neurochemical, inflammatory responses, and visceral 
hyperalgesia in the colon and CNS comparable to IBS subjects.  A study to explore the 
childhood events among IBS adults confirmed that loss and separation during childhood, in the 
current family and conflicted or dependent maternal relationships were common among some 
IBS patients.
100  
Further psychosocial factors, for example coping strategies and social support 
are not further discussed here as they fall beyond the scope of the central theme being addressed.   
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1.5. Current IBS treatment 
Treatment recommendations for IBS were presented in the Rome III consensus document for 
functional bowel disorders in 2006.
2  
Since then no further up-to date treatment recommendations 
have been published by this working group.  A number of reviews provide current treatment 
options, especially dealing with pharmacologic treatments.
101 
 There is no single curative 
treatment for IBS, and therapy is aimed at reducing the symptoms, often with very little 
success.
19  
A caring and therapeutic physician-patient relationship is one of the cornerstones of 
managing IBS.  A confident diagnosis, assurance of the benignity of the condition, an 
explanation as to why symptoms occur and suggestions on how to cope with them are key 
elements.  The patient’s need for reassurance and knowledge is reflected in health care 
utilization, as those patients feeling insufficiently informed will have more health care visits.
102  
Overall, patients have more confidence in the effectiveness of education and advice about 
lifestyle modification than in pharmacotherapy.
103  
The traditional approach to therapy for IBS 
has been largely limited to an individual symptom-specific approach.  Such symptom-based 
therapies have had limited efficacy in treating the entire syndrome complex and have had no 
impact on the natural history of the disorder.
104  
Current mainstays of treatment include; diet and 
lifestyle modification, pharmacological treatment, psychological treatment and pro, pre and 
symbiotics.  Diet and probiotic treatment are discussed in sections 3.2 and 2.5 respectively.   
 
1.5.1. Pharmacological treatment 
Pharmacotherapy is not necessary for all IBS patients, but when needed, it should be directed 
towards the predominant symptom (Table 2).  Because of the abnormalities in bowel states 
associated with each IBS subtype, it is not likely that one agent would successfully treat all three 
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subtypes.  As a result, clinical trials have focused, for the most part, on one IBS subtype.  Over 
the past two decades very few agents have achieved regulatory approval for the treatment of 
IBS.
101  
Significant methodological inadequacies were recognised in early IBS trials and the 
classic publication by Klein
105
over two decades ago concluded that not a single study offered 
convincing evidence that any therapy is effective in treating IBS.  In spite of improvement in the 
design of more recent trials, meta-analysis sums up that many of the routinely used therapies for 
IBS are of dubious efficacy.
45  
The traditional approach to therapy for IBS has largely been 
limited to an individual symptom-specific approach.  These therapies include the use of bulking 
agents, antidiarrhoeal and antispasmodics.  With the developing understanding of the 
mechanisms and mediators involved in GI motility and secretory function, novel therapies are 
emerging that hold promise.  These therapies include new generation 5-HT4 agonists, novel 5-
HT3 antagonists, secretagogues, anti-inflammatory agents, peripheral visceral analgesics and a 
centrally acting benzodiazepine receptor modulator.  Diarrhoea is treated primarily with 
loperamide, constipation with dietary fiber or commercial fiber analogues and pain with smooth-
muscle relaxants and serotonergic agents.     
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Table 2. Pharmacological treatment for IBS 
Type of drug Drug IBS subtype Rationale for use 
Bulking agent Psyllium 
(soluble fiber) 
Ispaghula 
(soluble fiber) 
Calcium 
polycarbophil 
(soluble fiber) 
C-IBS Historically, evidence for bulking agents role in IBS was limited.
106  
However, meta-analysis has 
consistently reported the effectiveness of bulking agents in improving global IBS symptoms and 
reducing symptom severity.
107,108  
Despite these findings, bulking agents have not been 
demonstrated to improve quality of life in IBS.
107  
Given their benign safety profile, bulking 
agents appear to be an appropriate initial therapy in those with mild symptoms. 
Antidiarrhoeal Loperamide D-IBS A traditional antidiarrhoeal that has been used in the treatment of D-IBS.  Although it has 
consistently demonstrated effectiveness in improving stool characteristics and improving 
diarrhoea, it has not been shown to be effective in ameliorating IBS symptoms or abdominal 
pain.
42,109
 Therefore, loperamide appears to have a limited role in the effectiveness of D-IBS. 
Antispasmodics Hyosine 
Peppermint oil 
D-IBS 
C-IBS 
A recent well performed meta-analysis reported on the relative risk (RR) of persistent symptoms 
after therapy with antispasmodics compared with placebo 0.68 (95% CI 0.57-0.81) with a number 
-needed-to –treat (NNT) to prevent symptoms of IBS of five.108  Hyoscine and peppermint oil 
appear to be the most effective agents in this class.
42,108
 
Serotonergic (5-
HT4 agonist) 
Prucalopride  A 5-HT4 agonist with high selectivity and affinity that has promising findings without significant 
adverse events in patients with chronic constipation, which include accelerating colonic transit, 
improving bowel function and the frequency of bowel movements, improving satisfaction with 
bowel movements, decreasing perceived severity of constipation and improving constipation-
related QoL.
110-113  
Should these findings extend similarly for patients with C-IBS, then 
prucalopride may become an important therapy in the near future. 
 Tegaserod 
(Zelnorm) 
C-IBS Significant improvement in the Subject’s Global Assessment (SGA) of relief, bloating, stool 
frequency, stool consistency, abdominal pain/discomfort, bowel habit and satisfaction with bowel 
habit and number of days with straining.
114
 
Secretagogues 
(prostone-
stimulates 
chloride ion 
secretion in gut) 
Lubiprostone 
(Amitiza) 
C-IBS A bicyclic fatty-acid derivative of prostaglandin E1 and an activator of CIC-2 (chloride channels), 
is thought to increase secretion of intestinal fluid and thereby have a positive enterokinetic effect 
on the small intestine and colon.
115-117  
It has shown to improve abdominal discomfort, bloating, 
constipation severity, straining and stool consistency
118
 and overall responder status in treatment 
compared to placebo group.
119
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Table 2. continued 
Type of drug Drug IBS subtype Rationale for use 
Guanylate 
cyclase-C 
agonist – 
secretion of 
chloride and 
bicarbonate into 
intestinal 
lumen) 
Linaclotide C-IBS A first-in-class guanylate cyclase-C (GC-C) agonist that activates GC-C receptors located on the 
luminal membrane of enterocytes which results in activation of cystic fibrosis transport regulator 
(CFTR) and leads to increased intestinal chloride, bicarbonate and fluid secretion.
120  
Linaclotide 
has been found to significantly accelerate ascending colon transit time, improve ease of stool 
passage, improve stool consistency and increase stool frequency in women with C-IBS.
120
  
Significantly greater spontaneous bowel movement in treatment compared to control group.
121
   
Furthermore, there is growing evidence of its benefits on stool frequency and even QoL in patients 
with chronic constipation.
122,123
 
Anti-
inflammatory 
Prednisolone  Has been investigated in one randomized, double-blind, placebo-controlled trial in post infectious 
IBS and was ineffective in improving symptoms.
124
 
 Mesalazine (5-
aminosalicyclic 
acid) 
 Traditionally used in the treatment of inflammatory bowel disease, has had positive preliminary 
findings in IBS. A recent RCT in IBS patients found that a significant reduction of colonic immune 
cells, inhibited mast cells and increased general well-being without serious adverse events, 
however, it did not significantly alter abdominal pain, bloating or bowel habits.
125 
 Ketotifen  A recent preliminary report found that it increased the threshold for discomfort in patients with IBS 
and visceral hypersensitivity versus ‘normosensitive’ IBS patients, significantly decreased 
abdominal pain and other IBS symptoms including bloating and diarrhoea and improved QoL.
126
 
Antibiotics Rifaximin D-IBS 
A-IBS 
A gut-selective nonabsorbable antibiotic that has broad activity against gram-positive and gram-
negative anaerobes, has demonstrated the most promise.
127  
Rifaximin therapy has been shown to 
improve IBS symptom as well as bloating.
128,129  
However, most notable is that symptom 
improvements have been shown to be sustained for up to 12 weeks following therapy.
129  
This 
particular finding from a phase-II trial is especially noteworthy as this suggests that rifaximin may 
alter the natural history of IBS. Statistically significant improvement on adequate relief of global 
IBS symptoms has been shown in a recent Phase – III trial.130 
Peripheral 
visceral 
modulation (ĸ-
opioid receptor 
agonist) 
Asimadoline D-IBS 
C-IBS 
A-IBS 
Potential role in the visceral modulation of IBS as they are involved in the inhibition of noxious 
stimuli from the gut and are without the adverse side effects (e.g. constipation, opioid dependence) 
seen in µ-receptor agonists.
131  Asimadolene, a novel selective ĸ-opioid receptor agonist, has been 
demonstrated to significantly improve pain/discomfort in IBS, global IBS symptoms, improve 
urgency and frequency of stools and reduce pain scores.
132
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Table 2. Continued 
Type of drug Drug IBS subtype Rationale for use 
   However, on-demand dosing of asimadoline in IBS has not been demonstrated to be an effective 
method of treatment.
133
 
Benzodiazepine 
receptor 
modulation 
Dextofisopam D-IBS An R-enantiomer of tofiospam that binds to 2, 3-benzodiazepine receptors found within the central 
nervous system which are thought to have a role in the modulation of autonomic function.
134  
The 
role of dextofisopam in the treatment of D-IBS has been suggested with one RCT reporting 
significant improvements in consistency and frequency of bowel movements with D-IBS or A-
IBS.
134
 
Alosetron (5-
HT3 antagonist) 
Lotronex D-IBS Alosetron was the first new agent approved for the treatment of IBS in decades.  Following its 
approval, it was withdrawn from the market within one year due to safety reasons related to 
constipation and ischaemic colitis.  Alosetron was subsequently reintroduced under a risk 
management program and has only been approved in the USA.  A total of six published articles 
have reported  the results from seven phase 2 or 3 trials since the beginning of 2000
135-140  
 With 
each of these studies, alosetron showed significant improvement in patients with D-IBS across 
multiple symptoms of relevance.  Evaluation of alosetron’s treatment effect by gender and by IBS 
symptom severity showed greater efficacy in females and in subjects with more severe 
symptoms.
135,138,141  
Specifically, significant improvement was seen with females on the adequate 
relief of IBS pain and discomfort, control of urgency, stool consistency and stool frequency.
135-
139,141  
Patients taking alosteron also reported greater treatment satisfaction as compared to 
placebo.
141  
Although alosteron provided effective treatment for many IBS symptoms, a dose-
dependent increase in the adverse event of constipation (ranging from 4-39%) was seen across the 
studies.  Constipation was often reported as the main reason for early study withdrawal.
135-142
 
Antidepressants Amitriptyline 
(tricyclic 
antidepressant) 
D-IBS A phase II study has demonstrated a significant reduction in the treatment (as compared to the 
control) group for number of loose stools, sensation of incomplete evacuation and a greater 
treatment response (defined as an absence of all symptoms).
143
 
C-IBS – constipation predominant irritable bowel syndrome; D-IBS – diarrhoea predominant irritable bowel syndrome; A-IBS – alternating 
irritable bowel syndrome; RCT – randomized controlled trial; QoL – Quality of life; RR – relative risk; NNT – number needed to treat; GC-C – 
guanylate cyclase-C.
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Other pharmacological trial results include those for LX 1031, a locally acting, small molecule 
inhibitor of tryptophan hydroxylase, which is presumed to decrease mucosal production of 
serotonin.  In a phase II clinical trial with D-IBS and M-IBS patients, clinically and statistically 
significant benefit was seen on the primary endpoint of adequate relief as well as stool 
consistency.  Diarrhoea was the most common adverse event noted, although caution must be 
exercised as LX 1031 is a serotonergic acting agent.
144  
Furthermore, confirmatory studies with 
crofelemer.
145 
and agents acting at the neurokinin receptor
146 
are needed for use in D-IBS.  
Phloroglucinol/trimethylphloroglucinol, an antispasmodic agent, has shown significant reduction 
in pain intensity in D-IBS and C-IBS patients,
147
 but further confirmatory studies are needed. 
. 
1.5.2. Psychological treatment 
Psychological treatments may be useful in patients with moderate to severe symptoms when 
medical treatments have failed or when there is proof that stress or psychological factors 
exacerbate symptoms.
148  
Interpersonal psychotherapy, relaxation/stress management and 
cognitive behavioural therapy are the most common approaches that have been considered in 
IBS.  Critical evaluation of the efficacy of psychological treatments is hampered by the fact that 
trials cannot be double-blind, even though certain studies have included some form of control or 
placebo group.  Generally, psychological treatment is time-consuming and expensive, and in 
many circumstances it is unavailable, which further limits its employment in IBS management.
2
 
Hypnotherapy, one form of cognitive behavioural therapy, is one of the most widely studied 
psychological treatments in IBS.  Hypnosis can improve GI symptoms and quality of life
149,150
 as 
well as rectal hypersensitivity
 
in IBS.
151,152
  However, a Cochrane review
153
 identified 25 studies 
on hypnotherapy in IBS, but included only four in the final review after excluding 
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methodologically inadequate trials.  Though hypnosis was found to be superior to usual medical 
management in those patients who fail standard therapy, the low number of high-quality trials 
does not allow for any conclusions to be drawn. 
 
Although a great deal of research has been carried out into the area of the pathophysiology of 
IBS, it is complex and by no means completely understood.  Furthermore the different treatments 
have varying degrees of success, illustrating the complex nature of the syndrome.  It is important 
to bear in mind that IBS requires a holistic approach in determining effective treatment and 
understanding the underlying mechanisms. 
 
2. GI microbiota 
2.1 Human GI microbiota 
The human gut consists of about 10
13 
micro – organisms, collectively known as microbiota or 
microflora and more than 50 genera and over 400 species of bacteria have been identified in 
human faeces.
154,155 
 The microbiota consists of bacteria, fungi, protozoa and viruses and plays an 
important part in digestive and metabolic processes necessary for general health.  The bacterial 
microbiota are the best described and studied.
156  
Importantly, the description of the human 
microbiota diversity is an on- going process and complete coverage has not been achieved. 
 
The GI microbiota in healthy adults is generally considered highly individual and stable over 
time.
157,158  
Environmental factors e.g. antimicrobials, certain dietary modifications, certain 
diseases and psychological stress can alter an otherwise stable microbiota.
159  
A limited number 
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of bacterial groups make up the dominant microbiota.  Based on molecular methods, the two 
dominant groups, Clostridium coccoides-Eubacterium rectale (28%) and Clostridium leptum 
(25%), represent more than half of the total bacteria.  The most abundant bacterial groups after 
C.coccoides and C.leptum are Bacteroides (9%), Bifidobacterium (4%) and Atopodium (3%).  
The Lactobacillus-Enterococcus group represents approximately 2% of the total bacteria.
160
   
 
The GI microbiota has a considerable influence on host health and disease, both in the GI tract 
and systemically.
161  
Variations in the GI microbiota balance have been linked with several 
human diseases.  These include obesity,
162,163 Crohn’s Disease, ulcerative colitis and celiac 
disease.
164-166  
These conditions have been linked to less species variation and abnormal immune 
responses to GI bacteria.  Disturbances in the sensitive balance between the host and their GI 
microbiota (dysbiosis) can lead to changes in the mucosal immune system that range from 
obvious inflammation as seen in Crohn’s Disease to low grade inflammation evidenced in a 
subset of IBS patients.
167  
Research verifies the significance of the colonizing microbiota in 
determining the equilibrium of pro-inflammatory to regulatory cells in the gut.
168,169
    
 
2.2 GI microbiota in IBS 
The GI microbiota is comprised of two distinct ecosystems: luminal bacteria that are associated 
with faeces or food particles and mucosa-associated bacteria that are bound to the mucus layer 
adjacent to the intestinal epithelium.
170  
The GI microbiota has been proposed to play a critical 
role in GI homeostasis, and has been proposed to have host effects from immune-microbial 
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interactions.
170  
The theorized importance of the GI microbiota has led to investigations which 
seek to detect either quantitative or qualitative alterations of the microbiota in IBS.   
 
Small intestinal bacterial overgrowth (SIBO) has been proposed as a quantitative alteration of the 
GI microbiota that results in symptoms of IBS.  The role of SIBO in IBS has been supported by 
evidence that SIBO based on breath testing is highly prevalent in patients with symptoms of IBS, 
and that treatment of presumed SIBO resulted in improvements in global symptoms of IBS, 
abdominal pain, bloating and diarrhoea.
171  
However, these findings have not been supported by 
other studies.
172  
Furthermore, there is considerable controversy regarding the most appropriate 
standard by which to diagnose SIBO, breath tests versus small bowel aspirates and culture.
173
  
Although a recent systematic review and meta-analysis reported the prevalence of SIBO in 
patients with IBS to be between 4% and 64%, the significant heterogeneity among studies, 
funnel plot asymmetry, as well as attenuation of significant findings based upon SIBO criteria 
used, limited any conclusions that could be drawn.
174  
Despite the uncertainty, it certainly is 
notable that recent preliminary studies have found rifaximin; to be effective not only in 
improving D-IBS symptoms, but also may have sustained effects after cessation of therapy.
129
  
Regardless of the uncertainty surrounding SIBO in IBS, disturbances of the GI microbiota in IBS 
have been found.   
 
Post-infectious IBS (PI-IBS) is a common disorder wherein symptoms of IBS begin after an 
episode of acute gastroenteritis.  The occurrence of IBS following episodes of bacteriologically-
confirmed gastroenteritis has now been documented in several studies.
175-178  
PI-IBS may explain 
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only a minority of cases of IBS (1-6,7% in one study).
179  
But it does represent a clear link 
between exposure to an environmental agent and IBS in predisposed individuals. 
 
The faecal microbiota of IBS patients differ significantly from that of healthy subjects.
180
  
  
Balsari et al. studied stool samples of 20 IBS patients and noted a decrease in Coliforms, 
Lactobacilli and Bifidobacteria compared to healthy individuals.
181  
Similar results have been 
found in other studies.
182  
In contrast to Balsari et al. a recent study, using similar plating 
methods, found a significantly higher number of Coliforms in IBS.
183  
Among culture–
independent methods, fluorescent in situ hybridisation (FISH) analysis indicates a higher total 
bacterial population in IBS patients vs. healthy subjects.
184  
A further study that divided IBS 
patients according to subtype showed that D-IBS patients had lower numbers of Lactobacilli spp. 
while C-IBS patients had increased amounts of Veillonella spp.
185  
A microarray based analysis 
with the Human Intestinal Tract Chip (HITChip) revealed that the total microbiota of IBS 
patients is more heterogeneous than healthy controls.
186  
The microbiota in IBS is also 
characterised particularly by lower levels of Bacteroides and increased levels of the bacilli 
order.
186  
No single deviance has been identified in IBS microbiota, but various quantitative and 
qualitative alterations in the GI bacterial composition have, nonetheless, been indicated by a 
range of techniques.  An increasing amount of evidence supports the hypothesis of microbiota 
involvement in IBS pathophysiology.  Table 3 summarises the culture and molecular studies of 
the colonic microbiota in IBS to date.  Results to date are inconsistent and sometimes 
contradictory.  This may reflect differences in molecular techniques employed, the use of single 
samples not linked to fluctuating symptoms and other factors such as diet and phenotypic 
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characterization of patients.  In addition it should also be realised that faecal samples do not 
necessarily reflect other parts of the GI tract.   
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Table 3. Summary of culture and molecular studies of colonic microbiome in IBS 
Study  Subject Sample Method Patient 
group 
Main finding Country of study 
Balsari et al.181 IBS (n = 20) Ctrls (n 
= 20) 
Faeces Culture IBS ↓Coliform bacteria 
↓Lactobacillus spp. 
↓ Bifidobacterium spp. 
Italy 
Si et al.187 IBS (n = 25) Crtls (n 
= 25) 
Faeces Culture IBS ↓ Bifidobacterium 
↑ Enterobacteriaceae 
↓ C perfringens 
China 
Malinen et al.185 IBS ( n = 27) Crtls 
(n = 22) 
Faeces qPCR IBS 
 
D-IBS 
C-IBS 
↓B catenulatum 
↓CI coccoides group 
↓Lactobacillus spp. 
↑ Veillonella spp. 
↑ Lactobacillus spp. 
Finland 
Mättö et al.183 IBS (n = 26) Ctrls (n 
= 25) 
Faeces Culture 
PCR-DGGE 
IBS ↑ Coliform bacteria 
↑ Aerobe to anaerobe ratio 
↓ Temporal stability 
Finland 
Maukonen et al.188 IBS (n= 24) Ctrls 
(n=16) 
Faeces PCR-DGGE 
Affinity capture 
IBS 
C-IBS 
↓ Temporal stability 
↓ CI coccoides group 
Finland 
Kassinen et al.180 IBS (n = 24) Ctrls (n 
= 23) 
Faeces GC profiling + sequencing of 16S 
rRNA genes 
qPCR 
IBS ↓ Collinsella aerofaciens 
↓CI cocleatum 
↓ Coprococcus eutactus 
Subgroup diff (D, C, M) 
Finland 
Rajilić-
Stojanović186 
IBS (n = 20) Ctrls (n 
= 20) 
Faeces Microarray IBS Proteobacteria and specific Firmicutes ↑ 
Other Firmicutes, Bacteroidetes and 
bifidobacteria ↓ 
Finland 
Kerckhoffs et al.189 IBS (n = 41) Ctrls (n 
= 26) 
Faeces 
Duodenal mucosa 
FISH 
qPCR 
IBS ↓ Bifidobacterium spp. 
↓B catenulatum 
The Netherlands 
Krogius-Kurikka et 
al.190 
IBS-D (n = 10) Crtls 
(n = 23) 
Faeces GC-profiling + sequencing of 16S 
rRNA genes 
D-IBS ↑ Proteobacteria 
↑Firmicutes 
↓Actinobacteria 
↓Bacteroidetes 
Finland 
Lyra et al.191 
 
 
 
 
IBS (n = 20) Ctrls (n 
= 15) 
Faeces qPCR D-IBS 
 
C-IBS 
A-IBS 
↑ R torques 94% 
↓ CI thermosuccinogenes 85% 
↑ R bromii-like 
↓ R torques 93% 
↑ CI thermosuccinogenes 85% 
Finland 
Tana et al.182 IBS (n = 26) Ctrls (n 
= 26) 
Faeces Culture 
qPCR 
IBS ↑Veillonella spp. 
↑Lactobacillus spp. 
Japan 
Codling et al.192 IBS (n = 41) Ctrls (n 
= 33) 
Faeces 
Colonic mucosa 
PCR-DGGE IBS ↑ Temporal stability 
No significant difference faecal/mucosal 
Ireland 
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Table 3. continued 
 
Study  Subject Sample Method Patient 
group 
Main finding Country of study 
Carroll et al.193 IBS –D (n = 10) 
Ctrls (n = 10) 
Faeces 
Colonic biopsies 
Culture 
qPCR 
D-IBS ↓ Aerobic bacteria Lactobacillus spp. USA 
Noor et al.194 IBS (n = 11) Crtls (n 
= 22) UC (n = 13) 
Faeces PCR-DGGE + sequencing of 16S 
rRNA genes 
IBS ↓ Bacterial species 
↓Biodiversity 
↑Biological variability of predominant 
bacteria 
UK 
Malinen et al.195 
 
IBS (n = 44) Faeces qPCR  R torques 94% symptom severity 
Other phylotypes neg assoc 
Finland 
Ponnusamy et al.196 IBS (n = 11) Crtls (n 
= 8) 
Faeces DGGE + qPCR of 16sRNA genes  ↑Diversity in Bacteroidetes & Lactobacilli 
↑Alanine & pyroglutamic acid & phenolic 
compounds 
Korea 
Rinttila et al.197 IBS (n = 96) Crtls (n 
= 23) 
Faeces qPCR IBS S aureus (17%) Finland 
Saulnier et al.198 IBS (n = 22) Crtls (n 
= 22) (Children) 
Faeces 16 Metagenomic sequencing and 
DNA microarray 
IBS ↑ γProteobacteria 
Classified IBS subtypes using sets of 
discriminant bacterial species 
USA 
Rajilić-Stojanović 
et al.199 
IBS (n = 62) Crtls (n 
= 42) 
Faeces Phylogenetic 16S rRNA 
microarray and qPCR 
IBS ↑ Proteobacteria and specific Firmicutes 
↓Other Firmicutes, Bacteroidetes and 
bifidobacteria 
Finland 
Carroll et al.200 IBS-D (n = 16)  
Ctrls (n = 21) 
Faeces 
Colonic mucosa 
T-RFLP fingerprinting of 16S 
rRNA – PCR 
D-IBS Diminished microbial biodiversity in 
faecal samples 
USA 
Parkes et al.201 IBS-D (n = 27), IBS 
– C (n = 26) Ctrls (n 
– 26) 
Colonic mucosa FISH 
Confocal microscopy 
IBS Expansion of mucosa-associated 
microbiota; mainly bacteroides and 
clostridia; association with IBS subgroups 
and symptoms 
UK 
Jeffrey et al.202 IBS (n = 37) Ctrls (n 
= 20) 
Faeces Pyrosequencing 16SrRNA  Clustering of IBS patients – normal-like 
versus abnormal microbiota composition 
(increased ratio of Firmicutes to 
Bacteroidetes); association with symptom 
profile 
Sweden 
Reprinted with permission from Simren et al.
203 
N – number of randomised subjects, B – Bifidobacterium, C – constipation, C-Clostridium, ctrls – controls, d- diarrhoea, DGGE – denaturing 
gradient gel electrophoresis, FISH – fluorescent in situ hybridisation, IBS – irritable bowel syndrome, L – Lactobacillus, qPCR – quantitative 
PCR, R – Ruminococcus, S – Staphylococcus, T-RFLP – terminal restriction fragment length polymorphism
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2.3 Overview of methods for analysing microbiota 
Until recent years, cultivation-based methods were the most widely applied means of studying 
the GI microbiota.
204  
Although broadly available, relatively inexpensive and having the 
potential for quantifying bacterial populations, its applicability is restricted to cultivable 
organisms.  It has been proposed that only 30 – 40% of the GI tract microbiota can be cultured 
by currently available methods.
205  
The development of culture-independent, molecular 
methods built on microbial nucleic acid sequence information has contributed to a dramatic 
increase in the knowledge of GI microbiota diversity.  Examples of these methods are 
quantitative polymerase chain reaction (qPCR), temperature/denaturing gradient gel 
electrophoresis, FISH, DNA microarrays and pyrosequencing.  Refer to Chapter 6 for further 
reading. 
 
2.4 Probiotics – definition and health effects 
The Food and Agriculture Organization of the WHO provides the most widely accepted 
definition of a probiotic as “live human microbial organisms that are administered to enhance the 
well-being of the host”.206  The most commonly used probiotics are lactobacilli, bifidobacteria 
and non-pathogenic yeasts such as Saccharomyces boulardii.  Products that are labelled 
‘probiotic’ are widely available; however few fulfil the above definition.  From a microbiological 
perspective, some may not contain sufficient live organisms following commercial or domestic 
storage or have been adequately tested to ensure they will survive transit through the GI tract.  
From an application perspective, some may not confer a claimed health benefit, either because 
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they have not undergone efficacy testing in humans or because what evidence is available is 
inadequate or negative.
207  
In the future, the definition of a probiotic may require modification, as 
there is experimental evidence that dead bacteria, bacterial components and substances secreted 
by bacteria (e.g. bacteriocins, conjugated linoleic acid) have physiologically relevant effects that 
contribute towards the well-being of an individual.
208 
 The more inclusive term ‘pharmabiotic’ 
has also been proposed to encompass entities that exert these potentially important effects.
209
  
There is growing interest in probiotics as a safe manner in which to change GI bacterial flora.  
Probiotic preparations can be found in the form of powders, tablets, capsules, pastes, sprays or 
fermented foods such as yoghurts, buttermilk, sour poi (a starchy paste made from the corm of 
taro plants) and miso (fermented soybean paste).  
 
There are several mechanisms by which probiotics exert their favourable effects.  Different 
strains of organisms have very different and specialised metabolic activity.  Main mechanisms 
include i) mucosal adherence and inhibition of pathogenic bacteria adherence, ii) enhanced 
barrier function of epithelium, iii) secretion of bacteriocins, iv) acidification of the colon by 
nutrient fermentation, v) immuno-modulatory actins, vi) alteration in mucosal response to stress 
and vii) inhibition of visceral hypersensitivity.
210
 
 
There is strong evidence for clinical effectiveness of probiotics in clinical conditions like 
antibiotic-associated diarrhoea (S. boulardii
211,212 
and Lactobacillus GG
213,214
), pouchitis (VSL 
#3, a combination of eight different strains
215,216
) and in the treatment of childhood diarrhoea 
(Bifodobacteria
217
).  There is suggestive evidence for the prevention of adult and childhood 
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diarrhoea (L. GG,
218,219 
L. casei,
220,221
L. acidophilus
222,223
 and S. boulardii
224
) and to improve 
immune response (L. GG,
225 
L.acidophilus,
226 
B. lactis
227 
and L. Johnsonii
228
).     There is 
evidence for the use of B. infantis,
229 
VSL #3,
230 
and L. plantarum 299v
231,232
 in the treatment of 
IBS although not enough studies to make a strong recommendation.
233
   
 
2.5 Probiotic clinical trials in IBS 
A number of randomised, placebo-controlled trials on the efficacy of probiotics or combinations 
of probiotics in IBS have been published (Articles 1 and 2 in Chapters 2 and 3 respectively).  
Furthermore, a recent Rome Foundation group report identified 28 randomised controlled trials 
(RCTs) of probiotics in adults with IBS and four RCTs in children
203
 and at least six systematic 
reviews (five of which included meta-analysis) that have been published on probiotics and 
IBS.
235  
Most of the meta-analysis indicated a beneficial impact of probiotics on global 
symptoms, abdominal pain and flatulence, whereas the impact on bloating was equivocal.  
However, aggregating the effects of different probiotics into a meta-analysis should be 
undertaken with caution.  Different probiotics have different microbiological characteristics that 
will inevitably impact on their efficacy.  Therefore, converting the findings from a meta-analysis 
into clinical guidelines (e.g. probiotics improve global symptoms of IBS) implies that all 
probiotics will result in a similar benefit, which may not be the case.
235
  
 
A systematic review by Brenner et al. assessed the effectiveness, safety and tolerability of 
probiotics in the treatment of IBS.  An assessment of the RCT’s methodology and statistical 
designs indicated that only B. infantis 35624 showed repeated efficacy.  The remaining study 
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designs were limited by poor study design suggesting that there is inadequate data to determine 
whether probiotics are an effective treatment for IBS.
236  
However the following studies do 
provide sufficient evidence to warrant further evaluation, particularly for single moieties L. 
plantarum 299v,
231,232,237 
L. salivarius UCC4331
229 
and L. acidophilus LB strain
238 
and 
combination probiotics; VSL #3
230
 and L.rhamnosus GG, L.rhamnosus LC705, B. Breve Bb99/B. 
anamalis spp. Lactis Bb12 and P. freudenreichii spp.shermanii JS.
239-241  
The Rome methodology 
scores as assessed by Brenner et al.
236
 for RCTs using L.plantarum 299v are given in Table 4.  
This data illustrates the poor study design used in these three RCTs. 
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Table 4.  Methodology scores for RCTs assessing L.plantarum 299v in IBS 
Study L. plantarum 299V
237
  L. plantarum 299V
232
  L. plantarum 299V
231
  
 
ROME criteria used to define IBS *  * 
Randomization  * * 
Parallel study design  * * 
Double-blinding  * * 
Complete follow-up (intention-to-
treat) 
* *  
No placebo run-in * * * 
Baseline observation period before 
trial initiation 
  * 
Treatment duration of 8 – 12 weeks 
or longer 
*   
Follow-up after treatment to assess 
symptoms 
  * 
Treatment compliance measured    
Sample size calculation is provided/ 
adequate sample enrolled 
   
Primary outcome = improvement in 
global 
IBS symptoms 
*   
Primary outcome based on patient 
Assessment 
* * * 
Validated scale used to measure 
improvement of IBS symptoms 
   
Rome methodology score 6/14 6/14 8/14 
Adapted from Brenner et al.
236
 
 
L. plantarum 299v has been the most studied strain from L. plantarum family.  It has shown in 
rats that it can reduce mucosal inflammation by adhering to the mucosal membrane and reducing 
gram-negative bacteria, which contain endotoxins.
242,243  
In vitro L. plantarum 299v increased IL-
10 synthesis and secretion and thereby demonstrated beneficial immunomodulatory activity.
244  
In a Swedish study of 60 patients with IBS given L. plantarum 299v or a placebo for 4 weeks, 
symptoms of flatulence and abdominal pain were significantly reduced in the intervention 
compared to control group.
231  
Johansson et al. showed a significant increase in stool volume and 
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a decrease in flatulence and slightly softer stools in an intervention group receiving L. plantarum 
299v as compared to controls.
245  
L. plantarum 299v has the following properties (demonstrated 
in animal models and/or humans); being of human origin, non-pathogenic, resistant to intestinal 
acid and bile, demonstrating the ability to adhere to human epithelial cells, demonstrating an 
ability to temporarily colonise and be metabolically active within the human GI tract, survive 
transit through the GI tract and be free of side effects.
242,246-250
    
 
The role of probiotics in GI disease, in particular IBS, has clearly not been determined 
adequately.  Although questions exist on dosage and viability of probiotic strains, lack of 
industry standardization and potential safety issues (with specific regard to immuno-
compromised or seriously ill patients),
251 
there is substantial clinical evidence for the 
advantageous use of probiotics over a wide range of clinical conditions.  
 
Probiotics may be a 
safe and effective solution urgently needed in the treatment and management of IBS.
  
 
3. Nutrient intake and IBS 
Postprandial worsening of symptoms, as well as adverse reactions to one or more foods are 
common in patients with IBS,
252 
and self-reported food intolerance in IBS is associated with a 
high symptom burden and reduced quality of life.
253  
In line with this, approximately two thirds 
of IBS patients exclude food items from their diet to improve symptoms.
254  
Foods rich in fat
252
 
and carbohydrates
255-257 
especially cause problems.  Female gender and anxiety seem to predict a 
higher degree of food-related symptoms in IBS patients.
252  
Food intake can be a trigger of GI 
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symptoms in IBS
252,258,259
 and patients often consider food intolerance to be relevant for many of 
their symptoms.
260  
Several studies report that people with IBS often avoid different food items as 
a way of coping with the disease, which possible could lead to a lower intake of essential 
nutrients.
252,254,261  
However, patients with IBS seem to have a body mass index (BMI) 
comparable to the general population.
252  
Despite the fact that IBS patients consider food and diet 
to be central issues,
262 
few studies have thoroughly explored the dietary intake of patients with 
IBS and problems with existing studies include the use of retrospective food frequency 
questionnaires, with the risk of recall bias,
263-265
 and the influence of IBS subtype is even less 
well studied.
253
   
 
3.1. Reproducibility and validity of dietary data in IBS  
To the writer’s knowledge there is no published data evaluating the validity and reproducibility 
of dietary intake in IBS patients.  The reproducibility of a dietary assessment method reflects the 
ability of the method to obtain identical results when administered at a later stage under similar 
circumstances, assuming nothing has changed in the interim.
266  
While the validity reflects the 
ability of a dietary method to accurately measure what the participants have actually eaten.
267
  
Researchers commonly use these two characteristics to evaluate the measurement properties of 
dietary assessment methods.
268
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3.1.1. Reproducibility 
Reproducibility sometimes called reliability is the minimum quality required for an assessment 
method.
268  
In reproducibility studies the instrument is compared with an earlier administration of 
the same instrument.  It should be recognised at the outset that a reproducibility study does not 
tell anything about whether the instrument is producing the correct answer, only whether it is 
producing the same answer.  There are a number of reasons for doing reproducibility studies.  
Firstly, they are relatively easy to do and provide a partial answer to the question of validity; an 
instrument surely cannot give the correct answer every time if it cannot give more or less the 
same answer each time.
269  
Reproducibility studies can also uncover problems in instrument 
design, respondent instructions, or quality control that can aid the investigator in improving the 
questionnaire.  Furthermore, once the reproducibility of the questionnaire is known, investigators 
can use that information to estimate the gain that would accrue from the use of two 
administrations of the questionnaire, instead of one, in the study design, or to judge the degree of 
dietary change that could be detected between two administrations.
269
 
 
Several factors can affect the reproducibility of estimates from a questionnaire, some of which 
are often overlooked.  Respondents may be simply unable to estimate their diets reliability; 
however, it is likely that this explanation of poor reproducibility is less important than other, 
more methodological explanations.  The most obvious of these is that in the elapsed time 
between the two administrations, real dietary change has taken place.  The longer the elapsed 
time, the more likely this is to have occurred.  For this reason, it might be preferable to 
administer the second questionnaire within a fairly short time, e.g. 4-8 weeks, long enough so 
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that the respondent is not simply remembering what he or she said before, and short enough to 
minimise real dietary changes in the interim.  An important factor affecting the reproducibility of 
a questionnaire is the variability which it permits.  An instrument which does not include 
variable portion sizes for each food permits less variability, and is likely to have a higher 
reproducibility score, than one which does not (e.g. food records).  Similarly, a questionnaire 
which limits responses about the frequency of consumption to a few categories is likely to be 
more reproducible than one in which the respondent has an unlimited choice of responses.  
Because of this, a high level of reproducibility, though welcome, is not sufficient; a high level of 
validity is also necessary.
269  
The error-proneness of the questionnaire design, or inadequate 
instructions to the respondent, can also affect reproducibility.  Finally, poor reproducibility can 
result from poor quality control, again something under the control of the investigator.  
Inadequate attention to recoding and double keying can produce simple coding or typing errors 
which lead to apparent poor reproducibility.
269
   
 
3.1.2. Validity 
Several terms are used to refer to investigations that collect dietary data from a subset of study 
subjects by using two different assessment methods and which compare the data of the one 
method to the other, with the aim to determine the level of comparability or the relationship 
between the two methods.  These terms include ‘validation’, ‘calibration’, and 
‘standardisation’.270  Dietary methods designed to characterise usual intakes of individuals are the 
most difficult to validate, since the ‘truth’ is never known with absolute certainty.272  Relative 
validity, in which a new method (i.e. test method) is compared to with an existing method known 
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to be valid (i.e. reference method) is the most practical validation method to use.  Absolute 
validity implies that the reference method reflects the true dietary intake, while relative validity 
recognises that the reference method itself is subject to error.
267 
 Therefore, the extent of 
agreement between the test and reference methods is used to indicate the relative validity of the 
test method and the extent to which the reference method is believed to yield the truth. 
 
All calibration studies may not have the same primary aim but the goal that has been most 
frequently described is to use information from the calibration study to adjust the relative risks 
estimated from the main epidemiologic study for the measurement error associated with the use 
of the questionnaire.  It is well known that the measurement error biases the estimated relative 
risks, thereby creating the need for such an adjustment.
271  
Another aim of calibration studies is to 
estimate the sample size required in the main study.  This estimate is important because the 
sample size required for an investigation depends heavily on the degree of measured error 
associated with the questionnaire.  A third aim is to estimate the correlation between intake from 
the food record or food frequency questionnaire and true usual intake.  This evaluation may be 
critically important if a food frequency questionnaire has been modified extensively from earlier 
versions or is to be used in a population from which little information has been previously 
obtained.  If the correlations are low, the investigators may postpone the main study until 
improvements are made in the design of the food frequency questionnaire or in the way in which 
the questionnaire is presented to the participants.  Finally, many calibration studies are conducted 
to estimate the slope of regression of intake from the food record on usual intake, a variable that 
is important in assessing the patterns of bias that may result from the use of the questionnaire.
271
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Food records (e.g. 3 day estimated food record as used in this study) are often used as a reference 
method for the determination of the relative validity of other dietary assessment methods (e.g. 
food frequency questionnaires), few studies report on the validity and reliability of food records 
themselves.  Numerous factors may affect the validity, or apparent validity, of a diet 
questionnaire.  These factors include 1) respondent characteristics, 2) questionnaire design and 
quantification, 3) adequacy of the reference data and 4) quality control of data management.  Of 
all of these, the latter three are likely to be more important than the first.
272
   
 
3.1.3. Biochemical markers  
Biomarkers are being increasingly used in nutritional epidemiology to assist in dietary 
measurement and to deal with the problems associated with self-reported dietary intake.  The use 
of biomarkers, such as plasma fatty acids (FA), is a more objective approach to assess the 
validity of dietary intake data.
273  
These methods may however, be expensive and impractical 
(e.g. the collection of 24-hour urine samples).  The fundamental advantage of using a biomarker 
is that measurement errors are unrelated with errors in any dietary assessments, e.g. do not rely 
on memory, self-reported information or interviewer bias.  There are no biomarkers that reflect 
absolute fat intake, however, measurement of FAs in various biological samples reflects to some 
extent, proportional intake of FAs.
274  
The intake of FAs may be reflected in various serum (or 
plasma) lipids, platelet and erythrocytes phospholipids.  The FA composition of plasma lipids 
reflects the type of dietary fat and may be an objective estimate of the type of fats proportionally 
consumed by an individual.  The FA composition of plasma reflects medium-term (weeks to 
months) dietary intake.
275  Essential polyunsaturated FAs (linoleic acid and α-linolenic acid) 
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cannot be synthesized de novo by humans and play an important role in health.  Øverby et al. 
performed a systematic review on 14 papers and found that blood lipid n-3 fatty acids correlated 
well with different dietary assessment methods.  The blood lipid correlations were similar to 
those observed for subcutaneous fat, which literature describes as the best reference method.
276
  
As the source of these biologically active FAs is exogenous they may be particularly good 
biomarkers markers to use.
274
   
 
3.2. Dietary management of IBS 
The British Dietetic Association recently published a set of evidence-based guidelines for the 
dietary management of IBS in adults.
277  
However, evidence-based guidelines for dietetic practice 
are difficult to give, as there are very few randomized, controlled trials on dietary treatment of 
IBS patients and much of the evidence is of poor quality and limited by the lack of suitable 
papers.  First-line dietary advice consists of assessing dietary choices, eating habits and lifestyle 
factors.  Before a first appointment, it may be useful to ask individuals to keep a food and 
symptom diary.  Consider the frequency and timing of symptoms (e.g. meal-related, daily, 
nocturnal, weekdays, weekends, holidays, exercise induced and, for women, whether symptoms 
are related to their menstrual cycle).  With specific food avoidances: explore how the individual 
thinks foods affect their IBS symptoms.  Assess the eating pattern and usual dietary intake of 
dietary fiber, fatty foods, fluid, caffeine, alcohol and milk and/or lactose.  Encourage healthy 
eating patterns with a good variety of foods to achieve nutritional adequacy.  Use general healthy 
eating guidelines with special attention to regular eating, good eating behaviour (taking time over 
meals, sitting down to eat, chewing food thoroughly and not eating late at night) and drinking 
plenty of caffeine free, alcohol free, non-fizzy fluids throughout the day.
277  
The clinical practice 
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recommendations as agreed by the IBS – dietetic guideline development group (IBS-DGDG)277 
are shown in Table 5 below.  Standard levels of evidence and grading recommendations as set 
out by the Scottish Intercollegiate Guidelines Network
278 
were used, an A grade evidence 
ranking as the highest and D the lowest.     
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 
 
Table 5. Dietary clinical practice recommendations for IBS 
 Grade of recommendation 
1.0 Removing milk and dairy products to improve IBS symptoms  
In individuals where sensitivity to milk is suspected and a lactose hydrogen breath test is not available or appropriate, a trial 
period of a low lactose diet is recommended. This is particularly useful in individuals with an ethnic background with a high 
prevalence of primary lactase deficiency.  A detailed dietary assessment of milk and/or lactose intake should be used not only 
to assess specific nutrient intake (e.g. calcium) but also to assess lactose intolerance. 
D 
Use a low lactose diet to treat individuals with a positive lactose hydrogen breath test.  Gradual lactose reintroduction may be 
useful to determine an individual’s lactose tolerance threshold 
D 
In individuals where milk is suspected as a problem food and symptoms do not improve on a low lactose diet, assess other 
components of milk (e.g. cow’s milk protein) as a contributing factor.  Recommend a milk free diet or, in some cases, an 
alternative mammalian milk (goat’s or sheep).  If cow’s milk protein is not tolerated, the initial recommendation should be a 
non-mammalian alternative milk (e.g. soya, rice, oat, quinoa, nut, coconut or pea), preferably calcium fortified. 
D 
2.0 Non starch polysaccharides  
Avoid using dietary supplementation of wheat bran to treat IBS. Individuals should not be advised to increase their intake of 
wheat bran above their usual dietary intake 
C 
For individuals with C-IBS, dietary supplementation of ground linseeds (initial dose to start at one teaspoon to one 
tablespoon per day and build to a maximum of four tablespoons per day with a drink, can be added to food, e.g. yoghurt, 
breakfast cereal, soup and salads) can be recommended for a 3-month trial.  Improvements in constipation, abdominal pain 
and bloating from linseed supplementation may be gradual 
D 
3.0 Fermentable carbohydrates  
For individuals with IBS and suspected or diagnosed fructose malabsorption, assess dietary intake of all short-chain 
fermentable carbohydrates (fructose, fructans, galacto-oligosaccharides and polyols). There is likely to be a benefit in 
reducing intake 
B 
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Table 5. continued 
3.0 Fermentable carbohydrates  
 
Grade of recommendation 
For individuals with IBS and abdominal bloating, abdominal pain and/or flatulence, assess dietary intake of fermentable 
carbohydrates because there may be a benefit in reducing intake 
D 
There may be individual tolerance levels to fermentable carbohydrates. A planned and systematic challenge of foods high in 
fermentable carbohydrates will identify which foods can be reintroduced to the diet and what individual tolerance levels are  
D 
4.0 Empirical and elimination diets  
Where food is considered to be a trigger for IBS symptoms, particularly D-IBS, an elimination or empirical diet can be 
considered 
D 
The initial phase of an elimination or empirical diet should be followed for 2–4 weeks, to complete they usually take 3-4 
months, including the re-introduction phase  
D 
If there is no symptom improvement within 2–4 weeks of the initial phase of an elimination or empirical diet and foods 
consumed within the diet were not suspected symptom triggers, specific foods are an unlikely cause of IBS symptoms 
D 
Adapted from McKenzie et al.
277  
IBS, irritable bowel syndrome; C-IBS, constipation predominant irritable bowel syndrome; D-IBS, 
diarrhoea predominant irritable bowel syndrome; IBS-M, irritable bowel syndrome with mixed bowel pattern. 
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3.2.1. Milk and dairy products  
Many individuals with IBS have tried milk or dairy avoidance and often have low calcium 
intakes.
279  
To avoid unnecessary exclusion and potential deficiencies, it is important to review 
the evidence for removing milk and dairy products, which includes lactose avoidance, and its 
effectiveness in improving IBS symptoms.  Lactose is a disaccharide uniquely found in 
mammalian milk that is hydrolysed by the enzyme lactase.  A genetically programmed decline in 
lactase activity after weaning resulting in lactase non persistence occurs in 70% of individuals, 
depending on ethnicity.
280  
Lactose malabsorption is defined as incomplete hydrolysis of lactase 
resulting in unabsorbed lactose in the colonic lumen,
281 
and leads to GI symptoms similar to 
those of IBS.
282  
Because IBS and lactose intolerance have similar symptom profiles, a lactose 
hydrogen breath test can be useful to distinguish between the two and may assist with dietary 
management.  However, hydrogen breath test facilities are not always available and the results 
may be inconclusive.  In such circumstances, exclusion and challenge with lactose containing 
foods can be useful for assessing tolerance.    Five non-randomized controlled trials assessed 
either a low lactose diet compared to no dietary restriction or no dietary intervention and were 
used to draw up the evidence based statements and recommendations
283-287
 given in Table 5. 
 
3.2.2. Non-starch polysaccharides (NSP) 
NSP (dietary fiber) are composed of ‘non-α-glucan polysaccharides that are mainly found in 
plant cell walls.  This includes cellulose, hemicellulose, pectin, arabinoxylans, plant gums, ß-
glucans.
288  
Soluble fiber (e.g. pectin, ß-glucan from oats and barley, and gums in psyllium) 
generally undergoes significant fermentation, whereas insoluble fiber (e.g. celluloses, some 
hemicellulose and lignin) tends to undergo slow and incomplete fermentation and has a greater 
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effect on bowel habit by increasing faecal weight.
288  
Alterations in NSP intake have traditionally 
been the mainstay of dietary management of IBS.  There is conflicting evidence for increasing or 
decreasing intakes.  The ten RCTs used to draw up the guidelines presented in Table 5,
289-298
 
assessed the research specifically relating to NSP that is provided within the diet, including food 
supplementation (i.e. using any wheat bran, ground linseeds and psyllium husk) and does not 
assess medicines or herbal preparations.  Nor did any intervention use oats, other bran types or 
whole linseeds.
277
   
 
3.2.3. Fermentable carbohydrates 
Fermentable carbohydrates are poorly absorbed, osmotically active and undergo bacterial 
fermentation in the human GI tract, leading to loose stools and gas production.
299-300  
They 
include fructo-oligosscarides (e.g. fructans in wheat and onion), galacto-oligosaccharides (GOS) 
(e.g. in beans and pulses), disaccharides [e.g. lactose in milk and dairy products, 
monosaccharides (in particular fructose in excess of glucose, e.g. mango, honey or a high 
fructose load, e.g. fruit juice, fructose ingredients in processed foods and drinks)], and polyols 
(e.g. sorbitol in various fruit and vegetables, polyol sweetened sugar-free manufactured foods 
and medicines) – acronym FODMAPS and resistant starches (e.g. in green banana, cold or 
reheated potato).  Four RCTs met the inclusion criteria and were used to compile the evidence 
statements developed in Table 5.  The studies assessed the intake of fructose, fructans, namely 
FOS, and sorbitol in relation to symptom provocation or trans-GOS in relation to symptom 
reduction.  No studies assessed resistant starch.
255,301-303
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The hypothesis that reducing intake of FODMAPs can improve GI symptoms stems from clinical 
observation that a proportion of patients with IBS tolerate intake of certain short –chain 
carbohydrates poorly.
304  
Moreover, these carbohydrates can be incompletely absorbed in the 
small intestine due to hydrolyzation (e.g. lactose maldigestion and non-digestible 
oligosaccharides), dependence on simultaneous intake of glucose for adequate absorption 
(fructose) or passive diffusion (certain monosaccharides and polyols).
305  
Therefore, the 
absorption of short-chain carbohydrates in the small intestine varies depending on different 
factors such as presence/absence of enzymes to digest disaccharides (e.g. lactase), small 
intestinal transit time, dose of the carbohydrate, meal composition, and also on the presence of 
mucosal disease.
305
 
 
The scientific evidence supporting a clinically relevant positive effect of reducing FODMAPS in 
IBS has so far been relatively limited, but gradually accumulating over the last few years and 
has, besides, observational reports, mainly been based on a randomized single-blinded FODMAP 
challenge study,
255 
a nonrandomized, comparative study,
306 
and a randomized, controlled trial 
comparing a low FODMAP diet with the habitual diet in IBS.
306  
Moreover, a recent study also 
demonstrated that a general reduction of FODMAPs in the diet was effective in patients with 
suspected nonceliac gluten sensitivity, and no gluten-specific effect beyond that of the effect of 
the general FODMAP reduction could be demonstrated.
307  
Because few clinical trials in this area 
exist, a very recent study by Halmos et al.
308
 is very important because it provides high-quality 
evidence supporting the effectiveness of a low-FODMAP diet in IBS.  By using a randomized, 
cross-over design (n = 30 IBS and n = 8 healthy controls), the authors were able to demonstrate a 
convincing reduction of the reported severity of all the key symptoms of IBS – abdominal pain, 
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bloating and bowel habit dissatisfaction – when the patients were on a low-FODMAP diet (22.8; 
95% confidence interval (CI), 16.7-28.8mm) compared to when they received a standard 
Australian diet (44.9; 95% CI, 36.6-53.1mm; p <0.001).  It is important to bear in mind that so 
far, no study has demonstrated that a low FODMAP diet is superior to the dietetic practise that 
has been used for patients with IBS before a low-FODMAP diet was suggested as a treatment 
alternative for IBS, that is, to encourage a regular meal pattern and a “healthy eating,” to avoid 
large meals, reduce the intake of fat, discourage excessive fiber intake (especially soluble fiber), 
reduce caffeine, and avoid gas-producing foods, such as beans, cabbage and onions.
309
 
 
3.2.4. Elimination and empirical diets   
Empirical and elimination diets have traditionally been used to identify food intolerances in 
individuals with IBS.  There is no standard diet describing which foods or ingredients should be 
excluded.  An exclusion diet excludes one or two foods suspected to be responsible for 
symptoms.  An elimination or few foods diet includes a selection of low allergen foods, usually 
one type of meat, one cereal, two fruit and vegetables, a milk substitute and a fat source.  An 
empirical diet excludes common food allergens associated with a specific condition when a 
dietary source is suspected but cannot be identified.
310  
Six studies met the inclusion criteria and 
were evaluated to draw up the evidence statements in Table 5.  Two were RCTs comparing an 
elimination diet to sodium chromoglicate and the remaining four were intervention studies using 
an empirical or elimination diet followed by food challenge.
311-316
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4. The GI microbiota and diet 
Diet is a factor that undoubtedly influences the composition of the GI microbiota.  Diet provides 
nutrients for both the host and bacteria in the GI tract.  Most of the enzymes needed to break 
down the structural polysaccharides in plant material are not encoded by mammalian 
genomes.
317  
However, the GI microbiota produces a large collection of degradable enzymes that 
exhibit a broad range of metabolic activities.
318
  
 
It is estimated that 20 – 60g of dietary carbohydrate reaches the colon on a daily basis, including 
resistant starch, NSP, plant cell wall polysaccharides and non-digestible oligosaccharides.
318
  
Some dietary proteins (e.g. collagen and elastin) as well as secondary plant metabolites (e.g. 
polyphenolic substances) can also reach the large intestine and undergo bacterial 
transformation.
319,320  
Changes to the composition of the GI microbiota in response to dietary 
intake occur because different bacterial species are better equipped (genetically) to utilize 
different substrates.
321  
Generally, bacteria favour carbohydrates as primary energy sources if 
they are available.
322
  
 
Early studies comparing dietary patterns (e.g. Japanese vs. Western) or examining the impact of 
changing the proportions of food categories on the GI microbiota have found only moderate 
effects on the GI microbiota involving a few genera.
323-325  
These studies relied on culture-based 
techniques and were, therefore, limited in their ability to detect changes in the finer detail of the 
composition of the GI microbiota.  More recent studies have employed culture-independent 
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approaches and have further elucidated the role of diet in the determination of the composition of 
the GI microbiota in humans (Table 6).
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Table 6. Associations of the human intestinal microbiota with habitual dietary patterns or interventions 
Authors Methods Study design Subjects Diets/nutrients Microbial response 
Claesson et al.326 16s rDNA sequencing Cross-sectional 178 elderly subjects (age 64-
102 years) – community, day 
hospital, rehabilitation and 
long-stay subjects 
“community” diet – diverse 
with low-moderate fat/high 
fiber 
“long-stay” diet –reduced 
diversity with moderate – 
high fat/low-moderate fiber 
↑ Diversity, ↑Firmicutes, ↑ Coprococcus, Roseburia 
 
↓Diversity, ↑Bactericides,  
↑Parabacteroides, Eubacterium, Anaerotruncus, 
Lactonifactor and Coprobacillus 
De Filippo et 
al.327 
16s rDNA sequencing and 
biochemical analysis 
Cross-sectional Twenty-nine children (1-6 
years) – African children 
from Burkina Faso (n = 14) 
and European children from 
Florence, Italy (n = 15) 
“Western” diet – high fat/ 
protein/sugar and low fiber 
“Rural diet – low fat/protein 
and high fiber 
↑ Firmicutes, ↑Enterobacteriaceae 
 
↑Bacteroidetes, Exclusively present: Prevotella, 
Xylanibacter, Butyrivibrio and Treponema, ↑SCFA 
De Palma et al.328 FISH and qPCR Feeding (1 month) Ten healthy subjects (mean 
age 30.3 years) 
Gluten-free diet (reduced 
polysaccharide) 
↓ Bifidobacterium, Lactobacillus, Clostridium lituseburense 
and Faecalibacterium prausnitzii 
↑ Enterobacteriaceae and Echerichia coli 
Kabeerdoss et 
al.329 
qPCR Cross-sectional Fifty-six healthy female 
subjects (age 18-27 years): n 
= 32 vegetarians and n = 24 
omnivores 
Vegetarian diet ↓Clostridium cluster XIVa, ↓Roseburia – Eubacterium 
rectale, ↓butyryl-CoA CoA-transferase gene 
Liszt et al.330 qPCR and PCR-DGGE Cross-sectional Twenty-nine healthy subjects 
(age 19-34 years) – n = 15 
vegetarians and n = 14 
omnivores 
Vegetarian diet ↑Bacterial DNA tendency for ↓ Clostridium cluster IV and ↑ 
Bacteroides (but not significant) 
Muegge et al.331 16s RNA sequencing and 
shotgun metagenomics 
Cross-sectional Eighteen lean subjects (mean 
age 59.6 years) – members of 
a Calorie Restriction Society 
Proteins 
Insoluble fiber 
Associated with KEGG orthology groups 
Associated with bacterial OTU content 
Walker et al.332 16s rDNA sequencing and 
qPCR 
Randomized 
cross-over (3-
week 
intervention) 
Fourteen overweight male 
subjects (age 27-73 years) 
Diet high in resistant starch 
(type III) 
 
Reduced carbohydrate diet 
(weight-loss diet) 
↔Phylum level, ↑Ruminococcus bromii and E. rectale, ↑ 
Ruminococcaceae, ↑Oscillibacter valericigenes, ↑ Firmicutes 
bacteria related to Roseburia and E. rectale, ↔ Phylum level 
↓Collinsella aerofaciens, ↑O. valericigenes, ↓Firmicutes 
bacteria related to Roseburia and E. rectale 
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Table 6. continued 
Authors Methods Study design Subjects Diets/nutrients Microbial response 
Wu et al.333 16s rDNA sequencing and 
shotgun metagenomics 
Cross-sectional Ninety-eight healthy subjects 
(age 18-40 years) 
Fat 
Fiber 
Animal fat and protein 
Carbohydrates 
↑Bacteroidetes, Actinobacteria, ↓ Firmicutes, Proteobacteria 
↓ Bacteroidetes, Actinobacteria, ↑ Firmicutes, Proteobacteria 
Positively associated with Bacteroides enterotype 
Positively associated with Prevotelia enterotype 
Wu et al.333 16s rDNA sequencing and 
shotgun metagenomics 
Controlled 
feeding ( 10 day 
intervention) 
Ten subjects having 
Bacteroides enterotype (high 
fat/protein) 
Low-fat/high fiber diet or 
high-fat/low fiber diet 
Changes in the composition of microbiome detectable within 
24 hours of consuming diet; no stable switch in enterotype 
after 10 days 
Zimmer et al.334 Culture-based methods Cross-sectional 295 healthy subjects – 144 
vegetarians, 105 vegans, 46 
controls 
Vegetarian diet 
Vegan diet 
↓ stool pH 
↓stool pH, ↓Bacteroides spp., Bifidobacterium spp., E.coli 
and Enterobacteriaceae spp. 
Adapted from Power et al.
317
  ↑ - increased, ↓- decreased, ↔ - no change, FISH – fluorescent in situ hybridization, qPCR – quantitative real time 
PCR, DGGE – denaturing gradient gel electrophoresis, KEGG – Kyoto Encyclopedia of Genes and Genomes, OTU – operational taxonomic unit. 
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Based on the available data, differences in the GI microbiota are demonstrable between groups 
of people living on different diets.  These diet-associated changes in composition can lead to 
changes in the metabolic activity of the GI microbiota, which, in turn, may provoke changes in 
inflammatory and immune responses.  Although attempts to change the composition of the GI 
microbiota by varying the diet have been successful in mice,
335,336 
there is a relative paucity of 
human dietary intervention studies.  A complex tripartite relationship exists between diet, 
microbes and the gut epithelium.  Dietary patterns have a strong influence on the composition of 
the GI microbiota, as demonstrated by data in Table 6.  Not surprisingly, diet and the microbiota 
are two factors in the pathogenesis of IBS.  Although diet is a tempting intervention for GI 
dysbiosis, the understanding of how to manipulate diet to promote healthy microbiota is still in 
its early days.  Bacteriotherapy provides a novel approach for restoring healthy homeostasis 
through GI microbiota.  This can be achieved through the use of various interventions, including 
the removal of pathogenic bacteria with antibiotics, supplementation with probiotics and most 
recently, introduction of a new healthy microbial ecosystem by transplanting faecal bacteria from 
a healthy donor. 
  
5. Rationale for the study 
There is no single curative treatment for IBS.  This leaves these patients very dependent on the 
support of their health care team.  Often health care professionals are expected to advise or treat 
patients with anecdotal treatments that might be detrimental to their health.  The findings of this 
thesis are relevant to health care workers, notably doctors, nurses and dietitians, and are 
important because patients as well as the general public are becoming increasingly aware of the 
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effects of diet and probiotics in IBS.  The latter as a result of considerable media interest and 
intensive advertising campaigns.  Consequently there is a need for health care professionals to 
provide advice on whether probiotics and dietary manipulation might be helpful for patients with 
IBS and, if so, what are these recommendations.  Continual probiotic research necessitates that 
healthcare professionals keep a breast and informed of what is happening in this dynamic field, 
review articles provide a summary of the current understanding on this topic.  This gap in 
knowledge is further illustrated in Figure 2, a conceptual framework.   
 
To date, most RCTs on the utility of probiotics in IBS have not used appropriate study design 
and fall short on methodology.  Areas of poor design include Rome criteria not used to define 
IBS, no randomisation, parallel study design, double blinding, placebo run-in, baseline 
observation period before trial initiation, short treatment duration (< 8 weeks), follow-up, 
validated scale to measure outcomes, incomplete follow–up (intention-to-treat), treatment 
compliance not measured and sample size inadequate.
236,337  
The low quality design of the trials 
inevitably leads to the likes of concluding statements such as “further studies are needed to 
determine whether the probiotic under study may offer clinical benefits for IBS.”  Furthermore, 
effective treatment of IBS is often masked by its various groupings (C-IBS, D-IBS or PI-IBS) 
and their response to a particular treatment.  Much of the published data do not differentiate 
between the groupings or subgroups, making interpretation of reported results difficult.  
Effective treatment outcomes are further compounded by variations in indigenous microbiota, as 
observed in stool microbiota, and possible varying aetiology among patients.  Specific probiotic 
strains may work better in patients with either C-IBS or D-IBS.  Most clinical trials base 
probiotic intervention response on a subjective assessment of symptom change.  In this study 
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stool microbiota will additionally be used for a more objective assessment.  These gaps in 
knowledge are further illustrated in Figure 2 and sub-aims to conduct a well- designed  RCT of a 
known probiotic as part of an intervention and to determine whether the probiotic can favourable 
influence GI microbiota and patient symptom outcomes addresses these gaps.  
 
To our knowledge there is no published literature on the nutrient intakes of South African IBS 
patients, this is important information to know when up to two thirds of IBS patients exclude 
food items from their diet to improve symptoms.
254  
Because of this, these patients may be a 
nutritionally at-risk group.  Furthermore, the validity and reliability of any dietary data from IBS 
patients is unknown.  These gaps in knowledge are further illustrated in Figure 2, a conceptual 
framework.   
   
There is enough evidence to believe that dietary changes alter or modify the substrate for GI 
microbiota which influences normal gut symbiosis between GI microbiota and the intestinal 
mucosa (epithelial) layer as well as aiding in competitive relationships between GI bacteria.  
Although there is evidence that diets high in fiber provide substrate for certain microbiota, there 
are no clinical studies reflecting which microbiota are associated with certain nutrients in IBS 
patients.  Part of this study will examine the relationship between nutrient intake (exposures), GI 
microbiota, and IBS (outcomes), and addresses this gap in knowledge as illustrated in Figure 2.  
 
Specific gaps in knowledge relating to this research project are provided in Figure 2 as part of a 
conceptual framework.
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Figure 2. Conceptual framework depicting the possible influences of nutrient intake, the GI microbiota and probiotics on the 
pathogenesis of irritable bowel syndrome and health outcomes 
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5.1.Aim of the study 
The overarching aim of this study was to investigate the nutrient intakes, GI microbiota and the 
impact of a probiotic, L.plantarum 299v in IBS patients.  
 
5.2. Sub-aims The gaps in knowledge as identified in Figure 2 will be addressed by the 
following sub-aims: 
 Literature review: To update healthcare professionals on current probiotic information and 
provide an overview of probiotic treatment approaches, with special emphasis on IBS 
(Article I, Chapter 2).  
 Probiotic supplementation: To conduct a well-designed randomised, double blind, placebo-
controlled clinical trial with L. plantarum 299v as part of an intervention and establish 
whether a course of probiotics may alleviate undesirable symptoms of IBS and improve 
quality of life (Article 2, Chapter 3).  
 Nutrient intake: To assess nutrient intake in patients with IBS compared to dietary 
recommendations.  This is with the hypotheses that in a condition in which subjects insist 
that diet or trigger foods play a part in symptom generation, may lead to risk of nutrient 
inadequacy (Article 3, Chapter 4). 
 Validation and reproducibility of dietary data: To validate and assess the reproducibility of 
food records in IBS patients (Article 4, Chapter 5). 
 Characterisation of probiotic action and the influence of nutrient intake on GI microbiota: 
Identify possible nutrient risk components for establishing GI microbiota involved in IBS 
and as part of an intervention determine whether a course of probiotics may alter stool 
microbiota (Article 5, Chapter 6). 
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By answering the stated research aims, this study endeavours to make a contribution to 
knowledge in the area of the IBS, particularly in South Africa.   
 
5.3. Study design 
This study consisted of two phases.  The first phase a descriptive, cross sectional, observational 
study was used for the collection of the dietary data (Article 3, Chapter 4).  During the second 
phase, a RCT with an eight week course of probiotic was conducted (Article 2, Chapter 3).  Data 
gathered during the RCT was used for Articles 4 and 5, Chapters 5 and 6 respectively. 
 
5.4. Study population and participants 
A multi-disciplinary team including a gastroenterologist, nursing sister, microbiologist and 
dietitian were involved in this study.  The study was conducted at a private gastroenterology 
clinic, in Port Elizabeth, South Africa.  The study population was men and women recruited at 
the gastroenterology clinic.  They were screened by the gastroenterologist and recruited 
according to the study inclusion criteria and their willingness to participate.  The subtypes C-IBS 
and D-IBS were included in the study.  Eighty-one participants were recruited and formed a part 
of the RCT [information gathered and used in Articles 2, 4 and 5, (Chapters 3, 4 and 6 
respectively)].  One hundred and twenty-two participants were recruited and their dietary data 
used for Article 3, Chapter 4. 
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5.5.The following null hypotheses were stated 
 An intervention of the probiotic, L.plantarum 299v at a dose of two daily 5 X 109 colony 
forming units (cfu), will not alleviate i) the undesirable symptoms of IBS nor ii) improve 
quality of life (Article 2, Chapter 3) in C-IBS and D-IBS subjects.   
 The nutrient intakes of IBS (C-IBS and D-IBS) subjects place them at risk of inadequacy 
compared to Dietary Reference Intake (DRI) recommendations (Article 3, Chapter 4).   
 Three day estimated food records demonstrate poor i) reproducibility and ii) validity in IBS 
(C-IBS and D-IBS) subjects (Article 4, Chapter 5).   
 Nutrient intakes do not have an influence on the faecal microbiota (i.e. Bifidobacterium 
bifidum, Lactobacillus plantarum and Bacteroides spp.) of IBS (C-IBS and D-IBS) subjects 
(Article 5, Chapter 6).    
 L.plantarum 299v does not have an influence on the faecal microbiota (i.e. Bifidobacterium 
bifidum, Lactobacillus plantarum and Bacteroides spp.) (Article 5, Chapter 6).   
  
5.6. Chapter overview, contribution of candidate and scope of work 
 Chapter 2 
This involved a thorough literature research and the compilation of a review article on 
probiotics, with special emphasis on their role in the management of irritable bowel 
syndrome. 
Article: Review: Probiotics, with special emphasis on their role in the management of 
irritable bowel syndrome. 
     Cheryl Stevenson and Renée Blaauw 
     South African Journal of Clinical Nutrition 2011; 24 (2): 63-73. 
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Candidate contribution:  
The first author performed the literature search and was responsible for writing the 
manuscript. 
 Chapter 3 
This involved a RCT with 81 participants.  Participants were randomised to receive either probiotic or 
placebo for eight weeks. 
Article: Randomized clinical trial: Effect of Lactobacillus plantarum 299v on symptoms 
of irritable bowel syndrome 
Cheryl Stevenson, Renée Blaauw, Ernst Fredericks, Janicke Visser and Saartjie Roux 
Nutrition 2014; 30: 1151-1157. 
Candidate contribution:  
The first author took part in the study design, performed the data collection, data capturing, 
data analysis, liaised with statistician, evaluated the results and was responsible for writing 
the manuscript.  
 Chapter 4 
This study looked at the nutrient intakes of patients with irritable bowel syndrome and 
compared to healthy controls and international recommendations.  A total of 122 subjects 
participated. 
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 CHAPTER 4 ADDENDUM 1 
Usual intake distributions were calculated and are presented in Table 1.  The mean intake of 
the estimated three day food record, non-consecutive days, was calculated to represent the 
observed intake distributions for energy, macro and micronutrients.  In this study adjustments 
to the observed intake distribution to obtain usual intake distribution estimates were made 
using the method described by Carriquiry.
1
  This is because, in all probability, an individual’s 
observed intake during a particular three-day period will differ from observed intake in a 
different three day period, and both three-day observed intakes will differ from true usual 
intake.  An individual’s observed mean intake over a few days may not be an accurate 
estimate of that individual’s usual intake.2   A number of statistical methods that have been 
developed to estimate usual intake distributions from observed intake distributions obtained 
using food records.
2
   
Table 1. Prevalence of risk of inadequate nutrient intakes in the IBS (combined C-IBS and D-IBS 
groups) group using the EAR cut-point method
a
 
Nutrients EARs or EER or AI IBS participants (n = 
103) mean intake 
Prevalence below 
EAR (%) or p value 
Energy (MJ) 9.28
b
 7.45 p < 0.0000 
Carbohydrates (g) 100
c
 189.11 4.85 
Protein (g) 76.29
d 
58.60 85.44 
Total dietary fiber (g) 25.04
e
 10.72 96.12 
Calcium (mg) 873
f
 529 95.15 
Iron (mg) 6.83
g 
6.33 61.17 
Vitamin C (mg) 62.2
h 
64.5 67.96 
Folate (µg) 320
i
 157.67 99.03 
Vitamin A (µg) 518.4
j
 512.49 66.02 
EAR – Estimated Average Requirement, EER – Estimated Energy Requirement, AI – Adequate Intake, IBS – 
Irritable Bowel Syndrome 
Stellenbosch University  http://scholar.sun.ac.za
129 
 
a
The Estimated Average Requirement (EAR) is the appropriate Dietary Reference Intake to use when assessing 
the adequacy of group intakes.  The EAR is defined as the average daily nutrient intake level estimated to meet 
the requirement of half the healthy individuals in a particular life stage and gender group.  Comparing the mean 
nutrient intake of a group either to the EAR or the Recommended Dietary Allowance (RDA) should not be used 
for assessment or to imply relative nutrient adequacy.
2  
The EAR cut-point method, used in Table I above, 
examines the prevalence of nutrient inadequacy in groups by estimating the proportion of individuals in the 
group with usual intakes below the EAR (the median requirement) for a specific nutrient.
2
   
b
Weighted for the study population for males and females as per Estiamted Energy Requirment (EER) formula, 
assumption of physical activity factor of 1.12 (low active) as average BMI >25kg/m
2
.  Due to the high 
correlation between energy intakes and requirements, energy adequacy cannot be assessed using either the 
probability approach or the cut-point method
2
 and a t - test was used to test for significance. 
cEAR for carbohydrates for males and females ≥ 19 years is 100g/day. 
dEAR for protein for males and females ≥ 19 years is 0,66g/kg/day. 
e 
Adequate Intake (AI) for total dietary fiber, weighted for the study population, AI for total fiber for males 19-
50 years is 38g/day and males’ ≥ 51 years is 30g/day; for females 19-50 years is 25g/day and ≥ 51 years is 
21g/day. 
f
EAR for calcium, weighted for the study population, EAR for males and females 19 – 50 years is 800mg/day; 
females 51-70 years is 1000mg/day; males 51-70 years is 800mg/day; males and females > 71 years is 
1000mg/day. 
g EAR for iron, weighted for the study population, EAR for all males ≥ 19 years is 6mg/day; females 19 – 50 
years is 8,1g/day; females’ ≥ 51 years is 5mg/day. 
h
EAR for vitamin C, weighted for the study population, EAR for males ≥ 19 years is 75mg/day and for females 
≥ 19 years is 60mg/day. 
i
EAR for folate for males and females is 320mg/day. 
jEAR for vitamin A, weighted for the study population, EAR for males ≥ 19 years is 625µg/day and for females 
≥ 19 years is 500µg/day. 
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Table 2. Comparisons of percentage macronutrient intakes with the AMDRs
a
 (adults > 18 years; 
using usual intake distributions) in the IBS group (D-IBS and C-IBS groups combined) 
  Prevalence 
below AMDR 
Prevalence 
within AMDR 
Prevalence 
above AMDR 
 AMDR % IBS % IBS % IBS 
Protein (%) 10-35% 8.74 91.26 0 
Fat (%) 20-35% 2.91 62.14 34.95 
Carbohydrate 
(%) 
45-65% 60.19 39.81 0 
AMDR – Acceptable Macronutrient Distribution Range; IBS – Irritable Bowel Syndrome 
a
The AMDRs are defined as range of intakes for a specific energy source that is associated with reduced risk of 
chronic diseases while contributing adequate intakes of essential nutrients.  Although mainly directed at 
individuals, the AMDRs also allow for assessment of groups and populations.
3  
 By determining the proportion 
of the group that falls below, within and above the AMDRs, it is possible to determine the proportion that is 
outside the range and to examine adherence to recommendations.  If considerable proportions of the group fall 
outside the range, concern for potential adverse consequences could be increased.
3
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ABSTRACT  
Background:  The reliability and validity of dietary data gathered from irritable bowel 
syndrome (IBS) patients is unknown.  This would be useful information to know, especially 
when patients insist that diet or trigger foods play a part in symptom generation.  
Aim: To examine the reliability and validity of three day estimated food records in a group of 
IBS patients. 
Design: Patients attending a private gastroenterology clinic in South Africa were recruited as 
part of a larger IBS study.  A small subsample of the total study group (n = 81) were used to 
assess validity (n = 5, 6.2%) and reproducibility (n = 6, 7.2%).  Reliability was assessed with 
a test-retest (eight week interval) of a three day estimated food record. Validity was assessed 
using dietary fatty acid (FA) intake from three day food records and comparing to plasma FA 
profiles.  Validity was analysed using Pearson and Spearman correlation coefficients and 
paired T-tests were used to analyse reliability.  Both absolute and percentage total FA intake 
were used for plasma and dietary FAs. 
Results: Correlation coefficients for validity ranged from -0.03 to 0.69, p > 0.05.  None of the 
macro and micronutrients differed significantly from each other in the reliability testing, 
except that of percentage energy intake from protein 12.33 ± 1.29 vs 17.48 ± 3.18g/day (p = 
0.015). 
Conclusions:  A three day estimated food record in a group of IBS patients demonstrated 
good reliability, however using plasma FAs to validatie dietary intake data was poor, 
suggesting that further research and testing are needed in a larger grouping of IBS patients. 
Keywords: irritable bowel syndrome, validity, reliability, dietary intake, biomarker 
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BACKGROUND 
Irritable bowel syndrome (IBS) is a chronic disorder characterized by abdominal pain or 
discomfort associated with disordered defecation, either constipation predominant IBS (C-
IBS), diarrhoea predominant IBS (D-IBS) or mixed/alternating symptoms of constipation and 
diarrhoea [1].  The natural history of IBS is one of relapsing and remitting symptoms [2].  
The aetiology of IBS is multi-faceted and ill defined, however the majority of IBS patients 
believe that certain food items are important triggers of their gastrointestinal (GI) symptoms.  
This is especially true for foods containing carbohydrates and fat and also may be relevant for 
histamine-releasing food items and foods rich in biogenic amines [3].  Many IBS patients 
associate one or more foods with the onset of IBS symptoms and approximately two thirds of 
IBS patients exclude food items from their diet to improve symptoms [4, 5].  The validity and 
reliability of dietary data gathered from IBS is necessary as patients insist that diet or trigger 
foods play a part in symptom generation.  This may lead to them avoiding certain foods and 
consuming nutritionally deficient diets.  Generally, fairly large numbers are needed for the 
reliability and validity testing of dietary data and this is possibly a reason why this data is not 
always reported. However to give credibility to dietary data, validity and reliability testing is 
required.  In this study we assess the validity and reliability of dietary data in a small 
subsample of IBS patients. 
 
The reliability of a dietary assessment method reflects the ability of the method to obtain 
identical results when administered at a later stage under similar circumstances [6].  The 
reliability of dietary data is not as often reported on as the validity.   Validity reflects the 
ability of a dietary method to accurately measure what the participants have actually eaten 
[7].  Dietary methods designed to characterize usual intakes of individuals are the most 
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difficult to validate, since the ‘truth’ is never known with absolute validity [8].  Relative 
validity, in which a new method (i.e. test method), is compared with an existing method 
known to be valid (i.e. reference method), is the most practical validation method to use.  
Absolute validity implies that the reference method reflects the true dietary intake, while 
relative validity recognizes that the reference method itself is subject to error [7].  Therefore, 
the extent of agreement between the test and reference methods is used to indicate the relative 
validity of the test method and the extent to which the reference method is believed to be the 
truth. 
 
While food records are often used as a reference method for the determination of the relative 
validity of other dietary assessment methods, few studies report on the validity and reliability 
of food records themselves.   Fat is one of the most difficult dietary components to measure 
for several reasons.  Fat is sometimes very difficult for an individual to recognise and 
quantify.  For instance, fat used in food preparation for frying and cooking or as sauces and 
dressings – is often added by someone other than the individual under study, making it nearly 
impossible to identify the source and brand of fat.  Even if this were known, it would be 
particularly tedious to report in detail [9].  In addition, the accuracy of reporting fat is 
especially prone to bias.  Underreporting of fat intake is greater among individuals whom are 
overweight because of social implications [10].   
 
Biomarkers are being increasingly used in nutritional epidemiology to assist in dietary 
measurement and to deal with the problems associated with self-reported intakes.  The use of 
biomarkers, such as plasma fatty acids (FA), is a more objective approach to assess the 
validity of dietary intake data [11].  The fundamental advantage of using a biomarker is that 
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measurement errors are unrelated with errors in any dietary assessments, e.g. do not rely on 
memory, self-reported information or interviewer bias.   
 
No biomarkers reflect absolute fat intake, however, measurement of FAs in various biological 
samples reflects to some extent, proportional intake of FAs [9].  The intake of FAs may be 
reflected in various serum (or plasma) lipids, platelet and erythrocytes phospholipids.  The 
FA composition of plasma lipids reflects the type of dietary fat and may be an objective 
estimate of the type of fats proportionally consumed by an individual.  The FA composition 
of plasma reflects medium-term (weeks to months) dietary intake [12].  Essential 
polyunsaturated FAs (linoleic acid and α-linolenic acid) cannot be synthesized de novo by 
humans and play an important role in health.  As the source of these biologically active FAs 
is exogenous they may be particularly good biomarkers markers to use [9]. 
 
In IBS patients, actual dietary intake, has not been extensively reported.  To date there have 
only been a few prospective studies assessing dietary intakes of IBS patients [13-15].  The 
reliability and validity of IBS dietary data is unknown and to the author’s knowledge there is 
no published data.  This is pertinent information to know in a condition where diet is thought 
to play such a significant role.  The aim of this methodological study was to assess the 
validity and reliability of dietary data gathered from estimated food records in a group of IBS 
patients.  This sub-group of patients (n = 6, 7.4% for reliability and n = 5, 6.2% for validity 
testing) formed part of a larger IBS research study (n = 81).  More specifically the null 
hypothesis of whether three day estimated food records demonstrate poor i)reproducibility 
and ii)validity in IBS patients will be tested.    
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METHODS 
Study Participants 
Participants for this study were a sub-group randomly selected from a larger probiotic clinical 
trial (Clinical Trials Registry number NCT01886781), where n = 81.   The study was 
approved by the Research Ethics Committee at Stellenbosch University (reference number: 
N10-08-270) and was conducted according to the ethical guidelines and principles of the 
International Declaration of Helsinki.  Written informed consent to participate was obtained 
from each participant on enrolment.  For the reliability (test-retest) analysis 7.4% (n=6) of the 
total study sample were selected and a further 6.2% (n=5) for the validity of the dietary 
information study.   
Medical information 
Participants were screened by a gastroenterologist and recruited according to the study 
inclusion criteria and their willingness to participate.  The diagnosis of IBS was made using 
Rome II criteria.  Pertinent medical information collected included recent antibiotic usage, 
current medication, background medical history, previous bowel surgery, family history of 
IBS, smoker/non-smoker, duration of IBS, triggers for IBS symptoms and ‘anti-IBS specific’ 
medication.  Participants underwent physical measurements, including weight and height, 
which were used to calculate body mass index (BMI kg/m
2
). 
Dietary Assessment 
A registered dietitian explained and trained each participant on the procedure for completing 
a prospective three day estimated dietary record (two weekdays and one weekend day 
included).  Portion sizes were estimated using household food measures like spoons, cups and 
bowls and a ruler, food portion photographs were also utiliased (MRC kit).  The importance 
of recording food(s) eaten immediately after it was eaten was emphasized.  The results were 
Stellenbosch University  http://scholar.sun.ac.za
139 
 
analysed by FoodFinder
TM
 III – a computer-based data evaluation system for South African 
foods [16].  For the validity testing, the 3-day estimated food record was correlated against 
plasma FA profiles, and the reliability of the dietary data was done by a test-retest with an 
eight week time difference between the two  three day estimated food records. 
Blood sampling, processing and analysis 
A five ml of blood was collected from each participant in a sterile vacutainer, with a clot-
activated gel, using a 21G needle.  Blood samples were collected following a 12 hour fast.   
Blood samples were taken within the same week as the three day estimated food records were 
completed.  Samples were left to stand for 15 min then centrifuged for 20 min at 3500g.  The 
serum was transferred into small sterile tubes and stored in freezer at -22
°
C for a maximum of 
a month before being transferred to a -80°C freezer until analyses.  Samples were thawed at 
room temperature.  Four hundred microlitres of each sample was spiked with 200µl/l of 
internal standard (C17.0) then extracted using a modified Bligh and Dyer method [17].  The 
samples were extracted in 2ml chloroform methanol (2:1) and one ml of 0.05% sulfuric acid 
for 60 minutes each.  One ml of 0.9% NaCl solution saturated with extraction solvent was 
added, and further shaken. The samples were then centrifuged at 2000g for 30 minutes. The 
aqueous and protein layer discarded and the organic phase, containing the lipids, was filtered 
completely dried under a stream of nitrogen gas at 40
o
C and the mass of extracted lipid 
determined.  The obtained lipid was then derivatised in 3% methanoic sulphuric and methyl 
esters (FAMEs) extracted in hexane.  The FAMEs were diluted (X2) and analysed by gas 
chromatography (model 7890, Agilent) and mass spectroscopy (model 5975, Agilent) (GC-
MS). The FAMEs were identified using an 11 component custom mix (Sigma) and a 37 
component mix (Sigma), on the highly polar HP-88 column (J&W 112 88-A7; 100m X 0.25 
ID X 0.2 micrometers; Agilent technologies). The GC and MS data obtained was analysed 
using Chemstation software (Agilent).  The GC-MS analytical conditions used were as 
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follows: Injection volume 1 µl (split-less mode), carrier gas Helium (2 ml/min constant flow); 
inlet temperature 250
o
C while the detector temperature was 280
o
C. The oven temperature 
was at 120
o
C for one minute then raised to 170
o
C at 10
o
C/min, 210
o
C to 5
o
C/min for five 
minutes. And finally increased to 230
o
C at 5
o
C/min and held for seven minutes.  
Statistical analysis 
In order to assess the validity the Pearson and Spearman correlation coefficient were 
calculated.  This was done for the absolute FA values as well as percentage of total FAs.  
Correlations were evaluated as poor (<0.2), moderate (0.2-0.6) or good (>0.6).  To evaluate 
the reproducibility, paired T-tests between the first and second food record (or test) were 
calculated. A p value < 0.05 was considered as significant.   
 
RESULTS 
Validity testing 
Demographic data of the participants for the validity study are shown in Table 1.  All five 
participants were women.  The average BMI fell within the normal range and one (20%) 
participant was a smoker.   
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Table 1 Demographics of validity study population (n = 5) 
Demographics Mean ± SD 
Age (years) 49.91 ± 11.23 
Height (cm) 1.65 ± 0.11 
Body weight (kg) 67.6 ± 21.67 
BMI (kg/m
2
) 24.58 ± 5.68 
Smokers 
(percentage current) 
20% (n=1) 
BMI – Body mass index 
Table 2 shows the dietary data of selected key nutrients.  Dietary data indicate a 
macronutrient composition within the normal recommendations with regards to percentage 
total energy contributions.   
Table 2 Dietary data of validity study population (n = 5) 
Dietary intake Mean ± SD 
Energy intake (MJ/day) 7.9 ± 2.3 
Total fat intake (g/day) 
(percentage of total energy) 
63.72 ± 26.68 
30.65 ± 7.50 
Protein intake (g/day) 
(percentage of total energy) 
80.34 ± 4.71 
19.16 ± 7.88 
Carbohydrate intake (g/day) 
(percentage of total energy) 
208.07 ± 95.38 
42.43 ± 12.41 
Alcohol intake (g/day) 
(percentage of total carbohydrate) 
9.02 ± 8.87 
4.15 ± 4.39 
SFA (g/day) 
(4:0) 
(6:0) 
(8:0) 
 
0.43 ± 0.26 
0.24 ± 0.14 
0.17 ± 0.10 
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(10:0) 
(12:0) 
(14:0) 
(16:0) 
(18:0) 
(20:0) 
(24:0) 
0.37 ± 0.19 
0.7 ± 0.35 
2.41 ± 0.94 
11.0 ± 3.62 
5.11 ± 1.68 
0.12 ± 0.21 
0.07 ± 0.08 
MUFA (g/day) 
(14:1) 
(16:1) 
Oleic (18:1) 
(20:1) 
(22:1) 
 
0.11 ± 0.06 
1.08 ± 0.71 
18.3 ± 8.56 
0.13 ± 0.09 
0.13 ± 0.15 
n-6 PUFA (g/day) 
Linoleic (18:2n-6) 
(percentage of total energy) 
Arachidonic (20:4n-6) 
 
11.65 ± 7.78 
5.6 ± 3.74 
0.07 ± 0.04 
n-3 PUFA (g/day) 
Linolenic acid (18:3n-3) 
(18:4n-3) 
(20:5n-3) 
(22:5n-3) 
(22:6n-3) 
 
0.40 ± 0.16 
0.01 ± 0.01 
0.03 ± 0.03 
0.02 ± 0.01 
0.14 ± 0.15 
MJ – megajoule; SFA – short chain FA; MUFA – monounsaturated FA; PUFA – 
polyunsaturated FA 
Table 3 shows the results of the plasma FA composition.  Mean FA (±SD) compositions of 
plasma are shown.  The FA intake is expressed as absolute intake (mg/ml) and percentage of 
total FA in the plasma.  No C18:3n3 was detected in the plasma of any of the participants.     
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Table 3 Plasma FA composition (n=5) 
FA Plasma FA 
Absolute value (mg/ml) 
Plasma FA 
Percentage of total FAs 
SFA 
(14:0) 
(16:0) 
(18:0) 
 
0.0152 ± 0.0156 
0.5104 ± 0.0965 
0.1738 ± 0.0780 
 
0.998 ± 1.110 
34.36 ± 8.47 
11.10 ± 2.68 
MUFA 
C18:1n7 
C18:1n8 
C18:1n9 
 
0.1532 ± 0.1657 
0.2076 ± 0.1761 
0.0968 ± 0.1661 
 
9.26 ± 9.86 
15.16 ± 13.14 
5.31 ± 8.12 
n-6 PUFA 
Linoleic (18:2n-6) 
Arachidonic (20:4n-6) 
 
0.272 ± 0.0995 
0.092 ±  0.0463 
 
17.97 ± 6.25 
5.84 ± 2.54 
FA – FA; SFA – short chain Fas; MUFA – monounsaturated Fas; PUFA – polyunsaturated 
FAs 
Correlations between the FA composition of plasma and dietary intake were calculated and 
are presented in Table 4.  None of the dietary FAs and plasma FAs correlate significantly.  
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Table 4 Correlation coefficients between dietary intake (g/day) vs plasma FAs (mg/ml) and 
percentage TFA between dietary intake and plasma  
FA Pearson’s correlation Spearman’s correlation 
 g/day vs 
mg/ml 
p 
value 
Percentage 
of TFA 
p value g/day 
vs 
mg/ml 
p value Percentage 
of TFA 
p value 
SFA 
C14:0 
C16:0 
C18:0 
 
-0.46 
-0.63 
-0.72 
 
0.43 
0.25 
0.17 
 
-0.01 
-0.43 
-0.48 
 
0.99 
0.47 
0.41 
 
-0.15 
-0.80 
-0.10 
 
0.80 
0.10 
0.87 
 
-0.36 
-0.60 
-0.30 
 
0.5 
0.28 
0.62 
PUFA 
C18:2 
C20:4 
 
-0.03 
0.69 
 
0.96 
0.19 
 
0.25 
0.26 
 
0.69 
0.67 
 
0.05 
0.67 
 
0.93 
0.22 
 
0.10 
0.30 
 
0.87 
0.62 
TFA – total Fas; SFA – short chain Fas; PUFA – polyunsaturated FAs 
 
Reliability testing 
Demographic details of the participants for the reproducibility study are shown in Table 5.  A 
different six participants were involved in this study and all were women.  The average BMI 
fell within the overweight range. 
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Table 5 Demographics of reproducibility study population (n = 6) 
Demographic Mean ± SD 
Age (years) 45.79 ± 17.32 
Height (cm) 1.62 ± 0.06 
Body weight (kg) 68.67 ± 6.12 
BMI (kg/m
2
) 26.39 ± 0.20 
Smokers 
(percentage current) 
33% (n = 2) 
BMI – Body mass index 
The dietary data of selected key nutrients (mean ± SD) and p value for paired T-test is shown 
in Table 6.  The assessed nutrient intake resulting from the second interview does not differ 
significantly from that of the first interview, except for percentage energy from protein (12.33 
± 1.29 % vs 17.48 ± 3.18, p = 0.015).  The dietary data indicates good reliability in this 
group. 
Table 6 Dietary data of reproducibility group (n=6) 
Dietary component Test (1) Retest (2) p value (paired T-
test) 
Energy intake (MJ/day) 6.94 ± 1.88 5.98 ± 1.84 0.386 
Total fat intake (g/day) 
(percentage of total energy) 
68.25 ± 16.90 
37.64 ± 4.69 
55.87 ± 19.80 
35.63 ± 4.82 
0.395 
0.451 
Saturated fat (g/day) 21.00 ± 5.16 18.48 ± 6.39 0.560 
Monounsaturated FAs (g/day) 20.95 ± 4.69 19.37 ± 8.26 0.747 
Polyunsaturated FAs (g/day) 19.79 ± 7.76 11.45 ± 5.21 0.141 
Cholesterol (mg/day) 203.99 ± 163.53 189.43 ± 
65.12 
0.858 
Protein intake (g/day) 51.29 ± 17.84 59.41 ± 15.23 0.396 
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(percentage of total energy) 12.33 ± 1.29 17.48 ± 3.18 0.015
* 
Carbohydrate intake (g/day) 
(percentage of total energy) 
194.67 ± 55.40 
47.59 ± 3.64 
154.32 ± 
48.95 
43.61 ± 5.32 
0.079 
0.451 
Total dietary fiber (g/day) 13.28 ± 6.86 12.65 ± 9.33 0.892 
Insoluble dietary fiber (g/day) 2.88 ± 1.62 2.71 ± 1.71 0.807 
Soluble fiber (g/day) 2.32 ± 1.30 1.92 ± 1.11 0.420 
Alcohol intake (g/day) 
 
0.400 ± 0.980 2.22 ± 4.34 0.366 
Vitamin A (RE/mcg/day) 495.95 ± 193.42 629.01 ± 
608.90 
0.506 
Vitamin C (mg/day) 37.61 ± 21.91 56.83 ± 29.36 0.082 
Folate (mcg/day) 172.89 ± 79.27 210.88 ± 
113.29 
0.439 
Calcium (mg/day) 559.32 ± 241.95 488.92 ± 
291.70 
0.595 
Iron (mg/day) 8.98 ± 2.46 10.90 ± 6.55 0.439 
* < 0.05 
DISCUSSION 
This study has shown good reproducibility and poor validity of dietary intake in a group of 
IBS patients using three day estimated food records and as such rejects the first part of the 
null hypothesis (that poor reliability would be demonstrated with food records) and accepts 
the second part of the null hypothesis that the validity as assessed by plasma fatty acids was 
poor.  Many IBS patients report restricting their dietary intake or eliminating certain 
provocative dietary agents in order to reduce their symptoms. The restriction of certain 
trigger foods could potentially distort macro- and micronutrient intake and place IBS 
individuals at risk of low nutrient intake [18].  This study has shown that with a fairly short 
assessment tool (a three day food record) dietary data is reliable in IBS in spite of them 
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reducing some dietary items when necessary.  In the literature the validity of an estimated 
food record is primarily determined by comparing this method with a weighted three day or 
longer food record.  However this study used plasma FAs to validate dietary FA intake and 
showed poor validity and indicates that larger numbers are needed to assess the use of this 
biomarker in IBS patients. 
  
Biomarkers of dietary fat intake have been more difficult to identify than for other nutrients.  
The ideal biomarker of dietary fat would be able to reflect both quantity and quality, but 
currently no marker of total fat intake exists [9].      FA composition is regulated leading to 
typical profiles that reflect the function and origins of the fraction.  Blood FAs, because they 
are mainly derived from the diet, are useful biomarkers of dietary intake and PUFAs have 
been shown to be the most useful as biomarkers of dietary intake [9].  Competition between 
metabolic pathways may lead to changes in FA composition not directly related to diet [19].  
Biomarker level measured in biological samples takes into account any effects of absorption, 
influences of microbiota (e.g. bioconversion, release of bioactive dietary compounds, 
enterohepatic circulation), interactions between nutrients, tissue turnover, metabolism and 
turnover [20].  Additional considerations are issues pertaining to nutrient bioaccessibility and 
bioavailability [21].   
 
The effects of genetic variability in FA biochemistry pathways, direct/indirect determinants 
of fat absorption, or gene-diet/nutrient or gene-gene interactions in FA profiles as dietary 
markers is largely unexplored [20].  For example, FA profiles may be altered by variations in 
genes encoding for enzymes in the elongase/desaturase pathway of n-3 and n-6 FA 
metabolism [22] or by interactions between high intake of dietary fat, obesity and variations 
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in FA binding protein 2 gene which may result in modulation of insulin resistance [23].  
These examples indicate that genetic factors that affect FA metabolism may also affect the 
utility and application of these compounds as dietary biomarkers – although this remains to 
be validated [20].  The current understanding of dietary biomarkers is limited by a very 
incomplete comprehension of how genetics, diet and nutrients interact to affect metabolism 
[20].   
 
The strength of the association between diet and biomarker depends on the FA analysed.  FAs 
not synthesised endogenously such as 18:2 n-6, tend to correlate well with diet.  In cross–
sectional studies, PUFA content of the diet has shown to correlate well with FA composition 
in all adipose and all blood lipid fractions.  Correlations are weaker for other SFA and MUFA 
[19], but SFAs are more subjected to hepatic elongation.  Homeostatic feedback systems 
involved in storage and metabolic mechanisms help to keep plasma FA levels as close to 
normal as possible.  This was illustrated by Poudyal et al. showing that chronic 
supplementation with chia seed (a rich source of α-linolenic acid (ALA), increased 
docosahexaenoic acid (DHA) accumulation in both the heart and liver, although no such 
change was seen in the plasma [24].   For some FAs, a possible explanation may be that it is 
difficult to modify the proportion of a FA that is already present in a relatively high 
percentage in the diet or in the body.  Therefore large numbers are needed for cross-sectional 
or epidemiological studies. 
 
The sample size in validation studies is usually small because they are logistically difficult 
and costly to carry out [25] and reproducibility and validity studies are generally conducted in 
a subsample of a population being investigated as a part of a larger investigation.  Cade et al. 
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in their reviews of food frequency questionnaires undertaken found a wide range of sample 
sizes ranging from 6 to 3750, with a median sample size of 110 subjects [26] and mean 
sample size of 255 subjects [27].  They found that the sample size of the validation study did 
not seem to greatly affect the study results.  Cade et al. reviewed the test and dietary intake 
reference method correlation coefficients and found sample sizes of between 100 -200 
subjects to be sufficient.  However, they indicated that some studies to not manage to come 
anywhere close to these sizes and that sample size inevitably depends on the available 
resources [26].  In terms of percentages, subsample sizes have ranged from between 0.25% to 
4.1%, although in terms of absolute amounts these were large studies by Astorg et al. and 
Sun et al. respectively [28, 29].  Differences between the sample used for the validity study 
and the overall study population with regard to education level, sex and age may influence 
the validity of the dietary assessment tool [30].  A limitation of the present study is the small 
sample size, which may mean that the results may be a result of random error.  As this was a 
very small study population the results cannot be used to estimate the gain in power which 
would result from the larger study [31]. 
 
The plasma linoleic acid level in this study was 17.97%, this is comparable to those found in 
Japan [32], Australia [33] and America [34], reflecting the high intakes of linoleic acid in 
most countries (4-6% of energy) [35].  In a systematic review by Hodson et al. plasma total 
FA composition in 472 men and 510 women from 9 studies was reported.  The most 
abundant FAs were 16:0 (23.0 mol%), 18: 1n-9 (19.5 mol%) and 18: 2 n-6 (30.4 mol%), the 
latter was the most variable [19].  This differs from our study where 16:0 was the most 
abundant (34.36 mol%), followed by 18:2 n-6 (17.97 mol%) and 18: 1 n-8 (15.16 mol%).  
This study did not detect plasma linolenic acid.  This may be because the proportion of FAs 
in the dietary lipid pool and not the diet plays a significant role in responses to the long chain 
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n-3 PUFA [24].   Surette et al. also raised the possibility that dietary omega-3 FAs compete 
with the omega-6 family of dietary polyunsaturated FAs for incorporation into all cell 
membranes and are preferentially incorporated [36].    
 
Regardless of the level of detail obtained from participants, all assessments of nutrient intake 
are limited by the available food composition database. The availability of a wide range of 
manufactured and processed foods, coupled with variations in the fats and oils used in the 
industry, increases the difficulty associated with the estimation of the FA composition of 
foods and subsequent estimation of intakes [37, 38].    The difficulties associated with 
incomplete food composition databases have been highlighted [39, 40].  The present study 
used the most complete FA food composition database currently available for the South 
African food supply, The South African Food Composition Database System (SAFOODS).  
However, there are often situations where alternative food items are coded because a specific 
food item is not available in SAFOOD.  In such cases, the coder searched for an item that 
best fitted the food item consumed [40].  Relative intakes of individual FAs in the diet are 
therefore, extremely difficult to estimate from reported dietary intakes.   
 
A limitation of this study is that no correction was considered or accounted for the effect of 
plasma lipoprotein concentrations.  The major lipoproteins in plasma (very low density 
lipoprotein, low density lipoprotein and high density lipoprotein) contain different 
proportions of phospholipids, triacylglycerol and cholesterol esters.  Because phospholipids, 
triacylglycerol and cholesterol esters have a distinctive FA content and composition, a change 
in the concentration of one or more of the lipoproteins could potentially make a difference in 
the total plasma FA composition [19].  Generally there are low concentrations of n-3 PUFAs 
Stellenbosch University  http://scholar.sun.ac.za
151 
 
and careful analysis is required to accurately measure this.  It is also important to consider 
factors that may influence the relationship between diet and biomarker such as total dietary 
fat, blood lipid concentrations, recent dietary changes, smoking habits, exercise and in this 
study the effect of IBS, dybiosis in GI microbiota and low-grade inflammation, the influence 
of which is unknown.  Measurement error is inherent in any biomarker [41]. 
 
This study demonstrates a good reproducibility of the three day estimated food record.  The 
time elapsed between the two administrations in this study was eight weeks.  It is 
recommended to administer the second questionnaire within a fairly short time 4-8 weeks, 
long enough so respondent is not simply remembering what they answered before and short 
enough to minimise real dietary changes [30].  There is a paucity of data evaluating the 
reliability and validity of three day food records in adults.  One study by Trumble-Waddell et 
al. showed both good reliability and validity using estimated three day food records, a test-
retest (6 week interval) and weighted three day food record for reliability and validity testing 
was used respectively in a group of preschool children, the data was provided by parents or 
caregivers [42]. 
 
In conclusion the results of this study indicate that a three day estimated food record gave 
reproducible results for estimations for energy, macro and micronutrient intakes in a small 
group of IBS patients.  The dietary data as provided by three day food records showed poor 
validity when validated against plasma FA using a very small subsample of 6.2% (n = 5).  
This suggests that linoleic acid is possible not a good biomarker for validity testing for IBS 
dietary data. 
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The effect of nutrient intakes and a probiotic on gastrointestinal microbiota 
in irritable bowel syndrome patients 
Cheryl Stevenson, Renée Blaauw, Ernst Fredericks, Janicke Visser, Saartjie Roux 
Introduction: Nutrient intakes and probiotics modulate the gastrointestinal (GI) microbiota 
and influence symptoms of irritable bowel syndrome (IBS).  The extent to which these 
factors influence the microbiota is still relatively unknown.     
Aim: Investigate the influence of nutrient intakes and a probiotic on the faecal microbiota 
and GI symptoms of IBS subjects 
Methods   This study formed part of a larger randomised controlled trial (RCT) assessing the 
efficacy of an eight-week treatment regime of Lactobacillus plantarum 299v on IBS 
symptoms and quality of life (QoL).  During the RCT nutrient intake was recorded by three 
day estimated food records.  Faecal samples were collected at three time points:  1) baseline 
(A), 2) after supplementation (B) and 3) following a two week washout period (C).  Total 
Bacteroides spp., Bifidobacteria bifidum and Lactobacillus plantarum were quantified by 
quantitative polymerase chain reaction (qPCR). 
Results: Fifty-two IBS patients were recruited [28 diarrhoea predominant IBS (D-IBS); 24 
constipation predominant IBS (C-IBS)].  There was a significant difference between the C-
IBS (includes treatment and placebo) and D-IBS (includes treatment and placebo) groups and 
the presence of Lactobacillus plantarum at baseline (point A) (-0.956±1.239 vs. -
1.700±1.239; p=0.024).  There was no significant change in bacterial counts after completion 
of the trial (B) and following the washout period (C) between C-IBS and D-IBS.  There were 
strong inverse correlations in the total IBS (combined C-IBS and D-IBS) groups for 
Bacteroides and total (r=-0.424; p=0.019), insoluble (r=-0.406; p=0.023) and soluble fiber 
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(r=-0.466; p=0.008).  A direct correlation was found for the same fiber fractions [(total 
(r=0.529; p=0.002), insoluble (r=0.465; p=0.008) and soluble fiber (r=0.433 p=0.015)] and 
Lactobacillus plantarum.  In the D-IBS group correlations were found for protein intake and 
Bifidobacteria (r=0.497; p=0.036) and Lactobacillus plantarum (r=0.487; p=0.041).  
Bifidobacteria was correlated with insoluble fiber (r=0.523; p=0.026) intake and Bacteroides 
inversely correlated with total (r=-0.528; p=0.024) and soluble dietary fiber (r=-0.571; 
p=0.013).  A strong correlation was found in the D-IBS group for percentage energy from fat 
and Bacteroides (r=0.617; p=0.006) and linolenic acid and Bifidobacteria (r=0.516; 
p=0.028).  In the C-IBS group Lactobacillus plantarum correlated well with total dietary 
fiber (r=0.584; p=0.036).  There was no difference in symptom severity scores between the 
treatment and placebo groups, (treatment group 272.89±93.76 to 209.08±110.63 vs. 
277.56±88.12 to 185.30±96.52; p=0.800) over the trial period. 
 
Discussion:   No significant beneficial effects of the probiotic were observed on the severity 
of GI symptoms in IBS patients.  The probiotic did not stabilise or exert changes on the GI 
microbiota analysed.  Certain dietary agents (e.g. protein and fiber) strongly correlate to 
certain bacterial profiles, highlighting that nutrient intakes are undoubtedly a factor that 
significantly influences the GI microbiota composition. 
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Introduction  
Irritable bowel syndrome (IBS) is a common multifactorial functional gastrointestinal (GI) 
disorder of unknown aetiology [1].  It is characterised by a variable combination of chronic 
and recurrent symptoms including abdominal pain or discomfort, irregular bowel movements, 
flatulence and constipation or diarrhoea.  According to the stool consistency, IBS subjects 
can be divided into three subcategories predominant in diarrhoea (D-IBS), constipation 
predominant (C-IBS) or mixed, alternating (A-IBS) [1,2].  The mechanisms of pathogenesis 
behind IBS are only partly understood and cannot be traced to one factor.  Proposed 
mechanisms include visceral hypersensitivity, abnormal motor function, low-grade mucosal 
inflammation, food intolerance, altered GI microbiota as well as psychosocial and genetic 
factors [3-5]. 
 
The human GI microbiota constitutes a complex ecosystem that is beneficial to the host under 
normal conditions [6].  GI infection or administration of antibiotics perturbs the GI 
microbiota composition and has been linked to the expression of dysfunctional GI symptoms 
[7].  One study showed that mice treated with antibiotics have a perturbed GI microbiota 
composition which was normalised with the administration of probiotics [8].   Clinical trials 
have demonstrated an improvement in IBS symptoms with the administration of probiotics in 
humans [9-11].  It therefore seems that the composition of GI microbiota plays an important 
role in IBS symptoms [12]. 
 
Although much has been discovered in the last decade about the GI microbiota, there are 
biases and limitations to the current knowledge related to trial study design, sample collection 
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and confounding variables, such as diet [13].  Diet is a factor that undoubtedly influences the 
composition of GI microbiota.  
 
There have been relatively few randomised controlleed trials (RCT) that have assessed the 
effects of a probiotic on IBS symptoms and GI microbiota [10] and to the authors’ knowledge 
none that have assessed the effect of diet on the GI microbiota in IBS subjects.  Whether a 
disease-prone microbial composition can be transformed into a healthier composition by a 
probiotic or dietary interventions and improve patient sense of well-being remains 
fundamentally an unanswered question.  The aim of the present study was to investigate the 
influence of nutrient intakes and L.plantarum 299v on the i) faecal microbiota and ii) GI 
symptoms of IBS subjects.  More specifically the two null hypotheses being tested were: i) 
nutrient intakes do not have an influence on faecal microbiota and ii) Lactobacillus 
plantarum 299v does not have an influence on the faecal microbiota of both C-IBS and D-
IBS patients. 
 
Materials and Methods 
Subjects 
A total of 52 IBS subjects participated in this study which formed a part of a larger probiotic 
RCT (Clinical Trials Registry number NCT01886781) evaluating the efficacy of an eight-
week treatment regime of Lactobacillus plantarum 299v for IBS [14].   The study was 
approved by the Research Ethics Committee at Stellenbosch University (reference number: 
N10-08-270) and was conducted according to the ethical guidelines and principles of the 
International Declaration of Helsinki.  Written informed consent to participate was obtained 
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from each participant on enrolment.  Twenty-four C-IBS and 28 D-IBS patients were 
included.  Probiotic treatment was given to 19 D-IBS patients and 16 C-IBS patients while 17 
patients from both D-IBS and C-IBS groups received placebo.  This was a double blind study 
and therefore patients were randomly given either the probiotic treatment or placebo.  The 
groups were therefore not matched for severity of symptoms or for other demographics.  
Participants were screened by a gastroenterologist and recruited according to the study 
inclusion criteria and their willingness to participate.  The diagnosis of IBS was made using 
Rome II criteria.  Participants underwent physical measurements, including weight and 
height, which were used to calculate body mass index (BMI kg/m
2
). 
 
Intervention 
The RCT was 12 weeks in duration, the active treatment phase eight weeks.  During the 
intervention, all subjects received once daily either L. plantarum 299v or placebo.  The study 
product contained 5 x 10
9
 cfu (colony forming units) of L. plantarum 299v and it was tested 
against placebo capsules, filled with micro crystalline cellulose powder, of identical taste, 
texture and appearance by the manufacturer (Ferlot Manufacturing and Packaging (PTY) 
Ltd).  The test product was analysed for viable units and this confirmed packaging quantity 
details.  The dose was two capsules taken orally every morning.   
 
Dietary Assessment 
A registered dietitian explained and trained each participant on the procedure for completing 
a prospective, three day estimated dietary record.  Portion sizes were estimated using 
household food measures like spoons, cups and bowls and a ruler.  The importance of food 
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recording immediately after it was eaten was emphasized.  The results were analysed by 
FoodFinder
TM
 III – a computer-based data evaluation system for South African foods [15].   
 
 
Faecal sampling 
Faecal samples were collected at three time points: baseline (A), after supplementation (B) 
and following a two week washout period (C).  Samples were collected with disinfected 
plastic equipment after defecation and immediately frozen, kept at -20
0
C for up to a month 
before being stored at -80
0
C until analysis.  Not all participants provided a stool sample at 
each time point (A, B and C). 
 
DNA extraction 
Total DNA was extracted using the QIAmp DNA stool extraction mini kit (Qiagen, Hilden 
GmbH, Germany).  Manufactures instructions were followed, lysozyme enzyme to a final 
concentration of 10mg/ml, was introduced during cell lysis to assist with degradation of gram 
positive peptidoglycan cell wall layers, thus ensuring that genomic DNA extracted was 
representative of the entire bacterial population.  The DNA concentration and integrity were 
determined using a Nanodrop spectrophotometer (Nanodrop Technologies). Only samples 
with integrity between 1.8 and 2.2 were used. 
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qPCR bacterial analysis 
Total Bacteroides spp. and Bifidobacteria bifidum as well as total Lactobacillus plantarum 
were quantified using The PrimerDesign™ genesig Kits (Primer Design, UK) and 
quantitative real-time polymerase chain reaction (qPCR) amplification and detection. These 
kits were designed to have the broadest detection profile possible for in vitro quantification of 
all Bacteroides species and all Bifidobacterium bifidum genomes. A detection kit was 
specifically developed for Lactobacillus plantarum (Primer Design, UK). 
 
IBS symptom severity score  
The severity of GI symptoms was assessed by a validated questionnaire for use in IBS 
patients, the Francis Severity Score (FSS) [16].  The FSS questionnaire was completed at six 
different time points over the 12 week trial.  The questionnaires were self-administered.    
 
Statistical methods 
In qPCR analyses, some of the target organisms remained below the detection limit.  These 
values may not have been truly zero or missing values, but caused by technical limitations of 
the qPCR technique.  Therefore, for data analysis, the undetected samples were given a value, 
which corresponded to the limit of detection of the respective qPCR assay.  The data were not 
normally distributed per treatment groups (i.e. placebo vs. probiotic) and per IBS (C-IBS vs. 
D-IBS) groups. Thus the variables were transformed with a log transformation to yield more 
normally distributed data. The analyses showed that the log-transformed data were still not 
normally distributed. Therefore the ANOVA comparisons were confirmed with Mann-
Whitney U tests. Correlations among the continuous variables were done with Pearson 
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and Spearman rank correlation coefficients. Repeated measures ANOVAs were done with the 
assumption of compound symmetry (i.e. equal-correlation among the FFS responses over 
time).   The statistical analyses were done with STATISTICA Version 11 (2012) and a 
significance level of 5% was used for all analyses. 
 
RESULTS 
A total of 52 IBS participants fulfilling Rome II criteria were included in this study.  
Demographic detail and clinical characteristics are shown in Table 1.  Participant’s BMIs fell 
either into the overweight (25.0 – 29.9kg/m2) or obese (>30kg/m2) categories.  IBS was 
longstanding i.e.> five years for most of the participants. 
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Table I Patient demographic and clinical characteristics (n = 52) 
 D-IBS C-IBS 
 Treatment Placebo Treatment Placebo 
Number of 
subjects 
19 9 16 8 
Average age 
(years) (range) 
52.2 ± 16.2 
(24.9 - 75) 
42.5 ± 7.2   
(31.9 - 51.2) 
51.5 ± 9.9   
(35.9 – 69) 
49.4 ± 13.9 
(33.0 – 72) 
Gender 
(female/male) 
18/1 9/0 16/0 8/0 
BMI (kg/m
2
) 
(range) 
29.4 ± 7.4 
19.26 – 42.0 
33.07 ± 9.3 
17.19 – 48.9 
30.9 ± 7.2 
20.2 – 49.0 
27.8 ± 6.3 
21.33 – 40.0 
Duration of IBS 
symptoms 
(years) 
7.3 ± 11.7 7.9 ± 7.1 12.7 ± 9.9 12.4 ± 8.2 
 
There was a significant difference between the C-IBS (includes treatment and placebo) and 
D-IBS (includes treatment and placebo) groups and the presence of Lactobacillus plantarum 
at baseline (point A) (-0.956 ± 1.239 vs. -1.700 ± 1.239; p = 0.024), the D-IBS group had 
significantly lower counts of Lactobacillus plantarum.  Bacteroides spp. and Bifidobacteria 
spp. were not different at baseline (A) between the C-IBS and D-IBS groups (data not in 
Table II).   The probiotic had no significant effect on bacterial profiles between those on 
treatment and those receiving the placebo from baseline (A) to end of treatment (B) in both 
C-IBS and D-IBS groups, see Table II.  There was no significant change in bacterial counts 
after completion of the trial (B) and following on into the washout period (C). 
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Table II  Bacterial counts in stool at baseline(A), after supplementation(B) and after washout(C). Mean ± SD  
 D-IBS C-IBS 
Mean count ± SE (log transformed per 
nanogram DNA) 
Mean count ± SE (log transformed per 
nanogram DNA) 
Bacteria Group Before (A) After (B) Washout (C) Before (A) After (B) Washout (C) 
Bacteroides Test group 2.16  ± 2.49 
(n = 15) 
2.30 ± 2.85  
(n = 15) 
2.48 ± 2. 91 
(n = 14) 
3.21 ± 2.61 
(n = 12) 
2.69 ± 2.60  
(n = 12) 
3.10 ± 2.52  
(n = 13) 
Bacteroides Placebo group 1.12 ± 2.13 
(n = 7) 
2.16 ± 2.93 
(n = 7) 
1.54 ± 2.39 
(n = 7) 
2.49 ± 2.99 
(n = 7) 
2.65 ± 3.13 
(n = 8) 
2.74 ± 2.94  
(n = 7) 
Bifidobacteria Test group -0.69 ± 1.50 
(n = 15) 
-0.67 ± 1.67 
(n = 17) 
-0.88 ± 1.36 
(n = 14) 
-0.16 ± 1.66 
(n = 13) 
-0.53 ± 1.44 
(n = 13) 
-0.24 ± 1.82 
(n = 12) 
Bifidobacteria Placebo group -1.14 ± 1.14 
(n = 7) 
-1.12 ± 1.21 
(n = 7) 
-0.95 ± 1.59 
(n = 7) 
-0.37 ± 1.66 
(n = 7) 
-0.59 ± 1.85 
(n = 8) 
-0.46 ± 1.54 
(n = 6) 
Lactobacillus plantarum Test group -1.88 ± 0.00 
(n = 12) 
-1.14 ± 1.18 
(n = 14) 
-1.34 ± 0.90 
(n = 13) 
-0.96 ± 1.31 
(n = 8) 
-0.44 ± 1.21 
(n = 10) 
-0.89 ± 1.39 
(n = 12) 
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Lactobacillus plantarum Placebo group -1.34 ± 0.82 
(n = 6) 
-1.80 ± 0.17 
(n = 6) 
-1.60 ± 0.58 
(n= 5) 
-0.95 ± 1.27 
(n  = 5) 
-0.96 ± 1.41 
(n = 7) 
-1.66 ± 0.48 
(n = 5) 
No significant differences 
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When the data of only those that provided all three stool samples were analysed, no 
significant differences were found between the C-IBS and D-IBS groups.   
 
Table III gives an overview of the participant’s dietary intake at baseline (time point A).  
There were no significant differences for any nutrients between the D-IBS and C-IBS groups.  
The C-IBS group had a higher intake of energy and macronutrients, fat, protein and 
carbohydrate, as well as a slightly higher fiber intake compared to the D-IBS group.  This 
data was used to correlate to the findings of the faecal microbiota Table IV.  There were 
significantly strong but inverse correlations in the total IBS (combined C-IBS and D-IBS) 
groups for Bacteroides and total (r = -0.424; p = 0.019), insoluble (r = -0.406; p = 0.023) and 
soluble fiber (r = -0.466; p = 0.008).  A direct correlation was found for the same fiber 
fractions ((total (r =0.529; p = 0.002), insoluble (r = 0.465; p = 0.008) and soluble fiber (r = 
0.433 p = 0.015)) and Lactobacillus plantarum.  In the D-IBS group correlations were found 
for protein intake and Bifidobacteria (r = 0.497; p = 0.036) and Lactobacillus plantarum (r = 
0.487; p = 0.041).  Bifidobacteria was correlated with insoluble fiber (r = 0.523; p = 0.026) 
intake and Bacteroides inversely correlated with total dietary fiber (r = -0.528; p =0.024) and 
soluble dietary fiber (r = -0.571; p 0.013).  A strong correlation was found in the D-IBS 
group for percentage energy from fat and Bacteroides (r= 0.617; p = 0.006) and linolenic acid 
(C18:3) intake and Bifidobacteria (r = 0.516; p = 0.028).  In the C-IBS group Lactobacillus 
plantarum correlated well with total dietary fiber (r = 0.584; p = 0.036). 
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Table III: Dietary intake of participants (n = 52), mean ± SD 
 All groups D-IBS ( n = 28) C-IBS (n = 24) 
Energy (MJ) 7.25 ± 1.95 7.02 ± 1.76 7.53 ± 2.22 
Total fat (g) 68.30 ± 22.93 66.13 ± 20.29 70.84 ± 26.29 
% energy from fat 35.72 ± 6.78 36.15 ± 7.35 35.21 ± 6.05 
Total protein (g) 61.04 ± 17.34 59.35 ± 17.09 63.02 ± 18.35 
% energy from protein 14.88 ± 4.57 14.77 ± 3.91 15.00 ± 5.14 
Total carbohydrate (g) 198.16 ± 69.29 191.49 ± 67.30 205.93 ± 71.13 
% energy from 
carbohydrate 
45.83 ± 7.34 45.64 ± 7.65 46.05 ± 7.34 
Total dietary fiber (g) 14.14 ± 7.92 13.66 ± 7.69 14.72 ± 8.03 
Insoluble dietary fiber 
(g) 
4.07 ± 2.62 3.99 ± 2.59 4.16 ± 2.50 
Soluble dietary fiber (g) 3.26 ± 2.41 3.28 ± 2.70 3.23 ± 1.77 
C18:2 (g) 16.11 ± 7.80 15.91 ± 7.67  16.34 ± 8.00 
C18:3 (g) 0.40 ± 0.19 0.39 ± 0.17  0.42 ± 0.20 
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Table IV Correlations between faecal microbiota and dietary components 
 All groups D-IBS C-IBS 
 Bacteroides Bifidobacteria Lactobacillus 
plantarum 
Bacteroides Bifidobacteria Lactobacillus 
plantarum 
Bacteroides Bifidobacteria Lactobacillus 
plantarum 
Total fat (g) 0.012 -0.126 0.201 0.207 0.292 -0.161 -0.167 -0.382 0.503 
% energy 
from fat 
0.333 -0.087 -0.097 0.617
* 0.099 -0.160 0.095 -0.021 0.179 
Total protein 
(g) 
-0.235 0.109 0.382
* -0.202 0.497
* 
0.487
* -0.334 -0.288 0.313 
% energy 
from protein 
0.008 0.188 0.031 -0.175 0.106 0.568
* 0.127 0.162 -0.289 
Total 
carbohydrate 
(g) 
-0.288 -0.181 0.284 -0.289 0.089 -0.183 -0.312 -0.445 0.551 
% energy 
from 
carbohydrate 
-0.250 -0.161 -0.011 -0.313 -0.126 -0.235 -0.193 -0.245 0.089 
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Table IV. continued 
Total dietary 
fiber (g) 
-0.424
* -0.057 0.529
** 
-0.528
* 0.175 0.240 -0.443 -0.309 0.584
* 
Insoluble 
dietary fiber 
(g) 
-0.406
* 0.083 0.465
** -0.417 0.523
* 0.253 -0.481 -0.338 0.539 
Soluble 
dietary fiber 
(g) 
-0.466
** 0.080 0.433
* 
-0.571
* 0.306 0.319 -0.493 -0.277 0.421 
C18:2 (g) 0.056 -0.196 0.126 0.038 -0.784 -0.277 0.081 -0.332 0.407 
C18:3 (g) -0.150 -0.035 0.756 0.218 0.516
* -0.265 -0.503 -0.379 0.279 
*
p < 0.05, 
**
p < 0.01. 
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There was no statistical difference in symptom severity score between the treatment and 
placebo groups, (treatment group 259,54 ± 104,59 to 197,56 ± 114,74 vs. placebo group 
258,71 ± 110,88 to 180,00 ± 96,1; p = 0.599) over the trial period.  The groups were also 
further divided into C-IBS vs. placebo and D-IBS vs. placebo, no significant differences were 
found.   Both the study group and placebo group had a significant improvement in (FSS) 
scores over the study period, from an average of 259,27 to 191,71 (p < 0.0001) indicating a 
large placebo effect.   A strongly significant positive correlation was found in D-IBS patients 
receiving placebo at time point B, higher symptom severity score correlated with higher 
Lactobacillus plantarum (r = 0.892, p < 0.05).  A strongly significant inverse correlation was 
seen in the C-IBS placebo group at time point A, lower Lactobacillus plantarum counts 
translated to a higher symptom severity score ( r = -0.907, p < 0.05).  No other significant 
correlations were found between FSS and microbiota.    
 
DISCUSSION 
This study investigated the effects of single strain probiotic supplementation, L.plantarum 
299v, and nutrient intake on GI microbiota and symptoms.  No significant beneficial effects 
of the probiotic were observed on severity of GI symptoms nor on GI microbiota 
composition.  However, nutrient intakes were shown to have significant impact on GI 
microbiota composition.  Therefore the first hypothesis that nutrient intakes do not have an 
influence on faecal microbiota is rejected and the second hypothesis that L.plantarum 299v 
does not have an influence on the faecal microbiota anlaysed is accepted.   
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The microbiota of the GI tract plays an important role in the maintenance and function of the 
GI ecosystem.  Dysbiosis has been associated with the development of inflammatory 
disorders such as Crohn’s disease [17] and ulcerative colitis [18].   GI microbiota alterations 
are increasingly being recognised as an important factor in the pathogenesis and 
pathophysiology of IBS [19].  In recent years, many research groups have focused on 
identifying the GI microbiota composition in IBS patients, using modern culture-independent 
techniques [20].  No single deviance has been identified in IBS microbiota, but various 
alterations in the bacterial composition have been characterised [21-24].  Work by Jeffrey et 
al. found that clustering by microbiota composition revealed subgroups of IBS patients, one 
of which showed normal-like microbiota composition compared with healthy controls.  The 
other IBS samples were defined by large microbiota-wide changes characterised by an 
increase of Firmicutes-associated taxa and a depletion of Bacteroidetes-related taxa [25].   A 
further study that divided IBS patients according to subtype showed that D-IBS patients had 
lower numbers of Lactobacilli spp. while C-IBS patients had increased amounts of 
Veillonella spp. [26].  In this study a significantly lower level of L.plantarum in the D-IBS 
group compared to the C-IBS group at baseline (time point A) was found.  This is similar to 
the findings of Malinen et al. [26].  Previous studies also demonstrate that D- IBS is 
associated with significant increases in detrimental bacteria like Proteobacteria [27,28], 
decreases in beneficial bacteria such as Lactobacillus spp. [26,29],  Actinobacteria and 
Bacteroidetes [30], as well as an overall reduction in microbial diversity [31].   
 
To date there have been very few RCT on IBS and probiotics that have investigated 
possible modifications of the microbiota by the probiotic.  Knowledge on the role of 
microbiota modulation in symptom relief is therefore limited [9,10].  Nobaek et al. 
Stellenbosch University  http://scholar.sun.ac.za
176 
 
 
examined the effect of L.plantarum DSM 9843 (299v) on faecal microbiota and IBS 
symptom relief.  They used culture-dependent techniques and investigated L.plantarum 
DSM 9843 (299v), Enterobacteriaceae, Sulphite-reducing clostridia and Enterococci 
counts before and after treatment.  There were no significant changes in 
Enterobacteriaceae, Sulphite-reducing clostridia and Enterococci counts following 
supplementation, although the Enterococci count remained the same in the test group, 
whereas there was a small increase in the placebo group at the end of supplementation.  The 
L.plantarum DSM 9843 faecal count increased significantly in the test compared to placebo 
group (p < 0.001).  Flatulence was rapidly and significantly reduced in the test group 
compared with the placebo group and abdominal pain was reduced in both groups [9].     
Kajander et al. showed a significant improvement in composite IBS scores with a 
multispecies probiotic in the treatment versus placebo group.  At the same time they 
demonstrated a stabilization of the microbiota, as the microbiota similarity index increased 
with the probiotic supplementation, it decreased in the placebo group, the difference 
between the two groups was significant (p = 0.0015) [10].  In another study, Ki Cha et al. 
evaluated the effects of a multispecies probiotic on IBS symptoms and the composition of 
faecal microbiota in D-IBS patients.  The proportion of responders was significantly higher 
in the probiotic vs. placebo group, for the primary outcome measure of adequate relief of 
overall IBS symptoms (48% vs. 12%, p = 0.01).  Comparison of denaturing gradient gel 
electrophoresis (DGGE) profiles of faceal flora showed that the concordance rate 
(similarity) between bacterial compositions before and after treatment was significantly 
higher in the probiotc vs. placebo group (69.5% vs. 56.5%, p = 0.0005)[32].    One recent 
study comparing the composition and temporal stability of intestinal microbiota between 
IBS and healthy controls by PCR-DGGE revealed a greater temporal instability in IBS 
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patients (43% instability) than in the control group (29% instability)[21].  These results 
suggest that the pathophysiology of IBS may be associated with temporal instability in the 
composition of intestinal microbiota.  However in this study we found that a probiotic 
exerted no beneficial changes on the GI microbiota and no consistent correlations were 
found between GI symptom severity and total Bacteroides, Bifidobacterium bifidum or 
Lactobacillus plantarum counts.  As studies suggest an association between microbes and 
symptoms in IBS and the relative importance of different taxa for IBS symptoms has been 
found to be inconsistent between existing studies [19].  
  
Data indicates that the composition and activity of the GI microbiota is affected by the 
genetic background, age, diet and health status of the host [33].  Dietary factors have effects 
on the GI microbiota composition and this might be of considerable importance for 
symptoms of IBS patients.  This study has clearly demonstrated strong correlations between 
certain dietary agents and the resulting GI microbiota.  It seems as though lower fiber diets 
predispose towards an increased Bacteroides and decreased Bifidobacteria, seen in both C-
IBS and D-IBS groups.  Higher fiber intake was strongly associated with increased 
Lactobacillus plantarum counts in both groups.  In the D-IBS group a higher percentage 
energy from fat and low fiber intake correlated to high Bacteroides counts.  These findings 
are in agreement with a previous study by Wu et al. By combining detailed nutritional 
analysis and microbiome determination in 98 individuals, Wu et al. sought to indentify 
nutrients that substantially affect abundances of microbial species.  They found that a higher 
fat intake and lower fiber intake were associated with the Bacteroides enterotype [34].  The 
dietary associations seen here parallel a recent study by De Filippo et al.  They compared 
European children, who eat a typical Western diet high in animal protein and fat, to children 
in Burkinda Faso, who eat high-carbohydrate diets low in animal protein.  The European 
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microbiome was dominated by taxa typical of the Bacteroides enterotype, whereas the 
African microbiome was dominated by the Prevotella enterotype [35]. 
 
A significant positive correlation was also found for both C-IBS and D-IBS groups in this 
study for Lactobacillus plantarum and total protein intake, as well as Bifidobacteria and 
protein intake in the D-IBS group.  De Palma et al. assessed the effects of a gluten free diet 
(GFD) in ten healthy subjects and analysed the the change in faecal microbiota by fluorence 
in situ hybridisation (FISH) and qPCR.  Bifidobacterium, Lactobacillus and Bifidobacterium 
longum counts decreased (p = 0.020, p = 0.001 and p = 0.017, respectively) after the GFD (a 
mean decreased intake of 72.99 ± 15.69 to 68.48 ± 13.19 g/day, p > 0.05, insignificant 
decrease) assessed by qPCR [36].  These findings are similar to those found in this study. 
 
Recent research has highlighted that dietary intervention that aimed at decreasing fermentable 
carbohydrates and FODMAPS, and as a result improved IBS symptoms, also resulted in the 
decrease of beneficial Bifidobacteria [37].  This opens the question as to whether probiotic 
supplementation is needed in addition to dietary advice to restrict fermentable carbohydrate.  
Our research has demonstrated that low fiber intake decreased Bifidobacteria but this did not 
translate over to improved GI symptoms.   
 
Based on the available data, differences in the compositions of the GI microbiota are 
demonstrable between groups of people living on different diets.  These diet associated 
changes in composition can lead to changes in the metabolic activity of the GI microbiota, 
which, in turn, may provoke changes in inflammatory responses.  Although attempts to 
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change the diet composition of the GI microbiota by varying the diet have been successful in 
mice, there is a relative paucity of human dietary intervention studies.  Moreover, 
mechanisms that link dietary changes to microbial composition alterations remain poorly 
defined and need to be investigated further [13].  Large, well-controlled trials are required to 
determine the impact of altering long term dietary patterns on the human GI microbiota and 
well controlled trials are needed to determine the extent to which (and in which IBS 
subpopulation) certain probiotics are useful therapeutic strategies in the management of IBS 
symptoms [38] and how GI microbiota modulation can have a positive impact on symptom 
management.   
 
Strengths of the present study include the simultaneous assessment of microbiota, IBS 
symptoms and dietary intake.  We also divided IBS subjects according to bowel habit sub-
type.  This study is not without limitations, we quantitatively analysed only a few major 
groups of bacteria that occur in the faeces and there may have been quantitative shifts 
between different factions within groups that were not detected in this analysis.  The small 
size of the study population may have failed to detect significant changes in the microbiota.  
 
Conclusion 
This study has shown that GI Lactobacillus plantarum differs between IBS phenotypes.  An 
eight week course of the single stain probiotic L. plantarum 299v did not have any significant 
changes on the GI microflora or GI symptoms.  Certain dietary agents strongly correlate to 
certain bacterial profiles and this provides an attractive explanation that dietary nutrients are a 
factor that influences the composition of GI microbiota. 
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Chapter 7 
Concluding discussion and summary 
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1. Discussion 
Gastrointestinal (GI) symptoms and gut dysfunction caused by irritable bowel syndrome 
(IBS) affect up to one fifth of the adult population worldwide.  IBS is multi-faceted in its 
aetiology and is seen as a complex condition in which a number of major mechanisms at the 
central and peripheral level interact.  These mechanisms are poorly understood and there is 
no single curative treatment.  Therapy is aimed at reducing the symptoms, often with very 
little success.  Previous studies propose the involvement of diet and GI microbiota in the 
pathophysiology of the condition as well as a beneficial effect of certain probiotics in the 
alleviation of IBS symptoms.  This study investigated the nutrient intakes, GI microbiota and 
the impact of a probiotic, L.plantarum 299v as part of a randomised controlled trail (RCT) in 
IBS patients. 
 
2. Methodological considerations 
This section contains a discussion on the methodology and limitations thereof.  
1.1 Subjects 
IBS patients were recruited from a single centre, private referral hospital by an experienced 
gastroenterologist.  Significant differences in treatment response may exist between primary 
and referred patients.
1,2 
  While the current study was being conducted, data on the same 
probiotic strain in a group of patients from India was published.
3
  Their study consisted of a 
multi-centre trial with patients attending primary care centres and significant superiority of L. 
plantarum 299v was demonstrated over placebo.  This is in contrast to our findings and may 
indicate that the benefit of the probiotic is effective in primary health care patients but not 
those of referred patients and that the type of patient we enrolled was experiencing a greater 
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severity of symptom or more resistant conditions than those experienced by patients attending 
primary health care facilities.   
 
All subjects fulfilled the Rome II criteria for IBS, and the number of patients needed for the 
clinical trial (Article 2, Chapter 3), was based on statistical power calculations, which is in 
line with current recommendations for trials in IBS.
4
  The majority (97.5% ) of patients 
studied were women, which may reflect the higher prevalence of IBS in women
5 
or the fact 
that women in general are more prone to seek medical advice for any health problems.
6
  For 
the RCT (Article 2, Chapter 3), D-IBS vs. C-IBS vs. placebo data was compared, no 
statistically significant differences between the C-IBS and D-IBS groups were found and the 
data was grouped together as the total IBS vs. placebo group.  Healthy subjects were 
recruited as controls in Article 3 (Chapter 4).  A limitation of this part of the study is that the 
control subjects were not age or gender matched with the patients.  To comply with ethical 
requirements, the control group had to be patients referred for a colonoscopy for specific 
clinical reasons, but otherwise as healthy as possible (generally controls were persons coming 
for screening as there was a family history of colorectal cancer).  All potential patients came 
from the same referral pool, but only those that met the study inclusion criteria were enrolled, 
the rest were controls.  Overall, it was considered that the controls represented the general, 
healthy adult population well.  The subjects recruited for Article 4 (Chapter 5) were recruited 
on a “first come, first serve” basis.  In total 11 patients were used for the reliability (7.4%, n= 
6) and validity testing (6.2%, n = 5 of the total study population, n = 81) of the dietary 
records.  This is considered a good percentage of the sample for a validity and reliability 
study, 4.1% and 0.25% used by Astorg et al. and Sun et al. respectively.
7,8
  However, in 
terms of absolute numbers, it falls short of the golden standard of n= 50 for validity testing, 
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using 50 in our study would have been 62% of the total study sample.  The aim of this thesis 
and part of this study was however not to conduct a validation study but to validate the 
dietary information collected.  Fifty-two people were included in the GI microbiota analysis 
(Article 5, Chapter 6), they formed part of the same group involved in the RCT (Article 2, 
Chapter 3) and this sample size is comparable to other studies (Table 5 of Introduction).  A 
total of 124 out of the 186 (67%) stool samples collected were analysed.   
 
2.1 Study designs 
RCTs are the gold standard in clinical research.
9
 This trial was conducted as a double-blind, 
randomised, placebo-controlled study, which is the recommended trial design in IBS.
4  
Unfortunately, many RCTs with probiotics and IBS, vary considerably in design,
10-13
 some of 
the older studies are of poor quality, and few attempt to define the mechanism of action or 
assess whether symptomatic improvement is accompanied by a change in the GI microbiota.  
A recent systematic review reported that studies of poorer quality tended to show larger 
effects and published data indicate a publication bias, with non-reporting of negative effects 
in small trials.
13  
The exceptionally high placebo response, estimated to vary between 16 and 
71%,
14
  makes the placebo treatment arm essential in all IBS trials.  The current guidelines 
differentiate between short-term studies with a minimum treatment of four weeks, and long 
term studies lasting at least six months.
4
  Enck et al. demonstrated in their RCT that a mean 
response time of four- five weeks for active treatment and more than eight weeks for placebo 
was needed when a combination probiotic was used for treatment in IBS.
14
  The current study 
(Article 2, Chapter 3) was of a longer duration than the previous four trials using the same 
strain probiotic in IBS.
3,15-17
  The dosage in this study was the same as most recently 
published data, using the same strain probiotic in primary-level IBS patients.
3
  We 
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investigated whether there was an improvement in this study at week four and whether this 
possible mimicked Ducrotte et al. however, this was not a finding.  This highlights the 
importance of follow-up over longer periods of time and maybe also explains why the results 
of this study differ from previous studies.  It seems from our study as though the effect of L. 
plantarum 299v becomes stable fairly quickly and is best seen over the short term. Similar 
findings were reported by Nobaek et al., Niedzielin et al. and Sen et al.
15-17 
 
2.3 Selection of probiotic  
Different strains of organisms have very different and specialised metabolic activity.  The 
level of specificity in describing a probiotic is important as effects can be and are strain-
specific.
18,19
  The value of using a single strain probiotic over a combination of probiotic 
strains or species remains a continuing debate (Article 1, Chapter 2).  Micro-organisms may 
behave differently when administered in combinations compared to in isolation.  The use of 
combinations or cocktails concerns some investigators as attempts to classify the mechanism 
of action are hard to define.
20
 The reasons for the selection of L.plantarum 299v has been 
explained in greater detail in Article 1, Chapter 2 and Article 2, Chapter 3.    
 
2.4 Questionnaires 
The use of validated measurement instruments are recommended in IBS.
4
  Fortunately these 
tools exist and approval has been granted for use in this study. In this study the Francis 
Severity Score (FSS)
21
 and IBS quality-of-life (QOL)
22
 were used (Article 2, Chapter 3).  
The IBS-QOL is a well- tested and validated questionnaire that has been used extensively 
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around the world as a tool for assessing quality of life.  The FSS questionnaire is also a 
validated questionnaire for use in IBS.  A three day estimated food record was used for the 
collection of dietary data.  The method of choice for the collection of dietary intake data in 
intervention studies/clinical trials is the weighted or estimated dietary intake record 
method.
23
 This method is also usually used as the reference method when other 
questionnaires e.g. quantified food frequency questionnaire, needs to be validated.  There 
are inherent limitations to using an estimated three day food record, e.g. incorrect portion 
size estimation.  This prospective method of dietary assessment may be influenced by the 
presence of active IBS symptoms and may distort usual dietary intake and symptom 
severity would need to be taken into account.  Changes in the dietary intake of patients 
based on symptom severity would be expected over time, however Article 4 (Chapter 5) 
shows good reliability of dietary data and indicates that patients did not change their diets 
as symptoms fluctuated.  The reliability and validity of the three day food records gathered 
(Article 4, Chapter 5) was assessed by a test-retest design and plasma biomarker 
respectively.  The validity of dietary data as assessed by plasma fatty acids was poor.  This 
suggests that further research and testing are needed in a larger grouping of IBS patients as 
plasma fatty acid levels may be influenced by factors causing IBS symptom generation (GI 
dysbiosis or altered fatty acid metabolism; Article 4, Chapter 5) hitherto unexplored. 
  
2.5 Microbiological and biochemical analysis 
In Article 5 (Chapter 6) quantitative polymerase chain reaction time (qPCR) was used 
detecting16S ribosomal RNA (16S) of Bacteroides spp. Bifidobacteria bifidum and 
Lactobacillus plantarum in bacterial DNA of patients’ stool samples.  Kits which included 
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positive controls were provided by Primer Design (United Kingdom, UK). A kit was 
specifically developed by Primer Design to detect Lactobacillus plantarum in this study. 
 
2.6 Plasma fatty acid analysis and short comings 
Total lipids were extracted from serum samples in 2 ml chloroform methanol (2:1) and 1ml  
0.05% sulfuric acid. Lipids were derivatised in 3% methanoic sulphuric and methyl esters 
(FAMEs) extracted in hexane and analysed by gas chromatography and mass spectroscopy 
(GC-MS). A highly polar HP-88 column (Agilent) was used and could detect long chain 
fatty acids, C12 to C26 and their different isomers. 
 
2.7 Protocol deviations 
There were five protocol deviations during the course of this research and they were: 
 One of the initial objectives was to establish whether a course of probiotics may alter 
stool short chain fatty acids (SCFA).  Unpublished results (from within the same study 
group) obtained at the end of 2012 on IBS patients entitled, “An investigation of short-
chain fatty acid profiles and influential GI microbiota associated with irritable bowel 
syndrome”24 did not show a direct correlation between Bacteroides, Bifidobacteria and 
SCFA in stool samples.  The conclusion was that the transit time which is the time 
available for SCFA to be taken up by the colon, differs between the different groups.  C-
IBS patients showed the least SCFA, but have the longest transit time.  A post hoc 
analysis of the current study showed no change in patient’s constipation or diarrhoea 
frequency as compared to controls.    These results only became available at the end of 
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2012.  To do the SCFA analysis would therefore in all likelihood prove to be a waste of 
time and money, because the probiotic has already shown to have no significant 
improvement on clinical outcomes.  More importantly however was that the researchers 
realised that the conclusions drawn from such an analysis would be invalid and could be 
misleading. SCFA in the stool do not reflect whether probiotics may influence SCFA 
production by the microbiota.  This is because SCFA do not take into account factors 
like transit time, available butyrate transporters and other possible role players.  Leaving 
out the investigation into SCFA would not influence the aim of the study, since the 
quantification and effects of Bacteroides spp. Bifidobacterium bifidum and 
Lactobacillus plantarum were still determined.   
 Initially only patients requiring a colonoscopy as a part of their diagnostic work up were 
eligible for study inclusion.  An amendment was approved by the Health Research 
Ethics Committee (HREC) (Ethics reference number N10/08/270) in August 2011 
allowing the use of the gastroenterology practice’s existing data base to recruit patients 
and use those that have had a colonoscopy within the last three years.  
 A further amendment was approved by the HREC (Ethics reference number 
N10/08/270) in August 2011 allowing a decrease in the total sample size.  The initial 
power calculation was with 90% power.  However, current guidelines
4
 recommend 80% 
power (ß error or type II error of 20%) and α (type I) error of 5% using a two-sided test.  
The sample size was adjusted accordingly from n= 123 to n = 81.   The sample size 
calculation was based on the expected behaviour of the primary outcome measure, i.e. 
abdominal pain relief at the end of week 8 on the visual analogue scale [(VAS), 0-
100%] pain severity score.  The minimally clinically important difference (MCID) 
based on the primary outcome measure with this instrument is 50 points.
21
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 Plasma linolenic acid (C18:3n3), an essential fatty acid was to be used to correlate with 
analysed C18:3 (linolenic acid) dietary intake.  However we used a wider spectrum of 
fatty acids, and not solely linolenic acid (Article 4, Chapter 5).  
 Total Bifidobacteria, total Lactobacilli, total Bacteroides, total Endobacteria, L. 
plantarum 299v, total anaerobes, gram negative anaerobes, total aerobes and clostridia 
were to be measured in the stool samples.  The costs associated with the microbiota 
analyses have also increased substantially since the protocol was compiled.  Due to cost 
and time constraints only Bifidobacteria bifidum, total bacteroides and Lactobacillus 
plantarum were analysed.  There is no available gene sequencing for L. plantarum 299v 
and so indigenous Lactobacillus plantarum was assessed, following the development of 
the assay by Primer Design (UK). 
 
2.8 Study limitations 
 Patients were recruited from a single centre to ensure uniform selection by a 
gastroenterologist.  The gastroenterologist is a referral specialist, and generally sees 
more complicated patients.  Therefore more exclusion factors were applied when 
patients were selected.   
 The cost for the analysis of the microbiota escalated dramatically over the course of the 
research and because of this not all the desired microbiota could be analysed.  This 
study showed significant correlations between the diet and the microbiota analysed.  
 Rome II criteria for patient recruitment were used, however for the rest of the RCT 
Rome III guidelines were strongly adhered to.  The prevailing trend at the beginning of 
this research was to use Rome II criteria for diagnosis. 
 Participants were not age and gender matched in Article 3 (Chapter 4) (already 
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discussed). 
 There are inherent limitations associated with the used of an estimated three day food 
record, Article 4, Chapter 5 (already discussed). 
 The drop- out (20%), although within the acceptable range4 for the RCT, could have 
clouded the interpretation of data (Paper 2, Chapter 3).  The study power was reduced 
through this level of drop-outs, and it therefore remains a possibility that an effect of the 
active product was missed.  
 The diet methodology used in Table II (Article 3, Chapter 4) was revised (Addendum 1 
of Chapter 4).  The methodology as primarily outlined by the Institute of Medicine was 
adhered to and is attached as Addendum 1 of Chapter 4. 
In summary, the methods used in the current study are considered to be of a good quality, 
suitable for the study settings and comply with current recommendations.  A range of 
diverse methods have been utilized.   A newly developed L. plantarum detection kit has 
been used in conjunction with well-established techniques.  As for the clinical trial, the 
duration of the trial was sufficiently long and the number of patients included considered 
sufficient. The study shows that the search is still on for a biomarker that can be used to 
confirm dietary intake using only small subsets of participants. 
 
Bearing in mind the study limitations as stated in section 2.8 and in chapters 2-6, the core 
conclusions of this study on the relationship between nutrient intakes, GI microbiota and 
IBS as detailed as the research aims in Chapter 1 Section 5.2, are discussed below, 
furthermore the specific contribution from each area are detailed in Figure 1 and illustrates 
the contribution to knowledge that this body of work presents: 
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1.1. Literature review: To update healthcare professionals on current probiotic information 
and provide an overview of probiotic treatment approaches, with special emphasis on IBS 
(Article I, Chapter 2).  
Article 1 updated the health care professional on probiotic usage as relates to IBS.  There 
are a number of systematic reviews and meta-analysis on probiotics usage in adult IBS 
patients.
10-13,25-28
  The meta-analysis of RCTs in adult IBS patients and probiotics indicated 
a beneficial effect of different probiotics on global symptoms, abdominal pain, and 
flatulence, whereas the influence on bloating was equivocal.
29  
To date the most commonly 
studied probiotic species remain Lactobacillus and Bifidobacteria.  A number of RCTs have 
been performed on investigating the effectiveness of probiotics in IBS, a common theme 
remains suboptimal study design.  More appropriately powered studies of longer duration 
are required to assess efficacy.  Treatment options for IBS remain limited in both number 
and efficacy and a therapeutic trial of probiotics is therefore reasonable for patients 
interested in this approach, especially considering probiotics’ good safety profile.   
 
1.2. Probiotic supplementation: To conduct a well-designed randomised, double blind, 
placebo-controlled clinical trial with L. plantarum 299v as part of an intervention and 
establish whether a course of probiotics may alleviate undesirable symptoms of IBS and 
improve quality of life (Article 2, Chapter 3).   
Article 2 presents the results of a RCT in adult IBS patients with probiotic L. plantarum 
299v.  Self-analysis on the trial’s methodology as found in Brenner et al. indicates that this 
RCT was well designed,
10  
Table 1.  Further methodological considerations relevant to this 
RCT are given in Sections 2.1-2.4 – Methodological Considerations. 
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Table 1.  Methodology score for this RCT assessing L.plantarum 299v in IBS 
Study L. plantarum 299V  
ROME criteria used to define IBS * 
Randomization * 
Parallel study design * 
Double-blinding * 
Complete follow-up (intention-to-treat) * 
No placebo run-in * 
Baseline observation period before trial initiation * 
Treatment duration of 8 – 12 weeks or longer * 
Follow-up after treatment to assess symptoms * 
Treatment compliance measured * 
Sample size calculation is provided/ adequate 
sample enrolled 
* 
Primary outcome = improvement in global IBS 
symptoms 
 
Primary outcome based on patient assessment * 
Validated scale used to measure improvement of IBS 
symptoms 
* 
Rome methodology score 13/14 
Adapted from Brenner
10 
 
The RCT as a part of an intervention in this study, contributed towards the field of original 
research in the field of IBS and probiotics.  Unfortunately, the single strain probiotic 
supplementation with L. plantarum 299v, did not significantly alleviate abdominal pain 
(primary outcome measure), as measured with the FSS.  The FSS, which incorporates both 
the severity and frequency of abdominal pain, was reduced by 23.3% (from 259.66 to 
199.13) with the probiotic supplementation and by 21.1% (from 256.04 to 201.98) with the 
placebo supplementation.  According to recent guidelines on clinical trial design in 
functional GI disorders,
4,30
 global symptom measures that integrate IBS symptoms into a 
single numerical index are one of the recommended outcomes.  There is no consensus on 
what constitutes a clinically meaningful improvement in IBS, but an approximately 50% 
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improvement in the primary endpoint has been suggested as a reasonable definition of a 
responder and a 10-15% improvement of the global outcome measure over placebo as a 
clinically significant gain.
30
  The minimally clinically important difference (MCID) based 
on the primary outcome measure with the FSS was 50 points.  The integration of Quality of 
Life (QoL) monitoring into the treatment trials for IBS is strongly encouraged.
4
  In Article 
2, no effect on QoL was seen as assessed by the IBS-QOL questionnaire for probiotic 
supplementation vs. placebo.  This IBS-specific questionnaire was developed and validated 
by Patrick et al.
22
 and further validated in terms of responsiveness to treatment in a referral-
based clinical population of patients with mild to moderate FBD.
31  
The participants of this 
study responded very well to the probiotic therapy, however they also responded very well 
to placebo.  The high placebo effect trend continues among trials, using a variety of 
endpoint measures.
32 
  It is known that IBS is a condition with few outcomes that are able to 
be objectively measured and a high degree of subjectivity in many outcome measures in 
IBS clinical trials exists.  
  
1.3. Nutrient intake: To assess nutrient intake in patients with IBS compared to dietary 
recommendations.  This is with the hypotheses that a condition in which subjects insist that 
diet or trigger foods play a part in symptom generation, may lead to risk of nutrient 
inadequacy (Article 3, Chapter 4). 
Food and diet are central issues that concern patients with IBS and food is one of the most 
commonly reported triggers of IBS symptoms.  Few studies have prospectively analysed 
dietary intake in IBS.
33  
Article 3 (Chapter 4) aimed to determine the nutrient intake in 
South African IBS patients in comparison to Dietary Reference Intakes (DRI), assess 
nutritional differences between IBS subgroups and evaluate nutrient intake in IBS patients 
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in comparison to the general population.  We hypothesized that IBS patients, or at least a 
substantial proportion of the patients, would demonstrate reduced intake of certain nutrients 
compared with the general population.  This may be due to patient’s food alterations and 
restrictions because to gastrointestinal symptoms.    In the current study, patients with IBS 
demonstrated no major differences in energy and nutrient intake compared with a control 
group from the general population (Table III, Article 3, Chapter 4), which is in accordance 
with earlier findings.
33-37  
Moreover, we were unable to find a relationship between nutrient 
intake and IBS subtype based on the predominant bowel habit (Table III, Article 3, Chapter 
4).  When the IBS (combined C-IBS and D-IBS groups) was assessed for risk of nutrient 
inadequacy using the EAR cut-point method (Addendum 1 of Chapter 4), the patients in 
this study were at risk for inadequate nutrient intakes of protein, fiber, calcium, iron, 
vitamin C, folate and vitamin A (Table 1, Addendum 1 of Chapter 4).   
 
There are currently very few randomized controlled trials on dietary treatment of IBS 
patients.  Instead the current recommendations are primarily based on studies assessing 
physiological function in relation to dietary components.
38  
Common dietary advice to 
reduce IBS symptoms are to reduce intake of lactose, FODMAPS, fat, gas-producing food 
items and also to decrease or increase the intake of dietary fiber depending on symptom 
profile.
39,40  
All this dietary advice implicates a risk of an inadequate nutrient intake.  For 
example, a decreased milk intake may imply a decreased intake of vitamin B12, calcium, 
riboflavin and vitamin D, if it is not replaced with a mineral, and vitamin –enriched 
substitute.
33
   
It is possible that the IBS patients in our study, to decrease symptoms, avoided some of the 
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above-mentioned food items, and consumed less milk products, which would result in a 
smaller intake of calcium, as usual intake places the patients at risk of inadequacy according 
to the EAR cut-point method (Table 1 in Addendum 1 of Chapter 4).  Unfortunately, we 
have no information if the IBS patients had altered their food intake to reduce IBS 
symptoms, or due to other reasons.   
 
Despite the fact that food is central to patients with IBS, and patients often complain of 
postprandial worsening of their symptoms,
41 
few studies exist, which have characterized 
nutrient intake in IBS patients. An American population-based, case-control study 
compared patients with functional gastrointestinal disorder (FGID) with control subjects 
and found no difference in intakes of nutrients, calories, dietary fiber, vitamins and minerals 
between the groups, similar to our findings.  However only a subgroup completed a 
prospective food diary in that study and the information reported mainly comes from a 
retrospective food frequency questionnaire, with the obvious risk of recall bias.
34
  
 
Food items exacerbate symptoms of IBS and exclusion of some food items form the diet is 
considered common,
42 
and it seems as though the nutrient intake in IBS patients in this 
study places them at risk of inadequacy.  This is in contrast to previous studies which show 
that IBS patients consume food in accordance to current nutritional recommendations
33-35 
but similar to the findings of McCoubrey et al. and Irvine et al. where they concluded that 
IBS patients may be at risk of low micronutrient intakes.
43,44
  However, symptoms for poor 
micronutrient intake (e.g. calcium, iron, folate) do not correspond with clinical symptoms in 
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our study.  In summary, we have used a dietary assessment tool aimed at estimating nutrient 
intakes in adult IBS patients.  There are no reported studies, which have used this strategy 
in the South African IBS population.  Our data suggests that this group is at risk of 
inadequate nutrient intakes.    
 
1.4. Validation and reproducibility of dietary data: To validate and assess the 
reproducibility of food records in irritable bowel syndrome patients (Article 4, Chapter 5). 
In Article 4 (Chapter 5) we examined the reliability and validity of three day estimated food 
records in a subgroup of IBS patients.  Actual nutrient intake in IBS, has not been 
extensively reported.  An even littler known fact is how reliable and valid the dietary data 
is.  To the author’s knowledge there has been no published data on the validity and 
reliability of IBS dietary data.  This is pertinent information to know in a condition where 
diet is thought to play such a significant role.  This study has shown that with a fairly short 
assessment tool (a three day food record) dietary data is reliable in IBS.  However, using 
plasma fatty acids as biomarkers for validating nutrient intake data showed weak 
correlations, suggesting that further research and testing are needed in a larger grouping of 
IBS patients.  The fundamental advantage of using a biomarker is that measurement errors 
are unrelated with errors in any dietary assessments, e.g. do not rely on memory, self-
reported information or interviewer bias.
43  
Studies have confirmed the use of plasma fatty 
acids as biomarkers of dietary intakes in healthy subjects.
7,45,46  
Their use in patients with 
disease –profiles are lesser known.  The effects of genetic variability in fatty acid 
biochemistry pathways, direct/indirect determinants of fat absorption, or gene-diet/nutrient 
or gene-gene interactions in fatty acid profiles as dietary markets is largely unexplored.   
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1.5. Characterisation of probiotic action and the nutrient intake on GI microbiota: Identify 
possible nutrient risk components for establishing GI microbiota involved in IBS and as 
part of an intervention, determine whether a course of probiotics may alter stool microbiota 
(Article 5, Chapter 6).   
Article 5 (Chapter 6) contributes to a growing body of knowledge on the role of probiotic 
modulation and diet on GI microbiota.  This study has clearly demonstrated strong 
correlations between certain nutrients (e.g. protein, fiber) and the resulting GI microbiota.    
Overall dietary changes can explain 57% of the total structural variation in GI microbiota 
whereas changes in genetics accounted for no more than 12%.
47 
  This indicates that diet has 
a dominating role in shaping GI microbiota and changing key populations may transform 
healthy GI microbiota into a disease-inducing entity.
48
   The altered microbiota resulting 
from diet-induced dysbiosis found in this study, may be a factor contributing towards 
symptom generation in IBS.  This is a field of study very little explored to date. 
   
No published work has been conducted on the faecal microbiota community of IBS in the 
South African population.  A better understanding of the prevalent bacterial community in 
faecal samples might be useful for either eliminating or restoring certain species to improve 
one’s health.  This is of particular importance in IBS patients where deviations in the GI 
microbiota as compared to healthy controls are well documented.
49-52  
Although findings 
vary between studies, many show that patients with IBS have lower Lactobacilli and 
Bifidobacteria (two organisms frequently used in probiotic preparations).
53  
Furthermore 
differences in IBS phenotype are also documented.
54,55
  In this study we looked at the GI 
microbiota between C-IBS and D-IBS patients for Bacteroides spp., Bifidobacteria bifidum 
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spp. and Lactobacillus plantarum.  The Lactobacillus plantarum was found to be 
significantly lower in D-IBS patients as compared to C-IBS (Article 5, Chapter 6).  No 
other differences were found between the two groups. 
 
Relatively few RCT on IBS and probiotics have investigated possible modifications of the 
GI microbiota by the probiotic.  Knowledge on the role of microbiota modulation in 
symptom relief is therefore limited.
15, 56-58  
Pervious trials have indicated that the probiotic 
seemed to exert a balancing effect on the microbiota.
58  
In this study the bacterial counts 
were analysed by genus and strain-specific qPCR assays.  We found that a probiotic exerted 
no beneficial changes on the GI microbiota (Article 5, Chapter 6).  Furthermore, no 
consistent correlations were found between GI symptom severity and the microbiota.  
Paradoxically, this confirms previous studies where probiotics did influence symptom 
severity and GI microbiota.  We found no improvement in GI symptoms and no change in 
the microbiota following a course of probiotics.  This may be due to the specific probiotic 
used in the trial.  It does seem then that GI symptoms improve only if GI microbiota 
improve in favourable response to probiotic administration.  Studies suggest an association 
between microbes and symptoms in IBS, however, these findings are inconsistent between 
existing studies.
59    
Figure 1 shows the contribution to knowledge achieved by this body of  
research. 
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IRRITABLE BOWEL 
SYNDROME 
 Symptoms 
 Behaviour 
OUTCOME 
 Medication 
 Health care visits 
 Daily function 
 Quality of life 
PHYSIOLOGY 
 Abnormal motility 
 Visceral pain hypersensitivity 
  Low grade inflammation and mast cell involvement 
  Serotonergic disorder 
 Nutrient intake 
 Altered microbiota 
  
 
EARLY LIFE 
 Genetics 
 Environment 
BRAIN-GUT INTERACTION 
 
Nutrient intake of South African IBS 
patients unknown 
Published article showing ↑ risk of 
nutrient inadequacy in key micro and 
macronutrients 
Validity and reliability of nutrient intake 
data unknown in IBS patients 
Good reliability but poor validity as 
measured by plasma fatty acids  
The effect of nutrient intakes and a 
probiotic on GI microbiota is poorly 
understood in IBS 
Significant impact of nutrient intakes on 
GI microbiota 
Insignificant impact of probiotic on GI 
microbiota 
 
The efficacy of L.plantarum 299v as 
part of a well conducted RCT in IBS is 
unknown  
Published article showing no significant 
improvement between treatment and 
placebo groups on symptom severity 
nor quality of life 
 
Literature search identifying gaps in 
probiotic research and IBS.  
Continuous need to keep health care 
professionals up to date with the 
latest probiotic research and IBS 
Published review article updating 
health professionals on current 
probiotic and IBS  information and 
identifying gaps in probiotic RCTs 
 
 
G
ap
s 
 a
n
d
  g
ai
n
s 
in
 
kn
o
w
le
d
ge
  
P
at
h
o
p
h
ys
io
lo
gy
  
H
ealth
 o
u
tco
m
es (sym
p
to
m
s 
an
d
 q
u
ality o
f life) 
PSYCHOSOCIAL FACTORS 
 Life stress 
 Psychological state 
 Coping 
 Social support 
Figure 1. Conceptual frame work depicting the contribution of knowledge gained from the research 
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The study hypotheses (as discussed on page 57) are therefore accepted / rejected as 
follows: 
 An intervention of the probiotic, L.plantarum 299v at a dose of two daily 5 X 109 colony 
forming units (cfu), will not alleviate the undesirable i) symptoms of IBS nor ii) improve 
quality of life (Article 2, Chapter 3) in C-IBS and D-IBS subjects.  Accepted point  i) and 
ii) of the null hypothesis 
 The nutrient intakes of IBS (C-IBS and D-IBS) subjects placed them at risk nutrient of 
inadequacy compared to Dietary Reference Intake (DRI) recommendations (Article 3, 
Chapter 4).  Accept the null hypothesis. 
 Three day estimated food records demonstrate poor i) reproducibility and ii) validity in 
IBS (C-IBS and D-IBS) subjects (Article 4, Chapter 5).  Reject point i) and accept point 
ii) of the null hypothesis. 
 Nutrient intakes do not have an influence on the faecal microbiota (i.e. Bifidobacterium 
bifidum, Lactobacillus plantarum and Bacteroides spp.) of IBS (C-IBS and D-IBS) 
subjects (Article 5, Chapter 6).  Reject the null hypothesis.  
 L.plantarum 299v does not have an influence on the faecal microbiota (i.e. 
Bifidobacterium bifidum, Lactobacillus plantarum and Bacteroides spp.) (Article 5, 
Chapter 6).  Accept the null hypothesis. 
 
Finally, it can be conclusively stated that this study provides original insights into i) the 
efficacy of L.plantarum 299v as a treatment option in IBS, ii) nutrient intakes in a population 
of South African IBS patients, iii) the validity and reliability of dietary data in IBS patients, 
iv) the modulatory effect of nutrients and a probiotic on GI microbiota and GI symptoms. 
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Recommendations for future research include the following: i) As no study has reliably 
assessed fluctuations over time in food intake in IBS patients and their relationship with 
fluctuations in the symptom pattern, this is a future research recommendation that would be 
of great value.  Prospective studies are needed to assess the association between fluctuations 
in symptom severity over time and changes in intake of nutrients and ii) as IBS is chronic in 
nature, longitudinal studies assessing GI microbiota during remission, and symptom flare-
ups, stress, infection or following dietary manipulation and the use of probiotics are 
warranted. 
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ADDENDUM 1        
           
               PATIENT STUDY CODE 
 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
 
TITLE OF THE RESEARCH PROJECT: The relationship between dietary intake, gut 
microflora and irritable bowel syndrome 
PRINCIPAL INVESTIGATOR: Cheryl Stevenson 
ADDRESS: Suite G2, Netcare Greenacres Hospital, Port Elizabeth 
CONTACT NUMBER: 041 581 0034 / 082 751 4411 
 
You are being invited to take part in a research project.  Please take some time to read the 
information presented here, which will explain the details of this project.  Please ask the 
dietitian (Cheryl Stevenson) or doctor (Dr Ernst Fredericks) any questions about any part of 
this project that you do not fully understand.  It is very important that you are fully satisfied 
that you clearly understand what this research entails and how you could be involved.  Also, 
your participation is entirely voluntary and you are free to decline to participate.  If you say 
no, this will not affect you negatively in any way whatsoever.  You are also free to withdraw 
from the study at any point, even if you do agree to take part. 
 
This study has been approved by the Health Research Ethics Committee (HREC) at 
Stellenbosch University and will be conducted according to the ethical guidelines and 
principles of the International Declaration of Helsinki, South African Guidelines for Good 
Clinical Practice and the Medical Research Council (MRC) Ethical Guidelines for Research. 
 
What is this research study all about? 
 This research study is looking at the relationship between food intake, probiotics 
(good bacteria that are normally found in the body) and irritable bowel syndrome.  
We suspect that there may be an imbalance of certain healthy bacteria in the gut of 
patients with irritable bowel syndrome (IBS).  We would like to investigate if a 
certain probiotic can rectify the imbalance and as a result decrease the symptoms (e.g. 
pain and bloating) of IBS. 
 The study will only be conducted at Suite G2, Netcare Greenacres Hospital, Port 
Elizabeth.  The total number of participants to be recruited for this study is 81. Only 
patients that suffer from IBS will be eligible for inclusion in this study. 
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 In this project we are aiming to: 
o Find out if there is a relationship between the bacteria found in your colon and 
food intake.  
o  Establish whether a course of probiotics may alleviate undesirable symptoms 
of IBS and improve quality of life.   
 Most of the procedures are routine for IBS patients consulted by Dr Fredericks and 
are required regardless of the study.  These include:  
 Your personal and relevant medical and surgical history (routine data). 
 The other procedures for which you will receive full instructions prior to the study 
include: 
The collection of three stool samples, before, during and after a course 
of probiotics 
The completion of a three day estimated food record 
The completion of irritable bowel syndrome symptoms and quality of 
health questionnaires (At six time points during the duration of the 
trial) 
 You will be required to take either an eight week course of probiotics or a placebo (an 
inactive substance that looks like a medicine but contains no active ingredient).  You 
will be unaware of whether you are receiving the probiotics or the placebo during the 
course of the trial.  You will be required to take the probiotics/placebo in the form of 
two daily capsules.  This will be given to you free of charge. 
 
Why have you been invited to participate? 
 You have been asked to participate in this study as you have irritable bowel 
syndrome.   
 
What will your responsibilities be? 
Your responsibility will be: 
  To collect three stool samples at home and deliver them to the practise at Netcare  
Greenacres Hospital.   
 Record your food intake for three days and return this information on the day of your 
second visit.  
  Complete an eight week course of probiotics or placebo.  
  Complete questionnaires on your IBS symptoms and Quality of Lifestyle at intervals 
during the trial.  
  Attend all five scheduled visits. 
 Be available for one telephonic consultation with the dietitian. 
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Will you benefit from taking part in this research? 
 If you are selected to receive the probiotic treatment, you will hopefully experience an 
alleviation of IBS symptoms, with specific regards to abdominal pain.  Future IBS 
patients will be given improved dietary advice based on the findings of this research. 
 
Are there in risks involved in your taking part in this research? 
 There are no risks involved with your taking part in this research.  Probiotics are safe 
for human consumption and should not cause any discomfort.  In previous research 
this probiotic had no side-effects.  In studies with other types of probiotics, some 
patients have complained of the taste of the product, nausea, headache and heartburn.  
In the unlikely event of an adverse effect you will be covered by the University of 
Stellenbosch Insurance for Clinical Trials. 
 
If you do not agree to take part, what alternatives do you have? 
 This study will not affect your medical assessment or treatment both now or in the 
future.  
 
Who will have access to your medical records? 
 The information collected will be treated as confidential and protected.  If it is used in 
a publication or thesis, the identity of you, the participant, will remain anonymous.  
The doctor, nursing sister and principal investigator of this project will have access to 
the information.   
 
What will happen in the unlikely event of some form of injury occurring as a direct 
result of your taking part in this research study? 
 The probiotic forms part of normal gut flora and we suspect that IBS patients have 
insufficient available numbers of this gut flora.  The probiotic has medical approval 
for human consumption and should therefore not be harmful.  If you experience any 
worsening of your symptoms and you suspect it may be due to the probiotic please 
contact Dr Fredericks to discuss your symptoms with him.  
 
Will you be paid to take part in this study and are there any costs involved? 
 You will receive R80 per visit for transport costs for all visits to the practise. There 
are no other additional expenses. 
 
Is there any thing else that you should know or do? 
 It is your right to be told any new relevant information that arises during the course of 
the trial and this will be done so by the investigator. 
 You can contact Dr Fredericks on tel. 041 3632870 or after hours at 082 859 6354 if 
you have any further queries or encounter any problems regarding your medical care. 
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 You can contact Cheryl Stevenson (the dietitian) at tel. 041 581 0034 or 082 751 4411 
with regards to dietary related questions.  
 You can contact the Health Research Ethics Committee at 021-938 9207 if you have 
any concerns or complaints that have not been adequately addressed by your study 
doctor. 
 You will receive a copy of this information and consent form for your own records. 
 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a 
research study entitled:  The relationship between dietary intake, gut microflora and irritable 
bowel syndrome. 
 
I declare that: 
 I have read or had read to me this information and consent form and it is written 
in a language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been adequately 
answered. 
 I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
 I may choose to leave the study at any time and will not be penalised or 
prejudiced in any way. 
 I may be asked to leave the study before it has finished, if the study doctor or 
researcher feels it is in my best interests, or if I do not follow the study plan, as 
agreed to. 
 I have no objections that data collected during the course of this study can be 
used for research purposes as stated and that my anonymity will be guaranteed. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2013. 
 
 
......................................................................   ...................................................................  
Signature of participant Signature of witness 
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Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
 I explained the information in this document to ………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer them. 
 I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2013. 
 
 
......................................................................   ...................................................................  
Signature of investigator Signature of witness 
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ADDENDUM 2 
                                                                                  PASIËNT STUDIEKODE 
 DEELNEMERINLIGTINGSBLAD EN -TOESTEMMINGSVORM 
TITEL VAN DIE NAVORSINGSPROJEK: Die verhouding tussen dieetinname, derm  
mikroflora en prikkelbare derm sindroom (“The relationship between dietary intake, gut 
microflora and irritable bowel syndrome”). 
HOOFNAVORSER: Cheryl Stevenson  
ADRES: Suite G2, Netcare Greenacres Hospitaal, Port Elizabeth 
KONTAKNOMMER: 041 581 0034 / 082 751 4411 
U word genooi om deel te neem aan ’n navorsingsprojek.  Lees asseblief hierdie 
inligtingsblad op u tyd deur aangesien die detail van die navorsingsprojek daarin verduidelik 
word.  Indien daar enige deel van die navorsingsprojek is wat u nie ten volle verstaan nie, is u 
welkom om die dieetkundige (Cheryl Stevenson) of die dokter (Dr Ernst Fredericks) daaroor 
uit te vra.  Dit is baie belangrik dat u ten volle moet verstaan wat die navorsingsprojek behels 
en hoe u daarby betrokke kan wees.  U deelname is ook volkome vrywillig en dit staan u vry 
om deelname te weier.  U sal op geen wyse hoegenaamd negatief beïnvloed word indien u 
sou weier om deel te neem nie.  U mag ook te eniger tyd aan die navorsingsprojek onttrek, 
selfs al het u ingestem om deel te neem. 
Hierdie studie is goedgekeur deur die Komitee vir Mensnavorsing van die Universiteit 
Stellenbosch en sal uitgevoer word volgens die etiese riglyne en beginsels van die 
Internasionale Verklaring van Helsinki, Suid-Afrikaanse riglyne vir Goeie Kliniese 
Praktykvoering en die Mediese Navorsingsraad (MNR) se etiese riglyne vir navorsing. 
 Wat behels hierdie navorsingsprojek? 
 Die studie ondersoek die verband tussen voedselinname, probiotika (goeie bakterieë 
wat normaalweg in die liggaam gevind word) en prikkelbare derm sindroom (PDS). 
Ons vermoed dat daar 'n wanbalans van sekere gesonde bakterieë in die derms van 
pasiënte met PDS is.  Ons wil graag ondersoek of 'n sekere probiotika die wanbalans 
reg kan stel en gevolglik die simptome (bv. pyn en winderigheid) van PDS verminder. 
 Die studie sal uitgevoer word by Suite G2, Netcare Greenacres Hospitaal, Port 
Elizabeth. Die totale aantal persone wat genooi gaan word om deel te neem aan 
hierdie studie is 81. Slegs PDS pasiënte sal in aanmerking kom vir insluiting in 
hierdie studie. 
 In hierdie projek wil ons: 
o  Uitvind of daar 'n verband is tussen die bakterieë in jou derm (kolon) en 
voedsel inname. 
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o  Vasstel of 'n kursus van probiotika die PDS ongewensde simptome kan verlig 
en kwaliteit van lewe kan verbeter. 
 Die meeste van die prosedures is roetine vir PDS pasiënte gekonsulteer deur Dr 
Fredericks en is nodig, ongeag van die studie. Dit sluit in: 
o U persoonlike en relevante mediese en chirurgiese geskiedenis (roetine data). 
o Die ander prosedures waarvoor u volledige instruksies sal ontvang voor die 
studie begin, sluit in: 
Die versameling van drie stoelgangmonsters, voor, tydens en na 'n 
kursus van probiotika. 
Die voltooiing van 'n drie-dag voedsel rekord. 
Die voltooiing van ‘n PDS-simptome en -kwaliteit van gesondheidsorg 
vraelyste (op ses tydspunte tydens die studie). 
 U sal gevra word om ‘n agt week kursus van probiotika óf ‘n plasebo (‘n onaktiewe 
stof wat lyk soos 'n medisyne, maar wat geen aktiewe bestandele bevat) te neem. U 
sal nie weet of u die probiotika óf die plasebo neem nie.  Daar sal van u verwag word 
om die probiotika/plasebo in die vorm van twee kapsules per dag te neem. Dit sal 
gratis aan u gegee word. 
 Hoekom is jy genooi om deel te neem? 
 U is gevra om deel te neem aan hierdie studie omdat want u prikkelbare derm 
sindroom het. 
 Wat sal u verantwoordelikhede wees? 
 U verantwoordelikheid sal wees: 
 Om drie stoelgang monsters by die huis te versamel en dit af te lewer by die praktyk 
by Netcare Greenacres-hospitaal. 
 Om rekord van u voedselinname oor drie dae te hou en dit in te handig op die dag van 
u kolonoskopie. 
 Om 'n agt week kursus van probiotika óf plasebo te volg. 
 Om vraelyste te voltooi oor u PDS simptome en die kwaliteit van lewe met 
tussenposes gedurende die studie. 
 Om al vyf geskeduleerde besoeke na te kom. 
 Om beskikbaar wees vir een telefoniese konsultasie met die dieetkundige. 
 Sal u voordeel trek deur deel te neem aan hierdie navorsingsprojek? 
 As u gekies word om die probiotika te ontvang, sal u hopelik verligting van PDS 
simptome ervaar, met spesifieke betrekking tot abdominale pyn. Toekomstige PDS 
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pasiënte sal moontlik beter dieetriglyne ontvang op grond van die bevindinge van 
hierdie studie. 
 Is daar risiko's verbonde aan u deelname aan hierdie navorsing? 
 Daar is geen risiko's verbonde aan u deelname aan hierdie navorsing nie. Probiotika is 
veilig vir menslike gebruik en behoort nie enige ongerief te verskaf nie. In die 
onwaarskynlike geval van enige newe-effekte, sal u gedek wees deur die Universiteit 
Stellenbosch Assuransie vir Kliniese Proewe. 
 Watter alternatiewe is daar indien u nie instem om deel te neem nie? 
 Hierdie studie sal nie u huidige of toekomstige mediese assessering of behandeling 
beïnvloed nie. 
 Wie sal toegang hê tot u mediese rekords? 
 Die inligting wat versamel word, sal as vertroulik hanteer en beskerm word. Indien dit 
gebruik word in 'n publikasie of tesis, sal u identiteit anoniem bly. Slegs die dokter, 
verpleegsuster en hoofnavorser van hierdie projek sal toegang hê tot die rekords. 
 Wat sal gebeur in die onwaarskynlike geval van ’n besering wat mag voorkom as 
gevolg van u deelname aan hierdie navorsingsprojek ? 
 Die probiotika vorm deel van die normale dermkanaal flora en ons vermoed dat PDS 
pasiënte onvoldoende hoeveelhede van die derm flora het.  Die probiotika het mediese 
goedkeuring vir menslike gebruik en behoort dus nie skadelik te wees nie.  In vorige 
navorsing het hierdie probiotika geen newe-effekte getoon nie.  In studies met ander 
vorme van probiotika, het sommige pasiënte gekla oor die smaak van die produk, 
naarheid, hoofpyn en sooibrand.  Indien u enige verergering van simptome ondervind 
en u vermoed dat dit moontlik te wyte aan die probiotika kan wees, kontak asb Dr 
Fredericks om die simptome met hom te bespreek. 
 Sal u betaal word om deel te neem in hierdie studie en is daar enige koste verbonde? 
 U sal R80 per besoek ontvang. Daar is geen ander addisionele uitgawes nie. 
 Is daar enige iets anders wat u moet weet of doen? 
 Dit is u reg om te weet van nuwe relevante inligting wat beskikbaar kom gedurende 
die uitvoering van die studie en dit sal gedoen word deur die navorser. 
 U kan Dr Fredericks kontak by tel.  041 3632870 of na ure by 082 859 6354 indien u 
enige verdere navrae of probleme het aangaande u mediese sorg. 
 U kan Cheryl Stevenson (die dieetkundige) kontak by tel.  041 581 0034 of 082 751 
4411 met betrekking tot voedingverwante vrae. 
 U kan die Komitee vir Mensnavorsing kontak by 021-938 9207 indien u enige 
bekommernis of klagte het wat nie bevredigend deur u studiedokter hanteer is nie. 
 U sal 'n afskrif van hierdie inligtings- en -toestemmingvorm ontvang vir u eie rekords. 
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 Verklaring deur deelnemer 
Met die ondertekening van hierdie dokument onderneem ek ………………………………… 
om deel te neem in 'n navorsingsprojek getiteld: Die verband tussen dieetinname, derm 
mikroflora en prikkelbare derm sindroom. 
 Ek verklaar dat: 
 Ek hierdie inligtings- en toestemmingsvorm gelees het of aan my laat voorlees het 
en dat dit in ’n taal geskryf is waarin ek vaardig en gemaklik mee is. 
 Ek geleentheid gehad het om vrae te stel en dat al my vrae bevredigend 
beantwoord is. 
 Ek verstaan dat deelname aan hierdie navorsingsprojek vrywillig is en dat daar 
geen druk op my geplaas is om deel te neem nie. 
 Ek te eniger tyd aan die navorsingsprojek mag onttrek en dat ek nie op enige 
wyse daardeur benadeel sal word nie. 
 Ek gevra mag word om van die navorsingsprojek te onttrek voordat dit afgehandel is 
indien my dokter of navorser van oordeel is dat dit in my beste belang. 
 Ek geen besware het dat die data wat versamel word gedurende die studie gebruik kan 
word vir navorsingdoeleindes soos uiteengesit is en dat my anonimiteit gewaarborg 
sal word nie. 
 
 Geteken te (plek) ..................................................... op (datum) ……………………… 2013. 
 
 
…………………………………...                                         ………………………………. 
 Handtekening van deelnemer                                              Handtekening van getuie 
 Verklaring deur die navorser 
 Ek, (naam)……………………………………………………………………. verklaar dat: 
  Ek die inligting in hierdie dokument verduidelik het aan…………………………. 
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  Ek hom/haar aangemoedig het om vrae te vra en voldoende tyd gebruik het om dit te 
beantwoord. 
  Ek tevrede is dat hy/sy al die aspekte van die navorsingsprojek soos hierbo bespreek, 
voldoende verstaan . 
 
 Geteken te (plek)…………………………………. op (datum)…………………………2013  
 
 
…………………………………..                                               ………………………………. 
 Handtekening van navorser                                            Handtekening van getuie  
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ADDENDUM 3 
 
INTERVENTION CHECKLIST – TO BE INITIALED ON COMPLETION BY 
INVESTIGATORS  
 
Patient code: 
Contact number: 
 
VISIT 1: (First consultation) WEEK -2 – 0 of trial (Run in period) DATE:…………………… 
Screening of 
patient by Dr for 
trial – Rome II 
criteria 
Informed consent 
doc. for study 
given to patient – 
dietitian/Dr 
Francis Severity 
Score (no.1) 
completed, if score 
< 75 can’t enrol in 
study - dietitian 
3 day dietary 
record explained - 
dietitian 
Stool sample 
collection (no. 1) 
explained – 
nursing sister 
Colonoscopy prep 
explained – 
nursing sister 
    
 
 
VISIT 2: (Colonoscopy procedure day) WEEK 0 of trial (Baseline) DATE:………................. 
Signed informed 
consent doc. 
handed in – to 
receptionist/nursin
g sister 
Stool sample (no. 
1) handed in – to 
receptionist/nursin
g sister 
Dietary info 
completed 
and handed 
in 
Francis 
Severity Score 
questionnaire 
(no. 2) 
completed at 
practise – 
dietitian/nursin
g sister 
Complete IBS-
QOL 
questionnaire 
(no.1) at 
practise – 
dietitian/nursin
g sister 
Randomisation to 
treatment product 
or placebo – 
dietitian/nursing 
sister 
Patient to take 
home capsules and 
start treatment 
(weeks 0 - 4 of 
trial) - 
dietitian/nursing 
sister 
Colonoscop
y - Dr 
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VISIT 3: TELEPHONIC CALL: WEEK 2 of trial (Treatment) DATE:……………. 
Francis 
Severity Score 
Questionnaire  
(no.3) 
completed by 
dietitian via 
telephone call 
Ask questions on 
tolerability/adverse 
events and 
compliance (see 
questions directly 
below) 
   
 
Please ask the patient the following: 
Tolerability of test product during weeks 0-2?: Good/poor, why? 
Adverse health event (this could be anything that happens in the time whilst on the test 
product e.g. angina or something that might be caused by the test product e.g. dyspepsia), 
weeks 0-2? Yes/no, what? 
 
 
Compliance in using test product during weeks 0-2?  
Do you have any leftover tablets  Yes/No 
If yes, why were you unable to take the tablet (s)? 
How many left over tablets do you have? 
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VISIT 4: WEEK 4 of trial (Treatment) DATE:……………. 
Stool sample 
collection (no. 
2) explained, 
give specimen 
bottle (same as 
for sample 1) – 
nursing 
sister/dietitian 
Francis 
Severity Score 
questionnaire 
(no.4) 
completed at 
practise – 
nursing 
sister/dietitian 
Ask questions on 
tolerability/adverse 
events and 
compliance (see 
questions directly 
below) – nursing 
sister/dietitian 
Patient to take 
home capsules 
(weeks 4-8 of 
trial) – nursing 
sister/dietitian 
Give participant 
travel money 
(R80) 
 
Please ask the patient the following: 
Tolerability of test product during weeks 3-4?: Good/poor, why? 
 
Adverse health event (this could be anything that happens in the time whilst on the test 
product e.g. angina or something that might be caused by the test product e.g. dyspepsia), 
weeks 3-4? Yes/no, what? 
 
 
Compliance in using test product during weeks 3-4?  
Do you have any leftover tablets  Yes/No 
If yes, why were you unable to take the tablet (s)? 
How many left over tablets do you have? 
Please hand tablets back: 
 
Stellenbosch University  http://scholar.sun.ac.za
227 
 
 
VISIT 5: WEEK 8 of trial (End of treatment) DATE:…………….. 
Stool sample 
(no. 2) handed 
in – nursing 
sister 
Francis 
Severity Score 
questionnaire 
(no.5) 
completed at 
practise – 
nursing 
sister/dietitian 
Complete IBS-
QOL 
questionnaire 
(no.2) at 
practise – 
nursing 
sister/dietitian 
Ask questions on 
tolerability/adverse 
events and 
compliance (see 
questions directly 
below) – nursing 
sister/dietitian 
Stool sample 
collection (no. 
3) explained 
(same as for no 
1 & 2), give 
specimen 
bottle- nursing 
sister/dietitian 
Give participant 
travel money 
(R80) 
    
 
Please ask the patient the following: 
Tolerability of test product during weeks 4-8?: Good/poor, why? 
 
 
Adverse health event whilst on test product, weeks 4-8? Yes/no, what? 
 
 
Compliance in using test product during weeks 4-8?  
Do you have any leftover tablets  Yes/No 
If yes, why were you unable to take the tablet (s)? 
How many left over tablets do you have? 
Please hand back: 
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VISIT 6: WEEK 10 of trial (Wash – out period) DATE:…………… 
Stool sample 
(no 3) handed 
in – nursing 
sister 
Francis 
Severity Score 
questionnaire 
(no.6) 
completed at 
practise – 
nursing 
sister/dietitian 
Complete QOL 
questionnaire 
(no.3) at 
practise – 
nursing 
sister/dietitian 
Ask questions on 
tolerability/adverse 
events and 
compliance (see 
questions directly 
below) – nursing 
sister/dietitian 
Give 
participant 
travel money 
(R80) 
 
Please ask the patient the following: 
Adverse health event during weeks 8-10? Yes/no, what? 
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ADDENDUM 4 
 PATIENT STUDY CODE 
      
DEMOGRAPHIC QUESTIONNAIRE 
1. Initials___________    2. DOB: ___________ 
 
3. Height: __________ 4. Weight: __________ 5. BMI: ________ 
 
6. Gender:    Male     7. Population group: 
  Female                Caucasian 
        Coloured 
8. Smoke: Y/N      Black 
 If yes: how many____/day    Indian 
 
9. Background medical history   10. Current medication: 
 ____________________    _________________ 
 ____________________    _________________ 
 ____________________    _________________ 
 ____________________    _________________ 
11. Previous bowel surgery:    12. Recent antibiotic use (name and date): 
 _____________________    __________________ 
 _____________________    __________________ 
_____________________    __________________  
_____________________    __________________ 
 
13. Family history of CRC: Y/N   If yes, 
 Relationship________________   Age at diagnosis: _______ 
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Relationship________________   Age at diagnosis: _______ 
Relationship________________   Age at diagnosis: _______ 
Relationship________________   Age at diagnosis: _______ 
 
14. Family history of IBD: Y/N  If yes, 
 Relationship________________   Diagnosis: ____________ 
Relationship________________   Diagnosis: ____________ 
 
15. Family history of metabolic syndrome: Y/N   If yes, 
 Relationship________________   Diagnosis: ____________ 
Relationship________________   Diagnosis: ____________ 
Relationship________________   Diagnosis: ____________ 
Relationship________________   Diagnosis: ____________ 
 
16. Family history of IBS: Y/N. If yes, 
 Relationship________________    
Relationship________________ 
 
17. Type of IBS 
Constipation pre-dominant  
Diarhhea pre-dominant 
Alternating (if alternating, what is the predominant symptom currently?) 
 
18. Frequent antibiotic use during childhood:  Y/N 
 
19. Trigger of IBS: 
 
None 
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Emotional 
Gastroenteritis 
Antibiotic treatment 
Other 
 
20. Lactose intolerance: Y/N 
 
If yes, was this a self-diagnosis or medical (doctor) diagnosis? 
Futhermore was the diagnosis lactose intolerance or lactose malabsorption? 
 
21. Use of anti-IBS treatment: Y/N 
 
If yes, what and for how long? 
 
22. Duration of IBS: 
 
 
 
o-------------------------------O---------------------------------o  
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ADDENDUM 5 
THREE DAY FOOD RECORD 
                                                                    PATIENT STUDY CODE                             (official use) 
(Please record all the food/drink eaten in the three days prior to the preparation for 
operational procedures) 
Name: 
Date of Birth:                                           Age: 
Male/Female 
Telephone no. (H):                                  (W):                             (cell): 
Please contact dietitian Cheryl Stevenson with any queries on 082 751 4411 
 
 
 
 
 
PLEASE REMEMBER: 
 
 COMPLETE FOR TWO WEEK DAYS AND ONE WEEKEND DAY 
 
 DO NOT COMPLETE ON COLON PREPERATION DAY PRIOR TO 
COLONOSCOPY 
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PROCEDURE FOR COMPLETING THE ESTIMATED DIETARY RECORD 
The participant is required to record all foods and drinks eaten/drank on three days (one 
weekend and two week days).  The dietary record RECORDING SHEET consists of a cover 
page and several recording pages. 
Steps to follow: 
Step 1: From the time you wake up in the morning until you go to bed at night you need to 
record everything you eat and drink on the recording sheets. DO NOT change the way you 
eat. Remember to record the day of the week every time you start a new day. 
Step 2: Every time you eat and drink something, remember to record the time of day in the 
first column. 
Step 3: In the next column describe the food item in as much detail as possible and according 
to the method of preparation, examples follow below: 
Liquids 
An average sized small or large glass can be filled to different levels, please specify. If even 
smaller or larger glasses were used (diagrams have been shown), record the height and width 
of the glass in centimeters if possible (a ruler should be available for these purposes) 
Dairy 
The type of milk used is important e.g. condensed, evaporated milk (e.g. Ideal Milk), fresh 
milk (e.g. skim milk (0% fat), low fat (2%), full cream (4% fat)), milk powder (e.g. Nespray), 
non-dairy creamer (not a dairy powder but is made from plant oils e.g. Cremora or Ellis 
Brown). How much milk is used if a little milk is used – tea/coffee only slightly cloudy, see 
through. If medium amount is used tea/coffee is cloudy/lighter and not see through.  If a lot 
of milk is used the tea/coffee is very light.  If a little milk is added to porridge/cereal the milk 
is equal to about ¼ the volume of the porridge/cereal.  If a medium amount of milk is added 
to porridge this is equal to ½ the volume of the porridge.  If a lot of milk is added the milk is 
equal to the total volume of the porridge. 
Fats 
Determine type of fat used (e.g. Lard, tallow, butter, white margarine like Wooden Spoon or 
normal margarine) Tub vs. brick margarine and state if possible whether it was light or 
regular.  How is fat spread on bread? If it is thinly spread it hardly covers the bread and the 
bread can still be clearly seen.  If it is medium spread it covers the bread well but not yet 
thick.  If it is thickly spread – shows teeth marks when a bite is taken.  If a sandwich is eaten 
is bread spread on both sides? 
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Fruit juice 
Is it fresh, sweetened, unsweetened, nectar, whole juice (pure) or reconstituted concentrate. 
E.g. of pure fruit juices which are unsweetened include Appetizer, Grapetiser, tomato juice 
(actually a vegetable juice), Liquifruit and Ceres.  Nectars are fruit juices that have 50% or 
less pure juice, e.g. Capri-Sonn, Minute Maid and Ice. 
Meat 
Determine if the cut of the meat was fatty/lean, with/without bones.  Determine the 
cooking/preparation method used to prepare foods e.g. 
 Roasting – cooking in an oven with the addition of little or no fat 
 Pan frying – cooking in a pan in shallow fat 
 Deep fat frying – cooking in deep oil 
 Grilling or boiling – cooking in the oven, over hot coals (braai) in an electric griller or 
heavy metal grilling pan where fat can drain off into the grooves 
 Pot roasting – cooking in an iron pot or saucepan on top of stove or fire 
 Braising – cooking by browning on its own or with a little fat and then adding small 
amounts of boiling water or other liquid. 
 Stewing – cooking in sufficient liquid to cover food 
 Boiling – food is placed in cold water that is brought to the boil, once boiling the heat 
is reduced and food allowed to cook until tender. 
Chicken 
Determine if light or dark meat was eaten and the preparation method used. 
Fish 
Fish is classified based on the fat content: 
 Fatty fish – Kipper, herring, butterfish, mackerel and salmon 
 Moderately fat fish – Yellow fish, trout, cod, galjoen, harder, pilchards, shad, snoek, 
trout and tuna 
 Low fat/white fish – Stockfish, sole, cob, kabeljou, kingklip, hake and geelbak. 
Protein sources 
Pieces of meat, cheese and fish can be expressed as number of matchboxes (1, 2, 3 etc). 
Fruit 
Fresh, canned or home-cooked (with/without sugar), whether it was peeled or unpeeled.  Fruit 
salad or stewed fruit may be a combination of different fruits.  Describe the fruits that were 
included and whether ±equal amounts of all fruits were included or whether some fruits 
‘dominated’. Determine if sugar was added to fruit salad/stewed fruit. 
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Vegetables 
Vegetables may be purchased fresh, frozen, sun-dried or canned. They may be eaten raw or 
cooked.  Fat (butter, margarine) sugar, mayonnaise, sour cream may be added to the 
vegetables. 
Indicate if you are not sure what you ate. Make use of brand names if possible. State 
whether homemade or commercial products were used (e.g. biscuits, cakes, puddings) 
Step 4: Describe the portion size of each item consumed according to the guidelines provided 
by the dietitian. Also see attached sheet of generic food portions.  
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DAY 1 
Date: 
Day:  M    T    W    Th   F   S    S          
 
Time Food Item Detail Detail of portion size 
e.g. 
06:30 
Bread 
 
Brown 
Margarine (Flora Light) 
3 thick slices 
Thinly spread on all 3 slices 
 Coffee Instant – caffeinated 
Milk – 2% fresh milk 
White sugar 
1 cup (250ml) 
2 Tablespoons (30ml) 
1 teaspoon (5ml) 
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DAY 2 
Date: 
Day:  M    T    W    Th   F   S    S          
 
Time Food Item Detail Detail of portion size 
e.g. 
06:30 
Bread 
 
Brown 
Margarine (Flora Light) 
3 thick slices 
Thinly spread on all 3 slices 
 Coffee Instant – caffeinated 
Milk – 2% fresh milk 
White sugar 
1 cup (250ml) 
2 Tablespoons (30ml) 
1 teaspoon (5ml) 
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DAY 3 
Date: 
Day:  M    T    W    Th   F   S    S          
 
Time Food Item Detail Detail of portion size 
e.g. 
06:30 
Bread 
 
Brown 
Margarine (Flora Light) 
3 thick slices 
Thinly spread on all 3 slices 
 Coffee Instant – caffeinated 
Milk – 2% fresh milk 
White sugar 
1 cup (250ml) 
2 Tablespoons (30ml) 
1 teaspoon (5ml) 
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ADDENDUM 6 
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PLEASE WRITE IN 
TODAY'S DATE: _____ ______  _____ 
 DAY MONTH YEAR 
 
 
 
 
 
PLEASE READ THIS CAREFULLY 
 
ON THE FOLLOWING PAGES YOU WILL FIND STATEMENTS CONCERNING BOWEL PROBLEMS (IRRITABLE BOWEL 
SYNDROME) AND HOW THEY AFFECT YOU. 
FOR EACH STATEMENT, PLEASE CHOOSE THE RESPONSE THAT BEST APPLIES TO YOU  
AND CIRCLE THE NUMBER OF YOUR RESPONSE. 
IF YOU ARE UNSURE ABOUT HOW TO RESPOND TO A STATEMENT, PLEASE GIVE THE BEST RESPONSE YOU CAN. 
THERE ARE NO RIGHT OR WRONG RESPONSES. 
YOUR RESPONSES WILL BE KEPT STRICTLY CONFIDENTIAL. 
IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT: 
**SITE ADDRESS AND PHONE NUMBER TO BE PLACED HERE** 
 
The Irritable Bowel Syndrome - Quality of Life questionnaire (IBS-QOL) was developed by Donald L. Patrick, Ph.D. at The 
University of Washington, Douglas A. Drossman, MD at The University of North Carolina, Novartis Pharmaceuticals Corporation, 
and Novartis Pharma AG. Authors hold joint copyright over the IBS-QOL and all its translations. 
PARTICIPANT/PATIENT ID: 
ADDENDUM 7 
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About Your Feelings 
 
Please think about your life over the past month (last 30 days) and look at the statements 
below.  Each statement has five possible responses. For each statement, please circle the one 
response that best describes your feelings. 
 
1. I feel helpless because of my bowel problems. (Please circle one number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
2. I am embarrassed by the smell caused by my bowel problems. (Please circle one 
number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
3. I am bothered by how much time I spend on the toilet. (Please circle one number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
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4. I feel vulnerable to other illnesses because of my bowel problems. (Please circle one 
number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
5. I feel fat or bloated because of my bowel problems. (Please circle one number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
6. I feel as though I am losing control of my life because of my bowel problems. (Please 
circle one number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
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7. I feel that my life is less enjoyable because of my bowel problems. (Please circle one 
number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
8. I feel uncomfortable when I talk about my bowel problems. (Please circle one 
number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
9. I feel depressed about my bowel problems. (Please circle one number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
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10. I feel isolated from other people because of my bowel problems. (Please circle one 
number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
11. I have to be careful about the amount of food I eat because of my bowel problems. 
(Please circle one number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
12. Because of my bowel problems sexual activity is difficult for me. (Please circle one 
number) 
 (If not applicable, please circle “NOT AT ALL”) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
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13. I feel angry that I have bowel problems. (Please circle one number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
14. I feel as though I irritate others because of my bowel problems. (Please circle one 
number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
 
 
 
15. I worry that my bowel problems will get worse. (Please circle one number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
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16. I feel irritable because of my bowel problems. (Please circle one number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
17. I worry that people think I exaggerate my bowel problems. (Please circle one 
number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
18. I feel that I get less done because of my bowel problems. (Please circle one number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
19. I have to avoid stressful situations because of my bowel problems. (Please circle one 
number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
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20. My bowel problems reduce my sexual desire. (Please circle one number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
21. My bowel problems limit what I can wear. (Please circle one number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
22. I have to avoid strenuous activity because of my bowel problems. (Please circle one 
number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
23. I have to be careful about the kind of food I eat because of my bowel problems. 
(Please circle one number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
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24. Because of my bowel problems I have difficulty being with unfamiliar people. 
(Please circle one number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
25. I feel sluggish because of my bowel problems. (Please circle one number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
26. I feel “unclean” because of my bowel problems. (Please circle one number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
27. Long trips are difficult for me because of my bowel problems. (Please circle one 
number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
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28. I feel frustrated that I cannot eat when I want to because of my bowel problems. 
(Please circle one number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
29. It is important to be near a toilet because of my bowel problems. (Please circle one 
number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
5 EXTREMELY 
 
30. My life revolves around my bowel problems. (Please circle one number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
31. I worry about losing control of my bowels. (Please circle one number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
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32. I am afraid that I won't be able to have a bowel movement. (Please circle one 
number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
33. My bowel problems are affecting my closest relationships. (Please circle one 
number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
34. I feel that no one understands my bowel problems. (Please circle one number) 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
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